| Main | News | Articles | Papers| About |

COVID-19 Scientific Papers
updated September 10, 2022 10:00 EDT

Caveat 1: There are thousands of papers being published and this is not in any way a representative sample.
Caveat 2: Research is happening at a very rapid pace, so keep in mind that something published just a few months or weeks ago may have already been superseded.

Earlier

  • 03/25/2008 Modeling targeted layered containment of an influenza pandemic in the United States | PNAS
  • 05/01/2007 Public health interventions and epidemic intensity during the 1918 influenza pandemic | PNAS
  • 09/02/2014 Quantification of Shared Air: A Social and Environmental Determinant of Airborne Disease Transmission
  • 03/02/2016 Pre-fusion structure of a human coronavirus spike protein | Nature
  • 07/11/2017 Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen | PNAS
  • 04/04/2018 Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin - PubMed

    January 2020

  • 01/27 Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China - Wang - 2020 - Journal of Medical Virology - Wiley Online Library
  • 01/30 Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany | NEJM

    February 2020

  • 02/09 Far-UVC light: A new tool to control the spread of airborne-mediated microbial diseases | Scientific Reports

    March 2020

  • 03/03 Fractal kinetics of COVID-19 pandemic | medRxiv
  • 03/09 Temperature and Latitude Analysis to Predict Potential Spread and Seasonality for COVID-19 :: SSRN
  • 03/16 Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand - Imperial College London [PDF]
  • 03/17 The proximal origin of SARS-CoV-2 | Nature Medicine
  • 03/17 Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 | NEJM
  • 03/27 Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma | JAMA | JAMA Network

    April 2020

  • 04/03 Respiratory virus shedding in exhaled breath and efficacy of face masks | Nature Medicine
  • 04/06 Quantifying the effect of quarantine control in Covid-19 infectious spread using machine learning | medRxiv
  • 04/07 Indoor transmission of SARS-CoV-2 | medRxiv
  • 04/07 Early Release - High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC
  • 04/10 Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China | Global Health | JAMA | JAMA Network
  • 04/10 Early Release - Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020 - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC
  • 04/11 OSF | The Small World Network of College Classes: Implications for Epidemic Spread on a University Campus | Cornell
  • 04/12 Face Masks Against COVID-19: An Evidence Review[v1] | Preprints
  • 04/13 Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period | Science
  • 04/13 Universal Screening for SARS-CoV-2 in Women Admitted for Delivery | NEJM
  • 04/15 COVID-19: Hydroxychloroquine & Hypoxic Pneumonia / Timing of Viral Shedding & Transmission / Coinfection with Other Respiratory Pathogens
  • 04/15 Fast spread of COVID-19 in Europe and the US and its implications: even modest public health goals require comprehensive intervention | medRxiv
  • 04/18 Relative disease burdens of COVID-19 and seasonal influenza in New York City, February 1 - April 18, 2020. | medRxiv
  • 04/20 Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor | Nature
  • 04/22 National Covid-19 Testing Action Plan - Rockefeller Foundation [PDF]
  • 04/23 Modeling infectious disease dynamics | Science
  • 04/23 Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 | medRxiv
  • 04/23 SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes | Nature Medicine
  • 04/24 Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial | Infectious Diseases | JAMA Network Open | JAM
  • 04/24 Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks | ACS Nano
  • 04/24 Early Release - Asymptomatic SARS-CoV-2 Infection in Household Contacts of a Healthcare Provider, Wuhan, China - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC
  • 04/30 A rapid systematic review of the efficacy of face masks and respirators against coronaviruses and other respiratory transmissible viruses for the community, healthcare workers and sick patients

    May 2020

  • 05/05 Rapid development of an inactivated vaccine candidate for SARS-CoV-2 | Science
  • 05/07 Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial | medRxiv
  • 05/08 Harnessing multiple models for outbreak management | Science discussed here: 05/07 Which COVID-19 models should we use to make policy decisions?
  • 05/08 Impact of climate and public health interventions on the COVID-19 pandemic: a prospective cohort study | CMAJ
  • 05/11 COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions | Infectious Diseases | JAMA | JAMA Network
  • 05/12 The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission | PNAS
  • 05/12 Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study - The Lancet
  • 05/13 An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study - The Lancet
  • 05/13 An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study - The Lancet discussed here: 05/13 Kawasaki-like disease: emerging complication during the COVID-19 pandemic - The Lancet
  • 05/14 Assessment of Deaths From COVID-19 and From Seasonal Influenza | Geriatrics | JAMA Internal Medicine | JAMA Network
  • 05/14 Strong Social Distancing Measures In The United States Reduced The COVID-19 Growth Rate | Health Affairs
  • 05/15 Early Release - Cluster of Coronavirus Disease Associated with Fitness Dance Classes, South Korea - Volume 26, Number 8—August 2020 - Emerging Infectious Diseases journal - CDC
  • 05/20 Nasal ACE2 Levels and COVID-19 in Children | Infectious Diseases | JAMA | JAMA Network
  • 05/25 Tail risk of contagious diseases | Nature Physics
  • 05/29 Differential Effects of Intervention Timing on COVID-19 Spread in the United States | medRxiv

    June 2020

  • 06/01 Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis - The Lancet
  • 06/03 Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review: Annals of Internal Medicine: Vol 0, No 0
  • 06/04 Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus-2: A Narrative Review: Annals of Internal Medicine: Vol 0, No 0
  • 06/05 False Negative Tests for SARS-CoV-2 Infection — Challenges and Implications | NEJM
  • 06/08 The effect of large-scale anti-contagion policies on the COVID-19 pandemic | Nature discussed here: 06/08 Emergency COVID-19 measures prevented more than 500 million infections, study finds | Berkeley News
  • 06/09 Rationing social contact during the COVID-19 pandemic: Transmission risk and social benefits of US locations | PNAS discussed here: 06/11 Which businesses should be open? | MIT News
  • 06/10 A modelling framework to assess the likely effectiveness of facemasks in combination with ‘lock-down’ in managing the COVID-19 pandemic | Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences
  • 06/10 Identifying airborne transmission as the dominant route for the spread of COVID-19 | PNAS
  • 06/11 Eurosurveillance | SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020
  • 06/11 Identifying airborne transmission as the dominant route for the spread of COVID-19 | PNAS
  • 06/12 Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen | The Journal of Antibiotics
  • 06/16 Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US | Health Affairs
  • 06/18 Cerebral Venous Thrombosis Associated with COVID-19 | American Journal of Neuroradiology
  • 06/18 Economic Vulnerability of Households With Essential Workers | Health Disparities | JAMA | JAMA Network
  • 06/22 Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States | Science Translational Medicine
  • 06/22 Early Release - Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 in Aerosol Suspensions - Volume 26, Number 9—September 2020 - Emerging Infectious Diseases journal - CDC
  • 06/29 Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City | medRxiv
  • 06/29 Multisystem Inflammatory Syndrome in U.S. Children and Adolescents | NEJM
  • 06/29 Multisystem Inflammatory Syndrome in Children in New York State | NEJM

    July 2020

  • 07/02 Eurosurveillance | Excess all-cause mortality during the COVID-19 pandemic in Europe – preliminary pooled estimates from the EuroMOMO network, March to April 2020
  • 07/02 The implications of silent transmission for the control of COVID-19 outbreaks | PNAS
  • 07/06 Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study - The Lancet
  • 07/09 Persistent Symptoms in Patients After Acute COVID-19 | Critical Care Medicine | JAMA | JAMA Network
  • 07/09 Socio-economic, environmental impacts of COVID-19 quantified
  • 07/09 Air recirculation role in the infection with COVID-19, lessons learned from Diamond Princess cruise ship | medRxiv
  • 07/10 Tracking the reach of COVID-19 kin loss with a bereavement multiplier applied to the United States | PNAS
  • 07/11 Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection | medRxiv
  • 07/14 An Mrna Vaccine Against Sars Cov 2 — Preliminary Report articles: NEJM.org
  • 07/15 Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. | medRxiv
  • 07/16 Reconstruction of the full transmission dynamics of COVID-19 in Wuhan | Nature
  • 07/16 Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study - The Lancet Public Health
  • 07/21 The Infectious Nature of Patient-Generated SARS-CoV-2 Aerosol | medRxiv
  • 07/28 Social distancing responses to COVID-19 emergency declarations strongly differentiated by income | PNAS
  • 07/29 Association Between Statewide School Closure and COVID-19 Incidence and Mortality in the US | Infectious Diseases | JAMA | JAMA Network
  • 07/29 Characteristics and Quality of US Nursing Homes Reporting Cases of Coronavirus Disease 2019 (COVID-19) | Geriatrics | JAMA Network Open | JAMA Network

    August 2020

  • 08/01 Long-term patient-reported symptoms of COVID-19: an analysis of social media data | medRxiv
  • 08/03 Use of facemasks during the COVID-19 pandemic - The Lancet Respiratory Medicine
  • 08/04 Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling | Journal of Experimental Medicine | Rockefeller University Press
  • 08/04 Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients | medRxiv
  • 08/06 Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea | Infectious Diseases | JAMA Internal Medicine | JAMA Network
  • 08/07 Low-cost measurement of facemask efficacy for filtering expelled droplets during speech | Science Advances
  • 08/07 Interferon responses in viral pneumonias | Science
  • 08/07 Successful Elimination of Covid-19 Transmission in New Zealand | NEJM
  • 08/10 Dental procedure aerosols and COVID-19 - The Lancet Infectious Diseases
  • 08/11 Management of post-acute covid-19 in primary care | The BMJ
  • 08/13 Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2 | medRxiv
  • 08/18 Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure | Annals of Internal Medicine
  • 08/19 Demographic perspectives on the mortality of COVID-19 and other epidemics | PNAS
  • 08/19 Social and behavioral consequences of mask policies during the COVID-19 pandemic | PNAS
  • 08/19 Characterizing superspreading events and age-specific infectiousness of SARS-CoV-2 transmission in Georgia, USA | PNAS
  • 08/21 COVID-19 is, in the end, an endothelial disease | European Heart Journal | Oxford Academic
  • 08/21 Efficacy of Remdesivir in COVID-19 | Infectious Diseases | JAMA | JAMA Network
  • 08/21 Early Release - Asymptomatic Transmission of SARS-CoV-2 on Evacuation Flight - Volume 26, Number 11—November 2020 - Emerging Infectious Diseases journal - CDC
  • 08/24 Full article: Exhaled respiratory particles during singing and talking
  • 08/26 Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis - Clinical Microbiology and Infection
  • 08/26 Population-scale longitudinal mapping of COVID-19 symptoms, behaviour and testing | Nature Human Behaviour
  • 08/27 Misconceptions about weather and seasonality must not misguide COVID-19 response | Nature Communications
  • 08/28 Salivary Detection of COVID-19 | Annals of Internal Medicine
  • 08/28 Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2 | NEJM

    September 2020

  • 09/02 Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics | PNAS
  • 09/04 An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction | Nature Communications
  • 09/08 Comparison of Clinical Features of COVID-19 vs Seasonal Influenza A and B in US Children | Infectious Diseases | JAMA Network Open | JAMA Network
  • 09/08 “When Will We Have a Vaccine?” — Understanding Questions and Answers about Covid-19 Vaccination | NEJM
  • 09/08 Facial Masking for Covid-19 — Potential for “Variolation” as We Await a Vaccine | NEJM
  • 09/08 Social and behavioral consequences of mask policies during the COVID-19 pandemic | PNAS
  • 09/08 Demographic perspectives on the mortality of COVID-19 and other epidemics | PNAS
  • 09/09 Clinical Outcomes in Young US Adults Hospitalized With COVID-19 | Critical Care Medicine | JAMA Internal Medicine | JAMA Network
  • 09/09 Use of “normal” risk to improve understanding of dangers of covid-19 | The BMJ
  • 09/09 Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score | The BMJ
  • 09/09 Covid-19 Molecular Diagnostic Testing — Lessons Learned | NEJM
  • 09/10 Trained Innate Immunity, Epigenetics, and Covid-19 | NEJM
  • 09/10 Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study - The Lancet
  • 09/11 COVID-19 and the Path to Immunity | Allergy and Clinical Immunology | JAMA | JAMA Network
  • 09/11 Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection | Infectious Diseases | JAMA Cardiology | JAMA Network
  • 09/14 Seasonal coronavirus protective immunity is short-lasting | Nature Medicine
  • 09/17 Patient-reported outcome measures after COVID-19: a prospective cohort study | European Respiratory Society
  • 09/17 A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity | Nature Communications
  • 09/17 Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong | Nature Medicine
  • 09/18 Artificial intelligence in COVID-19 drug repurposing - The Lancet Digital Health
  • 09/21 COVID-19 in children and young people | Science
  • 09/21 Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients | Science Translational Medicine
  • 09/22 Quantifying and contextualizing the impact of bioRxiv preprints through automated social media audience segmentation
  • 09/22 Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis - PLOS
  • 09/23 National Trends of Cases of COVID-19 in Children Based on US State Health Department Data | American Academy of Pediatrics
  • 09/23 The rise of COVID-19 cases is associated with support for world leaders | PNAS
  • 09/23 Physics of virus transmission by speaking droplets | PNAS
  • 09/25 Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis | Adolescent Medicine | JAMA Pediatrics | JAMA Network
  • 09/25 Speech can produce jet-like transport relevant to asymptomatic spreading of virus | PNAS
  • 09/25 Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation | PNAS
  • 09/25 Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study - The Lancet
  • 09/28 Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity | Science
  • 09/28 Effects of ventilation on the indoor spread of COVID-19 | Journal of Fluid Mechanics | Cambridge Core
  • 09/28 Direct detection of SARS-CoV-2 using CRISPR-Cas13a and a mobile phone | medRxiv
  • 09/29 Epidemiology and transmission dynamics of COVID-19 in two Indian states | Science
  • 09/29 A Cytokine Circus with a Viral Ringleader: SARS-CoV-2-Associated Cytokine Storm Syndromes: Trends in Molecular Medicine - Cell
  • 09/29 Genetic mechanisms of critical illness in Covid-19 | medRxiv
  • 09/29 Low risk of SARS-CoV-2 transmission by fomites in real-life conditions - The Lancet Infectious Diseases
  • 09/29 Early Release - Flight-Associated Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Corroborated by Whole-Genome Sequencing - Volume 26, Number 12—December 2020 - Emerging Infectious Diseases journal - CDC
  • 09/30 In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study | The BMJ
  • 09/30 Spinal cord dysfunction after COVID-19 infection - Nature

    October 2020

  • 10/01 Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: An observational cohort study - PLOS
  • 10/01 COVID-19 Vaccine Predictions: Using Mathematical Modelling and Expert Opinions to Estimate Timelines and Probabilities of Success of COVID-19 Vaccines | Center For Global Development
  • 10/01 Frontiers | Pandemic Dreams: Network Analysis of Dream Content During the COVID-19 Lockdown | Psychology
  • 10/02 Airborne transmission of SARS-CoV-2 | Science
  • 10/05 Long-term Health Consequences of COVID-19 | Cardiology | JAMA | JAMA Network
  • 10/05 Follow-up of adults with non-critical COVID-19 two months after symptoms' onset - ScienceDirect
  • 10/05 Neuropathology of patients with COVID-19 in Germany: a post-mortem case series - The Lancet Neurology
  • 10/06 Children and Adolescents With SARS-CoV-2 Infection Epidemiology, Clinical Course and Viral Loads - The Pediatric Infectious Disease Journal
  • 10/06 Symptoms and Transmission of SARS-CoV-2 among Children—Utah and Wisconsin, March–May 2020 | American Academy of Pediatrics
  • 10/06 SARS-CoV-2-specific T-cells in unexposed humans: presence of cross-reactive memory cells does not equal protective immunity | Signal Transduction and Targeted Therapy
  • 10/06 Cross-reactive memory T cells and herd immunity to SARS-CoV-2 | Nature Reviews Immunology
  • 10/06 Characteristics of SARS-CoV-2 and COVID-19 | Nature Reviews Microbiology
  • 10/06 Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases | PNAS
  • 10/07 The effect of temperature on persistence of SARS-CoV-2 on common surfaces | Virology Journal | Full Text
  • 10/07 Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19 | Nature Immunology
  • 10/08 Characteristics of Hospitalized Children With SARS-CoV-2 in the New York City Metropolitan Area - PubMed
  • 10/08 SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses: Cell
  • 10/08 Remdesivir for the Treatment of Covid-19 — Final Report | NEJM
  • 10/08 Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet Respiratory Medicine
  • 10/09 Economic hardship and mental health complaints during COVID-19 | PNAS
  • 10/10 Convalescent plasma for patients with severe COVID-19: a matched cohort study | Clinical Infectious Diseases | Oxford Academic
  • 10/11 Global projections of potential lives saved from COVID-19 through universal mask use | medRxiv
  • 10/12 Excess Deaths From COVID-19 and Other Causes, March-July 2020 | Cardiology | JAMA | JAMA Network
  • 10/12 Outcomes of Neonates Born to Mothers With Severe Acute Respiratory Syndrome Coronavirus 2 Infection at a Large Medical Center in New York City | Infectious Diseases | JAMA Pediatrics | JAMA Network
  • 10/12 SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies | Nature
  • 10/12 The role of environmental factors on transmission rates of the COVID-19 outbreak: an initial assessment in two spatial scales | Scientific Reports - Nature
  • 10/12 Seasonality and uncertainty in global COVID-19 growth rates | PNAS
  • 10/12 Genomic evidence for reinfection with SARS-CoV-2: a case study - The Lancet Infectious Diseases
  • 10/13 Sudden irreversible hearing loss post COVID-19 | BMJ Case Reports
  • 10/13 Regeneron’s Antibodies Prevent and Treat SARS-CoV-2 Infection in Monkeys
  • 10/13 SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates - The Lancet
  • 10/13 COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study - The Lancet Public Health
  • 10/15 Synthesis and systematic review of reported neonatal SARS-CoV-2 infections | Nature Communications
  • 10/16 Emergency Use Authorization of Covid Vaccines — Safety and Efficacy Follow-up Considerations | NEJM
  • 10/19 Herd Immunity and Implications for SARS-CoV-2 Control | JAMA | JAMA Network
  • 10/19 Asymptomatic and Presymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates in a Multistate Sample of Skilled Nursing Facilities | Geriatrics | JAMA Internal Medicine | JAMA Network
  • 10/19 Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity | Science
  • 10/19 Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate | Science
  • 10/20 Numerical investigation of aerosol transport in a classroom with relevance to COVID-19: Physics of Fluids: Vol 32, No 10
  • 10/20 Building Trust to Achieve Confidence in COVID-19 Vaccines | Infectious Diseases | JAMA Network Open | JAMA Network
  • 10/20 Factors Associated With US Adults’ Likelihood of Accepting COVID-19 Vaccination | Infectious Diseases | JAMA Network Open | JAMA Network
  • 10/20 Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study | The BMJ
  • 10/20 Eurosurveillance | A large national outbreak of COVID-19 linked to air travel, Ireland, summer 2020 - Eurosurveillance
  • 10/21 Early Release - Susceptibility of Raccoon Dogs for Experimental SARS-CoV-2 Infection - Volume 26, Number 12—December 2020 - Emerging Infectious Diseases journal - CDC
  • 10/22 Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) | The BMJ
  • 10/23 Trends in COVID-19 Risk-Adjusted Mortality Rates | Journal of Hospital Medicine
  • 10/24 Identification of required host factors for SARS-CoV-2 infection in human cells: Cell
  • 10/26 Preventing the Spread of SARS-CoV-2 With Masks and Other “Low-tech” Interventions | Infectious Diseases | JAMA | JAMA Network
  • 10/26 Return to Play for Athletes After Coronavirus Disease 2019 Infection—Making High-Stakes Recommendations as Data Evolve | Infectious Diseases | JAMA Cardiology | JAMA Network
  • 10/26 Coronavirus Disease 2019 and the Athletic Heart: Emerging Perspectives on Pathology, Risks, and Return to Play | Infectious Diseases | JAMA Cardiology | JAMA Network
  • 10/26 Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans | Nature Microbiology
  • 10/27 Aerosol persistence in relation to possible transmission of SARS-CoV-2: Physics of Fluids: Vol 32, No 10
  • 10/27 COVID-19 associated arterial ischaemic stroke and multisystem inflammatory syndrome in children: a case report - The Lancet Child & Adolescent Health
  • 10/27 What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 - The Lancet Infectious Diseases
  • 10/28 Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study | The BMJ
  • 10/28 Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19: Cell
  • 10/28 SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM
  • 10/29 Wearable sensor data and self-reported symptoms for COVID-19 detection | Nature Medicine
  • 10/30 Association between SARS-CoV-2 infection, exposure risk and mental health among a cohort of essential retail workers in the USA | Occupational & Environmental Medicine
  • 10/30 The Effects of Large Group Meetings on the Spread of COVID-19: The Case of Trump Rallies by B. Douglas Bernheim, Nina Buchmann, Zach Freitas-Groff, Sebastián Otero :: SSRN
  • 10/30 SARS-CoV-2 direct cardiac damage through spike-mediated cardiomyocyte fusion | Research Square

    November 2020

  • 11/02 Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 | Science Translational Medicine
  • 11/02 Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection | bioRxiv
  • 11/03 Dispersion of evaporating cough droplets in tropical outdoor environment: Physics of Fluids: Vol 32, No 11
  • 11/03 Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production: Cell
  • 11/03 Revealing fine-scale spatiotemporal differences in SARS-CoV-2 introduction and spread | Nature Communications
  • 11/03 Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City | Nature
  • 11/04 Lack of antibodies to SARS-CoV-2 in a large cohort of previously infected persons | Clinical Infectious Diseases | Oxford Academic
  • 11/04 An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike | Science
  • 11/04 Case Study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised cancer patient.: Cell
  • 11/04 High Prevalence of Pericardial Involvement in College Student-Athletes Recovering From COVID-19 | JACC: Cardiovascular Imaging
  • 11/05 Differential effects of intervention timing on COVID-19 spread in the United States | Science Advances
  • 11/05 Preexisting and de novo humoral immunity to SARS-CoV-2 in humans | Science
  • 11/05 Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum | Nature Immunology
  • 11/06 Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19 | American Society of Nephrology
  • 11/06 Epidemiology and transmission dynamics of COVID-19 in two Indian states | Science
  • 11/06 Cardiovascular impact of COVID-19 with a focus on children: A systematic review - NIH
  • 11/09 Real-time, interactive website for US-county-level COVID-19 event risk assessment | Nature Human Behaviour
  • 11/09 Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids | Nature Medicine
  • 11/09 Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: a prospective national cohort study using active surveillance - The Lancet Child & Adolescent Health
  • 11/10 Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration | Vaccination | JAMA Internal Medicine | JAMA Network
  • 11/10 Mobility network models of COVID-19 explain inequities and inform reopening | Nature
  • 11/11 Sixty-Day Outcomes Among Patients Hospitalized With COVID-19 | Annals of Internal Medicine
  • 11/11 Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers | Nature Structural & Molecular Biology
  • 11/12 The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19) | Scientific Reports
  • 11/13 Enhancing host cell infection by SARS-CoV-2 | Science
  • 11/13 Real-time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles: Cell Host & Microbe
  • 11/13 SARS-CoV-2 Cell Entry Factors ACE2 and TMPRSS2 are Expressed in the Microvasculature and Ducts of Human Pancreas but are Not Enriched in β Cells: Cell Metabolism
  • 11/14 Staying sane in our new COVID-19 world - The Lancet
  • 11/16 Trends in Outpatient Care Delivery and Telemedicine During the COVID-19 Pandemic in the US | Infectious Diseases | JAMA Internal Medicine | JAMA Network
  • 11/16 Diaphragm Pathology in Critically Ill Patients With COVID-19 and Postmortem Findings From 3 Medical Centers | Critical Care Medicine | JAMA Internal Medicine | JAMA Network
  • 11/16 COVID-19-associated Non-Occlusive Fibrin Microthrombi in the Heart | Circulation
  • 11/16 Immunological memory to SARS-CoV-2 assessed for greater than six months after infection | bioRxiv
  • 11/16 Ranking the effectiveness of worldwide COVID-19 government interventions | Nature Human Behaviour
  • 11/17 Ensuring vaccine safety | Science
  • 11/17 Expecting the unexpected with COVID-19 vaccines - The Lancet Infectious Diseases
  • 11/18 The known unknowns of T cell immunity to COVID-19 | Science Immunology
  • 11/18 Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers: A Randomized Controlled Trial: Annals of Internal Medicine: Vol 0, No 0 - ACP Journals
  • 11/18 COVID-19-associated olfactory dysfunction reveals SARS-CoV-2 neuroinvasion and persistence in the olfactory system | bioRxiv
  • 11/18 Antibodies to SARS-CoV-2 are associated with protection against reinfection | medRxiv
  • 11/18 Pre-symptomatic detection of COVID-19 from smartwatch data | Nature Biomedical Engineering
  • 11/18 Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19 | Nature Immunology
  • 11/18 Event-specific interventions to minimize COVID-19 transmission | PNAS
  • 11/18 Age and frailty in COVID-19 vaccine development - The Lancet
  • 11/19 Ct values and infectivity of SARS-CoV-2 on surfaces - The Lancet Infectious Diseases
  • 11/19 SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis - The Lancet Microbe
  • 11/20 Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening | Science Advances
  • 11/20 Air-Filtering Masks for Respiratory Protection from PM2.5 and Pandemic Pathogens: One Earth
  • 11/23 Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2 | Science
  • 11/23 Functional SARS-CoV-2-specific immune memory persists after mild COVID-19: Cell
  • 11/24 Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020 | Infectious Diseases | JAMA Internal Medicine | JAMA Network
  • 11/24 Antibodies, Immunity, and COVID-19 | Infectious Diseases | JAMA Internal Medicine | JAMA Network
  • 11/24 SARS-CoV-2 receptors and entry genes are expressed in the human olfactory neuroepithelium and brain: iScience
  • 11/24 A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 | NEJM
  • 11/24 A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia | NEJM
  • 11/24 Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion | PNAS
  • 11/26 Nucleic Acid-Based Technologies Targeting Coronaviruses: Trends in Biochemical Sciences
  • 11/26 Rethinking Covid-19 Test Sensitivity — A Strategy for Containment | NEJM
  • 11/27 Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate | Science
  • 11/27 SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy - The Lancet Neurology
  • 11/28 The effectiveness of population-wide, rapid antigen test based screening in reducing SARS-CoV-2 infection prevalence in Slovakia | CMMID Repository
  • 11/28 A tribute to some of the doctors who died from COVID-19 - The Lancet
  • 11/30 Frontiers | Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection | Immunology
  • 11/30 COVID-19 in a case previously infected with MERS-CoV: No cross immunity - Journal of Infection
  • 11/30 Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 | Nature Neuroscience

    December 2020

  • 12/01 Post-infectious inflammatory disease in MIS-C features elevated cytotoxicity signatures and autoreactivity that correlates with severity | medRxiv
  • 12/01 Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer | NEJM
  • 12/02 Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results - PubMed
  • 12/02 Reversible Myocardial Injury Associated With SARS-CoV-2 in an Infant | JACC: Case Reports
  • 12/02 Placebo-Controlled Trials of Covid-19 Vaccines — Why We Still Need Them | NEJM
  • 12/03 Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19 - PubMed
  • 12/03 Fast detection of SARS-CoV-2 RNA via the integration of plasmonic thermocycling and fluorescence detection in a portable device | Nature Biomedical Engineering
  • 12/03 Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host | NEJM
  • 12/03 Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination | NEJM
  • 12/03 Cytokine Storm | NEJM
  • 12/04 Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy: Cell
  • 12/04 Correlates of protection against SARS-CoV-2 in rhesus macaques | Nature
  • 12/04 Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison | Nature Immunology
  • 12/07 IgA dominates the early neutralizing antibody response to SARS-CoV-2 | Science Translational Medicine
  • 12/07 Enhanced SARS-CoV-2 neutralization by dimeric IgA | Science Translational Medicine
  • 12/07 Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis | The BMJ
  • 12/07 Model-informed COVID-19 vaccine prioritization strategies by age and serostatus | medRxiv
  • 12/07 Effect of internationally imported cases on internal spread of COVID-19: a mathematical modelling study - The Lancet Public Health
  • 12/08 iGenomics: Comprehensive DNA sequence analysis on your Smartphone | GigaScience | Oxford Academic
  • 12/08 Effect of sneezing on the flow around a face shield: Physics of Fluids: Vol 32, No 12
  • 12/08 Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic | Science
  • 12/08 Simultaneous COVID-19 in Homozygous Twins | Annals of Internal Medicine
  • 12/08 Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial: Annals of Internal Medicine: Vol 0, No 0
  • 12/08 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet
  • 12/08 SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England - The Lancet Infectious Diseases
  • 12/09 Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants | Occupational & Environmental Medicine
  • 12/09 Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2 | Science Translational Medicine
  • 12/10 Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic | Infectious Diseases | JAMA Internal Medicine | JAMA Network
  • 12/10 Using Cardiovascular Cells from Human Pluripotent Stem Cells for COVID-19 Research: Why the Heart Fails: Stem Cell Reports
  • 12/11 The kinetics of humoral response and its relationship with the disease severity in COVID-19 | Communications Biology
  • 12/11 Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2 | PNAS
  • 12/12 Is my cough COVID-19? - The Lancet
  • 12/13 SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome | bioRxiv
  • 12/14 Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis | Global Health | JAMA Network Open | JAMA Network
  • 12/15 Effects of mask-wearing on the inhalability and deposition of airborne SARS-CoV-2 aerosols in human upper airway: Physics of Fluids: Vol 32, No 12
  • 12/15 Effects of space sizes on the dispersion of cough-generated droplets from a walking person: Physics of Fluids: Vol 32, No 12
  • 12/15 COVID-19 neutralizing antibodies predict disease severity and survival: Cell
  • 12/15 Nursing home staff networks and COVID-19 | PNAS
  • 12/15 Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study - The Lancet Child & Adolescent Health
  • 12/15 SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study - The Lancet Infectious Diseases
  • 12/16 All-Cause Excess Mortality and COVID-19–Related Mortality Among US Adults Aged 25-44 Years, March-July 2020 | Infectious Diseases | JAMA | JAMA Network
  • 12/16 The S1 protein of SARS-CoV-2 crosses the blood–brain barrier in mice | Nature Neuroscience
  • 12/16 Emergence of a Highly Fit SARS-CoV-2 Variant | NEJM
  • 12/17 COVID-19 Myocardial Pathology Evaluation in AthleTEs with Cardiac Magnetic Resonance (COMPETE CMR) | Circulation
  • 12/17 A Crisp(r) New Perspective on SARS-CoV-2 Biology: Cell
  • 12/17 Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses | Nature Medicine
  • 12/17 T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial | Nature Medicine
  • 12/17 Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study - The Lancet Respiratory Medicine
  • 12/18 Kinetics of antibody responses dictate COVID-19 outcome | medRxiv
  • 12/18 Infectivity of asymptomatic versus symptomatic COVID-19 - The Lancet
  • 12/20 Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations - nCoV-2019 Genomic Epidemiology - Virological
  • 12/20 Threat Assessment Brief: Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom - ECDC
  • 12/21 Excess Mortality in California During the Coronavirus Disease 2019 Pandemic, March to August 2020 | Infectious Diseases | JAMA Internal Medicine | JAMA Network
  • 12/21 Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study - The Lancet Microbe
  • 12/22 Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic | Infectious Diseases | JAMA Internal Medicine | JAMA Network
  • 12/22 Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid: Immunity
  • 12/22 COVID-19 and the Swedish enigma - The Lancet
  • 12/23 Assessment of Air Contamination by SARS-CoV-2 in Hospital Settings | Infectious Diseases | JAMA Network Open | JAMA Network
  • 12/23 SARS-CoV-2 mutations among minks show reduced lethality and infectivity to humans | bioRxiv
  • 12/23 Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers | NEJM
  • 12/24 Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact | medRxiv
  • 12/25 Reverse Engineering the source code of the BioNTech/Pfizer SARS-CoV-2 Vaccine - Articles
  • 12/25 SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity: Med
  • 12/28 One Year Later, How Does COVID-19 Affect Children? | Infectious Diseases | JAMA Pediatrics | JAMA Network
  • 12/28 Superspreading in early transmissions of COVID-19 in Indonesia | Scientific Reports
  • 12/29 Assessment of Neutrophil Extracellular Traps in Coronary Thrombus of a Case Series of Patients With COVID-19 and Myocardial Infarction | Acute Coronary Syndromes | JAMA Cardiology | JAMA Network
  • 12/29 Update Alert 4: Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings | Annals of Internal Medicine
  • 12/29 Masks and Face Coverings for the Lay Public: A Narrative Update: Annals of Internal Medicine: Vol 0, No 0
  • 12/30 Fluid dynamics of COVID-19 airborne infection suggests urgent data for a scientific design of social distancing | Scientific Reports
  • 12/30 Microvascular Injury in the Brains of Patients with Covid-19 | NEJM
  • 12/30 Neutralizing Antibody LY-CoV555 for Outpatient Covid-19 | NEJM
  • 12/30 Maintaining Safety with SARS-CoV-2 Vaccines | NEJM

    January 2021

  • 01/01 Airflows inside passenger cars and implications for airborne disease transmission | Science Advances
  • 01/02 Mutations arising in SARS-CoV-2 spike on sustained human-to-human transmission and human-to-animal passage - SARS-CoV-2 coronavirus - Virological
  • 01/02 Mutations arising in SARS-CoV-2 spike on sustained human-to-human transmission and human-to-animal passage - #12 by rfgarry - SARS-CoV-2 coronavirus - Virological
  • 01/04 Risk Factors Associated With All-Cause 30-Day Mortality in Nursing Home Residents With COVID-19 | Dementia and Cognitive Impairment | JAMA Internal Medicine | JAMA Network
  • 01/05 Endemic SARS-CoV-2 will maintain post-pandemic immunity | Nature Reviews Immunology
  • 01/05 Early Release - Genomic Evidence of In-Flight Transmission of SARS-CoV-2 Despite Predeparture Testing - Volume 27, Number 3—March 2021 - Emerging Infectious Diseases journal - CDC
  • 01/06 Genetic Variants of SARS-CoV-2—What Do They Mean? | Infectious Diseases | JAMA | JAMA Network
  • 01/06 Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection | Science
  • 01/07 The value of decreasing the duration of the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection - PLOS
  • 01/07 COVID-19 vasculitis and novel vasculitis mimics - The Lancet Rheumatology
  • 01/08 A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis | Science
  • 01/08 Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK | Science
  • 01/08 Findings from Cardiovascular Evaluation of NCAA Division I Collegiate Student-Athletes after Asymptomatic or Mildly Symptomatic SARS-CoV-2 Infection | medRxiv
  • 01/11 Immunological characteristics govern the transition of COVID-19 to endemicity | Science
  • 01/11 Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice | Science
  • 01/11 A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection | Nature Genetics
  • 01/11 The distribution of cellular turnover in the human body | Nature Medicine
  • 01/11 Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals | Nature Medicine
  • 01/11 A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent | Nature Structural & Molecular Biology
  • 01/11 Retail store customer flow and COVID-19 transmission | PNAS
  • 01/12 MuSK Antibody–Associated Myasthenia Gravis With SARS-CoV-2 Infection: A Case Report | Annals of Internal Medicine
  • 01/12 The Sensitivity and Costs of Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs: A Systematic Review and Meta-analysis: Annals of Internal Medicine: Vol 0, No 0 - ACP Journals
  • 01/12 Adaptive immunity to SARS-CoV-2 and COVID-19: Cell
  • 01/12 First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020 - The Lancet Infectious Diseases
  • 01/13 Messenger RNA vaccines against SARS-CoV-2: Cell
  • 01/13 Immune determinants of COVID-19 disease presentation and severity | Nature Medicine
  • 01/13 Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19 | NEJM
  • 01/13 Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM
  • 01/13 SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia - Volume 28, Number 2—February 2022 - Emerging Infectious Diseases journal - CDC
  • 01/14 Evaluation for Myocarditis in Competitive Student Athletes Recovering From Coronavirus Disease 2019 With Cardiac Magnetic Resonance Imaging | Cardiology | JAMA Cardiology | JAMA Network
  • 01/14 SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population: Cell Reports Medicine
  • 01/14 Long COVID in the skin: a registry analysis of COVID-19 dermatological duration - The Lancet Infectious Diseases
  • 01/14 Public health surveillance of infectious diseases: beyond point mutations - The Lancet Microbe
  • 01/15 Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2: A Systematic Review and Meta-analysis | Infectious Diseases | JAMA Internal Medicine | JAMA Network
  • 01/15 Isolation of SARS-CoV-2 from the air in a car driven by a COVID patient with mild illness | medRxiv
  • 01/15 Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data - The Lancet Respiratory Medicine
  • 01/18 Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19 - PubMed
  • 01/18 Sociodemographic disparities in energy insecurity among low-income households before and during the COVID-19 pandemic | Nature Energy
  • 01/18 Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study - The Lancet Infectious Diseases
  • 01/19 mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants | bioRxiv
  • 01/19 Vaccinology in the post−COVID-19 era | PNAS
  • 01/19 Mask-wearing and control of SARS-CoV-2 transmission in the USA: a cross-sectional study - The Lancet Digital Health
  • 01/21 Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8+ T cells | Science Immunology
  • 01/21 Model-informed COVID-19 vaccine prioritization strategies by age and serostatus | Science
  • 01/21 Optimizing age-specific vaccination | Science
  • 01/22 Sex differences in immune responses | Science
  • 01/22 Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody | Science
  • 01/22 The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review: Annals of Internal Medicine: Vol 0, No 0
  • 01/22 The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review: Annals of Internal Medicine: Vol 174, No 5
  • 01/23 B cell memory: understanding COVID-19: Immunity
  • 01/25 Global absence and targeting of protective immune states in severe COVID-19 | Nature
  • 01/25 Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis | Nature
  • 01/25 Early warnings of COVID-19 outbreaks across Europe from social media | Scientific Reports
  • 01/26 A novel SARS-CoV-2 related coronavirus in bats from Cambodia | bioRxiv
  • 01/26 Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases: Cell Reports Medicine
  • 01/26 Antibodies, epicenter of SARS-CoV-2 immunology | Cell Death & Differentiation
  • 01/26 An evidence review of face masks against COVID-19 | PNAS
  • 01/27 The case against delaying SARS-CoV-2 mRNA vaccine boosting doses | Clinical Infectious Diseases | Oxford Academic
  • 01/27 Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera | bioRxiv
  • 01/27 Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19 | NEJM
  • 01/27 Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence - The Lancet
  • 01/28 Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera | Science
  • 01/28 Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity: Cell
  • 01/28 SARS-CoV-2 testing for public health use: core principles and considerations for defined use settings - The Lancet Global Health
  • 01/29 Translating viral vaccines into immunity | Science
  • 01/29 Insights from SARS-CoV-2 sequences | Science
  • 01/29 Genomic monitoring of SARS-CoV-2 uncovers an Nsp1 deletion variant that modulates type I interferon response: Cell Host & Microbe
  • 01/29 Public health actions to control new SARS-CoV-2 variants: Cell
  • 01/29 Leveraging the antiviral type-I interferon system as a first line defense against SARS-CoV-2 pathogenicity: Immunity
  • 01/29 Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine | medRxiv
  • 01/30 SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses - EBioMedicine

    February 2021

  • 02/01 Age groups that sustain resurging COVID-19 epidemics in the United States | Science
  • 02/02 Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape | Science
  • 02/02 Naive human B cells can neutralize SARS-CoV-2 through recognition of its receptor binding domain | bioRxiv
  • 02/02 Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity | Nature Immunology
  • 02/02 Sixteen novel lineages of SARS-CoV-2 in South Africa | Nature Medicine
  • 02/02 Timing matters when correcting fake news | PNAS
  • 02/02 Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia - The Lancet
  • 02/02 Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study - The Lancet Infectious Diseases
  • 02/02 Understanding the drivers of transmission of SARS-CoV-2 - The Lancet Infectious Diseases
  • 02/03 Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents | Nature Biotechnology
  • 02/03 SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas | Nature Metabolism
  • 02/04 Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial | Infectious Diseases | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
  • 02/04 Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study - The Lancet Public Health
  • 02/05 Cardiac arrest occurrence during successive waves of the COVID-19 pandemic: direct and indirect consequences | European Heart Journal | Oxford Academic
  • 02/05 Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1 | medRxiv
  • 02/05 SARS-CoV-2 evolution during treatment of chronic infection | Nature
  • 02/05 COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics - The Lancet Public Health
  • 02/05 Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial - The Lancet Respiratory Medicine
  • 02/07 Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States | medRxiv
  • 02/08 Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies: Cell Host & Microbe
  • 02/08 SARS-CoV-2 transmission among children and staff in daycare centres during a nationwide lockdown in France: a cross-sectional, multicentre, seroprevalence study - The Lancet Child & Adolescent Health
  • 02/09 Simulation-based study of COVID-19 outbreak associated with air-conditioning in a restaurant: Physics of Fluids: Vol 33, No 2
  • 02/09 Prevalence and Outcomes of SARS-CoV-2 Infection Among Migrant Workers in Singapore | Global Health | JAMA | JAMA Network
  • 02/09 Public Health Interventions, Epidemic Growth, and Regional Variation of the 1918 Influenza Pandemic Outbreak in a Swiss Canton and Its Greater Regions | Annals of Internal Medicine
  • 02/09 A SARS-CoV-2 Cluster in an Acute Care Hospital | Annals of Internal Medicine
  • 02/09 Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection: Cell
  • 02/09 COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses: Immunity
  • 02/09 Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals | medRxiv
  • 02/09 COVID-19 Modeling and the Path to Herd Immunity - Medscape
  • 02/09 The hygiene hypothesis, the COVID pandemic, and consequences for the human microbiome | PNAS
  • 02/10 Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A case report | Clinical Infectious Diseases | Oxford Academic
  • 02/10 Effectiveness of Mask Wearing to Control Community Spread of SARS-CoV-2 | Infectious Diseases | JAMA | JAMA Network
  • 02/10 Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa | medRxiv
  • 02/10 Public policy and health in the Trump era - The Lancet
  • 02/10 Effect of the new SARS-CoV-2 variant B.1.1.7 on children and young people - The Lancet Child & Adolescent Health
  • 02/11 The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types | eLife
  • 02/11 Emergence of a Novel SARS-CoV-2 Variant in Southern California | Public Health | JAMA | JAMA Network
  • 02/11 The role of children in the spread of COVID-19: Using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children - PLOS
  • 02/11 Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors - PLOS
  • 02/11 Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study | The BMJ
  • 02/11 Hydrating the respiratory tract: an alternative explanation why masks lower severity of COVID-19: Biophysical Journal
  • 02/12 Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021 | Allergy and Clinical Immunology | JAMA | JAMA Network
  • 02/12 Assessing Brain Capillaries in Coronavirus Disease 2019 | Infectious Diseases | JAMA Neurology | JAMA Network
  • 02/12 Single-domain antibodies make a difference | Science
  • 02/12 Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice | Science
  • 02/12 A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection | bioRxiv
  • 02/12 Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection: Cell
  • 02/15 Viral load of SARS-CoV-2 in adults during the first and second wave of COVID-19 pandemic in Houston, TX: the potential of the super-spreader | The Journal of Infectious Diseases | Oxford Academic
  • 02/15 OSF Preprints | Superspreaders drive the largest outbreaks of hospital onset COVID-19 infection
  • 02/15 Diagnostics for SARS-CoV-2 infections | Nature Materials
  • 02/15 Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup | NEJM
  • 02/16 Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2 - Harvard
  • 02/16 Ocular MRI Findings in Patients with Severe COVID-19: A Retrospective Multicenter Observational Study | Radiology
  • 02/16 COVID-19 and the human innate immune system: Cell
  • 02/17 Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study | SpringerLink
  • 02/17 Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets | Science
  • 02/17 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM
  • 02/17 Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report | NEJM
  • 02/18 Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera: Cell
  • 02/18 Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity | medRxiv
  • 02/18 Could mutations of SARS-CoV-2 suppress diagnostic detection? | Nature Biotechnology
  • 02/19 Immunogenicity of clinically relevant SARS-CoV-2 vaccines in non-human primates and humans | Science Advances
  • 02/19 SARS-CoV-2 Positivity on or After 9 Days Among Quarantined Student Contacts of Confirmed Cases | Infectious Diseases | JAMA | JAMA Network
  • 02/19 Sequelae in Adults at 6 Months After COVID-19 Infection | Infectious Diseases | JAMA Network Open | JAMA Network
  • 02/19 Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection | Leukemia | Nature
  • 02/19 Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet
  • 02/19 Delayed-onset myocarditis following COVID-19 - The Lancet Respiratory Medicine
  • 02/23 Relationship between human exhalation diffusion and posture in face-to-face scenario with utterance: Physics of Fluids: Vol 33, No 2
  • 02/23 Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events | eLife
  • 02/23 Prolonged evolution of the human B cell response to SARS-CoV-2 infection | Science Immunology
  • 02/23 SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape | bioRxiv
  • 02/23 Extremely potent human monoclonal antibodies from COVID-19 convalescent patients: Cell
  • 02/23 Mechanistic transmission modeling of COVID-19 on the Diamond Princess cruise ship demonstrates the importance of aerosol transmission | PNAS
  • 02/23 Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort | PNAS
  • 02/23 Pandemic precarity: COVID-19 is exposing and exacerbating inequalities in the American heartland | PNAS
  • 02/23 Exhaled aerosol increases with COVID-19 infection, age, and obesity | PNAS
  • 02/24 Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection - Authorea
  • 02/24 BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting | NEJM
  • 02/25 Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals - The Lancet
  • 02/25 Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine - The Lancet
  • 02/26 SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis | JACC: Basic to Translational Science
  • 02/26 SARS-CoV-2 spike D614G change enhances replication and transmission | Nature

    March 2021

  • 03/01 Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2 | Vaccination | JAMA | JAMA Network
  • 03/01 COVID-19 -- exploring the implications of long-term condition type and extent of multimorbidity on years of life lost: a modelling study | Wellcome Open Research
  • 03/01 Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees | bioRxiv
  • 03/02 Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19 | Science Immunology
  • 03/02 High-Throughput Wastewater SARS-CoV-2 Detection Enables Forecasting of Community Infection Dynamics in San Diego County | mSystems
  • 03/02 Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization | bioRxiv
  • 03/02 ‘nAb’ the self-reactive activity in the COVID-19 combat | Signal Transduction and Targeted Therapy
  • 03/02 The prevalence of antibodies to SARS-CoV-2 among blood donors in China | Nature Communications
  • 03/02 Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics | Nature Medicine
  • 03/02 SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma | Nature Medicine
  • 03/02 Quantifying asymptomatic infection and transmission of COVID-19 in New York City using observed cases, serology, and testing capacity | PNAS
  • 03/02 The effects of school closures on SARS-CoV-2 among parents and teachers | PNAS
  • 03/02 The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2 | PNAS
  • 03/02 A genomic region associated with protection against severe COVID-19 is inherited from Neandertals | PNAS
  • 03/02 An interactive website tracking COVID-19 vaccine development - The Lancet Global Health
  • 03/03 Filtering Facepiece Respirator (N95 Respirator) Reprocessing: A Systematic Review | Infectious Diseases | JAMA | JAMA Network
  • 03/03 Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England | Science
  • 03/03 Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates | Science Translational Medicine
  • 03/03 SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines: Cell Host & Microbe
  • 03/03 Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant | medRxiv
  • 03/03 Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 | NEJM
  • 03/03 Multisystem inflammatory syndrome in a neonate, temporally associated with prenatal exposure to SARS-CoV-2: a case report - The Lancet Child & Adolescent Health
  • 03/04 Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening | Cardiology | JAMA Cardiology | JAMA Network
  • 03/04 SARS-CoV-2 on Ocular Surfaces in a Cohort of Patients With COVID-19 From the Lombardy Region, Italy | Infectious Diseases | JAMA Ophthalmology | JAMA Network
  • 03/04 Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial - The Lancet Respiratory Medicine
  • 03/04 Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Respiratory Medicine
  • 03/04 IL-6 blockade for COVID-19: a global scientific call to arms - The Lancet Respiratory Medicine
  • 03/05 An early warning approach to monitor COVID-19 activity with multiple digital traces in near real time | Science Advances
  • 03/05 Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution | Science Advances
  • 03/06 The impact of Spike mutations on SARS-CoV-2 neutralization: Cell Reports
  • 03/06 Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Naïve and Recovered Individuals Following mRNA Vaccination | medRxiv
  • 03/08 Acute Allergic Reactions to mRNA COVID-19 Vaccines | Allergy and Clinical Immunology | JAMA | JAMA Network
  • 03/08 Higher COVID-19 vaccination rates are linked to decreased county-level COVID-19 incidence across USA | medRxiv
  • 03/08 Long-term clinical, virological and immunological outcomes in patients hospitalized for COVID-19: antibody response predicts long COVID. | medRxiv
  • 03/08 Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2 | Nature Genetics
  • 03/08 Neutralizing Activity of BNT162b2-Elicited Serum | NEJM
  • 03/08 Clinical Characteristics, Activity Levels and Mental Health Problems in Children with Long COVID: A Survey of 510 Children[v1] | Preprints
  • 03/08 18Fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine - The Lancet
  • 03/08 Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis - The Lancet Global Health
  • 03/09 Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes | Science
  • 03/09 SARS-CoV-2 within-host diversity and transmission | Science
  • 03/09 The cytosolic DNA sensor cGAS recognizes neutrophil extracellular traps | Science Signaling
  • 03/09 Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission | Annals of Internal Medicine
  • 03/09 The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD | medRxiv
  • 03/09 Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein | Nature
  • 03/10 Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening | Clinical Infectious Diseases | Oxford Academic
  • 03/10 Effectiveness of three versus six feet of physical distancing for controlling spread of COVID-19 among primary and secondary students and staff: A retrospective, state-wide cohort study | Clinical Infectious Diseases | Oxford Academic
  • 03/10 Infodemics: Do healthcare professionals detect corona-related false news stories better than students? - PLOS
  • 03/10 Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization - PubMed
  • 03/10 Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study | The BMJ
  • 03/10 Virus vaccines: proteins prefer prolines: Cell Host & Microbe
  • 03/10 The great escape? SARS-CoV-2 variants evading neutralizing responses: Cell Host & Microbe
  • 03/10 Long-Haul Post–COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome: The Swedish Experience | JACC: Case Reports
  • 03/10 Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England | medRxiv
  • 03/10 Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial | medRxiv
  • 03/10 Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine | NEJM
  • 03/10 Children and young people remain at low risk of COVID-19 mortality - The Lancet Child & Adolescent Health
  • 03/10 Surveillance of SARS-CoV-2 in Zimbabwe shows dominance of variants of concern - The Lancet Microbe
  • 03/11 Transmission of SARS-CoV-2 from asymptomatic and presymptomatic individuals in healthcare settings despite medical masks and eye protection | Clinical Infectious Diseases | Oxford Academic
  • 03/11 What level of neutralising antibody protects from COVID-19? | medRxiv
  • 03/11 Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies | Nature
  • 03/12 Immunity to SARS-CoV-2 variants of concern | Science
  • 03/12 T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals | Science Translational Medicine
  • 03/12 Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite: Cell Host & Microbe
  • 03/12 Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity: Cell
  • 03/12 Are vaccines safe in patients with Long COVID? A prospective observational study. | medRxiv
  • 03/12 Perfect as the enemy of good: tracing transmissions with low-sensitivity tests to mitigate SARS-CoV-2 outbreaks - The Lancet Microbe
  • 03/12 Could a good night's sleep improve COVID-19 vaccine efficacy? - The Lancet Respiratory Medicine
  • 03/13 Probable airborne transmission of SARS-CoV-2 in a poorly ventilated restaurant - ScienceDirect
  • 03/15 Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients | Surgery | JAMA | JAMA Network
  • 03/15 Association of Clinical, Biological, and Brain Magnetic Resonance Imaging Findings With Electroencephalographic Findings for Patients With COVID-19 | Neurology | JAMA Network Open | JAMA Network
  • 03/15 SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19 | Science Translational Medicine
  • 03/15 The first 12 months of COVID-19: a timeline of immunological insights | Nature Reviews Immunology - Nature
  • 03/15 Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 | Nature
  • 03/15 Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans | Nature Machine Intelligence
  • 03/16 Structural impact on SARS-CoV-2 spike protein by D614G substitution | Science
  • 03/16 SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms: Cell
  • 03/16 N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2: Cell
  • 03/16 Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein: Cell
  • 03/16 Spread of a Variant SARS-CoV-2 in Long-Term Care Facilities in England | NEJM
  • 03/16 Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM
  • 03/16 Vaccinating the oldest against COVID-19 saves both the most lives and most years of life | PNAS
  • 03/16 SARS-CoV-2 infection and transmission in primary schools in England in June–December, 2020 (sKIDs): an active, prospective surveillance study - The Lancet Child & Adolescent Health
  • 03/16 Arthritis after SARS-CoV-2 infection - The Lancet Rheumatology
  • 03/17 SARS-CoV-2 Epidemiology on a Public University Campus in Washington State | medRxiv
  • 03/17 An integrated analysis of contact tracing and genomics to assess the efficacy of travel restrictions on SARS-CoV-2 introduction and transmission in England from June to September, 2020 | medRxiv
  • 03/17 Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities | medRxiv
  • 03/17 Factors associated with myocardial SARS-CoV-2 infection, myocarditis, and cardiac inflammation in patients with COVID-19 | Modern Pathology
  • 03/17 Shifting attention to accuracy can reduce misinformation online | Nature
  • 03/17 Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM
  • 03/17 Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study - The Lancet
  • 03/18 Myocarditis in naturally infected pets with the British variant of COVID-19 | bioRxiv
  • 03/18 Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England | The BMJ
  • 03/18 Antivirals with common targets against highly pathogenic viruses: Cell
  • 03/18 Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February - Eurosurveillance
  • 03/18 Early Release - Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 during Border Quarantine and Air Travel, New Zealand (Aotearoa) - Volume 27, Number 5—May 2021 - Emerging Infectious Diseases journal - CDC
  • 03/19 Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination | Infectious Diseases | JAMA | JAMA Network
  • 03/19 Combining initial chest CT with clinical variables in differentiating coronavirus disease 2019 (COVID-19) pneumonia from influenza pneumonia | Scientific Reports
  • 03/20 Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19 - PubMed
  • 03/20 Infection and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant: Cell Host & Microbe
  • 03/20 SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies: Cell
  • 03/20 Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study - The Lancet
  • 03/22 Association of Age With SARS-CoV-2 Antibody Response | Adolescent Medicine | JAMA Network Open | JAMA Network
  • 03/22 COVID-19 Survivors’ Reports of the Timing, Duration, and Health Impacts of Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection | medRxiv
  • 03/23 Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation | eLife
  • 03/23 Trends in Health Care Worker Intentions to Receive a COVID-19 Vaccine and Reasons for Hesitancy | Health Care Workforce | JAMA Network Open | JAMA Network
  • 03/23 Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers” - Graham - - Annals of Clinical and Translational Neurology - Wiley Online Library
  • 03/23 The impact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in Slovakia | Science
  • 03/23 Emergence of the E484K Mutation in SARS-CoV-2 Lineage B.1.1.220 in Upstate New York | medRxiv
  • 03/23 Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. | medRxiv
  • 03/23 SARS-CoV-2 Infection after Vaccination in Health Care Workers in California | NEJM
  • 03/23 BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers | NEJM
  • 03/23 Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine | NEJM
  • 03/23 Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center | NEJM
  • 03/23 Higher airborne pollen concentrations correlated with increased SARS-CoV-2 infection rates, as evidenced from 31 countries across the globe | PNAS
  • 03/23 Using artificial intelligence to improve COVID-19 rapid diagnostic test result interpretation | PNAS
  • 03/23 Impacts of introducing and lifting nonpharmaceutical interventions on COVID-19 daily growth rate and compliance in the United States | PNAS
  • 03/23 Rapid identification and tracking of SARS-CoV-2 variants of concern - The Lancet
  • 03/23 Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study - The Lancet Microbe
  • 03/24 B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies | bioRxiv
  • 03/24 Quadrivalent influenza nanoparticle vaccines induce broad protection | Nature
  • 03/24 New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications | NEJM
  • 03/24 Serologic Screening of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Cats and Dogs during First Coronavirus Disease Wave, the Netherlands - Volume 27, Number 5—May 2021 - Emerging Infectious Diseases journal - CDC
  • 03/25 Emergence of porcine delta-coronavirus pathogenic infections among children in Haiti through independent zoonoses and convergent evolution | medRxiv
  • 03/25 Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England | Nature
  • 03/25 SARS-CoV-2 infection of the oral cavity and saliva | Nature Medicine
  • 03/25 Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study - The Lancet Infectious Diseases
  • 03/26 Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient | medRxiv
  • 03/26 Dramatic drop of new SARS-CoV-2 infections among health care workers after the first dose of the BNT162b2 mRNA Covid-19 Vaccine | medRxiv
  • 03/26 First manifestation of adult-onset Still's disease after COVID-19 - The Lancet Rheumatology
  • 03/28 Emergence of a SARS-CoV-2 E484K variant of interest in Arizona | medRxiv
  • 03/29 SARS-CoV2 Nsp16 activation mechanism and a cryptic pocket with pan-coronavirus antiviral potential: Biophysical Journal
  • 03/29 Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR | medRxiv
  • 03/29 Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma | Nature
  • 03/29 The spatial landscape of lung pathology during COVID-19 progression | Nature
  • 03/29 Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine | Nature Medicine
  • 03/29 Early Release - Epidemiologic Evidence for Airborne Transmission of SARS-CoV-2 during Church Singing, Australia, 2020 - Volume 27, Number 6—June 2021 - Emerging Infectious Diseases journal - CDC
  • 03/30 Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States: Cell
  • 03/30 Antibody evasion by the P.1 strain of SARS-CoV-2: Cell
  • 03/30 mRNA vaccines take on immune tolerance | Nature Biotechnology
  • 03/30 Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial - The Lancet
  • 03/30 Pandemic moves and countermoves: vaccines and viral variants - The Lancet
  • 03/31 Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study | The BMJ
  • 03/31 Alterations in T and B cell function persist in convalescent COVID-19 patients: Med - Cell

    April 2021

  • 04/01 Quantitative Microbial Risk Assessment for Airborne Transmission of SARS-CoV-2 via Breathing, Speaking, Singing, Coughing, and Sneezing | Environmental Health Perspectives | Vol. 129, No. 4
  • 04/01 Computational epitope map of SARS-CoV-2 spike protein - PLOS
  • 04/01 Systems serology detects functionally distinct coronavirus antibody features in children and elderly | Nature Communications - Nature
  • 04/01 Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 | Nature Medicine
  • 04/01 Early Release - Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil - Volume 27, Number 5—May 2021 - Emerging Infectious Diseases journal - CDC
  • 04/02 X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease | Science
  • 04/02 Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants | medRxiv
  • 04/03 Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States - ScienceDirect
  • 04/05 Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses: Immunity
  • 04/05 SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission | medRxiv
  • 04/06 Trends in Geographic and Temporal Distribution of US Children With Multisystem Inflammatory Syndrome During the COVID-19 Pandemic | Pediatrics | JAMA Pediatrics | JAMA Network
  • 04/06 Administration of a Second Dose of the Moderna COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports | Annals of Internal Medicine
  • 04/06 Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19 | Nature Reviews Immunology
  • 04/06 Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization | NEJM
  • 04/06 Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 | NEJM
  • 04/06 Overdispersion in COVID-19 increases the effectiveness of limiting nonrepetitive contacts for transmission control | PNAS
  • 04/06 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records - The Lancet Psychiatry
  • 04/07 Reactive Infectious Mucocutaneous Eruption Associated With SARS-CoV-2 Infection | Dermatology | JAMA Dermatology | JAMA Network
  • 04/07 Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study | medRxiv
  • 04/07 Drugs that inhibit TMEM16 proteins block SARS-CoV-2 Spike-induced syncytia | Nature
  • 04/07 Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 | NEJM
  • 04/07 Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351) | NEJM
  • 04/07 SARS-CoV-2 spike E484K mutation reduces antibody neutralisation - ScienceDirect
  • 04/07 Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study - The Lancet Microbe
  • 04/08 Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset: Med
  • 04/09 Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals | medRxiv
  • 04/09 Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination | NEJM
  • 04/09 Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination | NEJM
  • 04/09 SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) - ScienceDirect
  • 04/09 Correlates of protection from SARS-CoV-2 infection - The Lancet
  • 04/09 Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial - The Lancet Respiratory Medicine
  • 04/12 Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV | Nature
  • 04/12 Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study - The Lancet Infectious Diseases
  • 04/12 Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes - The Lancet Infectious Diseases
  • 04/12 Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study - The Lancet Public Health
  • 04/12 Epidemiology of Confirmed COVID-19 Deaths in Adults, England, March–December 2020 - Volume 27, Number 5—May 2021 - Emerging Infectious Diseases journal - CDC
  • 04/13 T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study by Adrienn Angyal, Stephanie Longet, Shona Moore, Rebecca P. P
  • 04/13 Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children: Immunity
  • 04/13 Is IL-6 a key cytokine target for therapy in COVID-19? | Nature Reviews Immunology
  • 04/13 Ranking the risk of animal-to-human spillover for newly discovered viruses | PNAS
  • 04/13 Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2 - The Lancet Microbe
  • 04/13 Suicide trends in the early months of the COVID-19 pandemic: an interrupted time-series analysis of preliminary data from 21 countries - The Lancet Psychiatry
  • 04/13 Introduction of ORF3a-Q57H SARS-CoV-2 Variant Causing Fourth Epidemic Wave of COVID-19, Hong Kong, China - Volume 27, Number 5—May 2021 - Emerging Infectious Diseases journal - CDC
  • 04/14 Spatiotemporal pattern of COVID-19 spread in Brazil | Science
  • 04/14 Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil | Science
  • 04/14 SARS-CoV-2 Antibody Response in Persons with Past Natural Infection | NEJM
  • 04/14 Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination | NEJM
  • 04/14 Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination - The Lancet
  • 04/14 Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination - The Lancet
  • 04/14 Longevity of Middle East Respiratory Syndrome Coronavirus Antibody Responses in Humans, Saudi Arabia - Volume 27, Number 5—May 2021 - Emerging Infectious Diseases journal - CDC
  • 04/15 COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital | Brain | Oxford Academic
  • 04/15 Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination | Science Immunology
  • 04/15 A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection: Cell Host & Microbe
  • 04/15 Ten scientific reasons in support of airborne transmission of SARS-CoV-2 - The Lancet
  • 04/15 SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study - The Lancet Respiratory Medicine
  • 04/16 The SARS-CoV-2 Spike variant D614G favors an open conformational state | Science Advances
  • 04/16 # AstraZeneca vaccine disinformation on Twitter | medRxiv
  • 04/16 Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer | NEJM
  • 04/16 SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia | NEJM
  • 04/16 Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination | NEJM
  • 04/17 BNT162b2 Vaccination Effectively Prevents the Rapid Rise of SARS-CoV-2 Variant B.1.1.7 in high risk populations in Israel: Cell Reports Medicine
  • 04/19 A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given i
  • 04/19 A systematic review and meta-analysis of psychological interventions to improve mental wellbeing | Nature Human Behaviour
  • 04/19 Statistical mechanics meets single-cell biology | Nature Reviews Genetics
  • 04/19 COVID-19 dynamics after a national immunization program in Israel | Nature Medicine
  • 04/19 Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma - The Lancet Haematology
  • 04/20 How accurately can we assess zoonotic risk? - PLOS
  • 04/20 Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World - PLoS
  • 04/20 SARS-CoV-2 Reinfection in a Liver Transplant Recipient | Annals of Internal Medicine
  • 04/20 Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.: Cell Reports Medicine
  • 04/20 Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant: Cell
  • 04/20 Single-cell multi-omics analysis of the immune response in COVID-19 | Nature Medicine
  • 04/20 Suicide in England in the COVID-19 pandemic: Early observational data from real time surveillance - The Lancet Regional Health – Europe
  • 04/21 Delayed Large Local Reactions to mRNA Vaccines | NEJM
  • 04/21 Vaccine Breakthrough Infections with SARS-CoV-2 Variants | NEJM
  • 04/22 SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity | Science Advances
  • 04/22 Detection of SARS‐CoV‐2 in respiratory samples from cats in the UK associated with human‐to‐cat transmission - Hosie - 2021 - Veterinary Record - Wiley Online Library
  • 04/22 SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason | Infectious Diseases | JAMA Internal Medicine
  • 04/22 Acute Ischemic Stroke During the Convalescent Phase of Asymptomatic COVID-2019 Infection in Men | Cerebrovascular Disease | JAMA Network Open | JAMA Network
  • 04/22 Rapid induction of antigen-specific CD4+ T cells guides coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination | bioRxiv
  • 04/22 High-dimensional characterization of post-acute sequalae of COVID-19 | Nature
  • 04/23 Resurgence of SARS-CoV-2: detection by community viral surveillance | Science
  • 04/23 Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees | bioRxiv
  • 04/23 B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV: Cell
  • 04/23 Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study - The Lancet
  • 04/23 Hospital admissions due to COVID-19 in Scotland after one dose of vaccine - The Lancet
  • 04/23 COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study - The Lancet
  • 04/24 Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel | medRxiv
  • 04/26 The SARS-CoV-2 RNA interactome: Molecular Cell
  • 04/27 Interrupting vaccination policies can greatly spread SARS-CoV-2 and enhance mortality from COVID-19 disease: The AstraZeneca case for France and Italy: Chaos: An Interdisciplinary Journal of Nonlinear Science: Vol 31, No 4
  • 04/27 Socioeconomic status determines COVID-19 incidence and related mortality in Santiago, Chile | Science
  • 04/27 Performance Evaluation of Serial SARS-CoV-2 Rapid Antigen Testing During a Nursing Home Outbreak | Annals of Internal Medicine
  • 04/27 Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms: Cell Reports Medicine
  • 04/27 Single‐cell analyses reveal SARS‐CoV‐2 interference with intrinsic immune response in the human gut | Molecular Systems Biology
  • 04/27 A guideline to limit indoor airborne transmission of COVID-19 | PNAS
  • 04/27 COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year - The Lancet Haematology
  • 04/27 Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study - The Lancet Infectious Diseases
  • 04/27 Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study - The Lancet Oncology
  • 04/28 Dynamic changes and prevalence of SARS-CoV-2 IgG/IgM antibodies: Analysis of multiple factors - International Journal of Infectious Diseases
  • 04/28 Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study - The Lancet Diabetes & Endocrinology
  • 04/29 Complications of COVID-19 Nasopharyngeal Swab Test | Coronavirus (COVID-19) | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
  • 04/29 Household COVID-19 risk and in-person schooling | Science
  • 04/29 Previously infected vaccinees broadly neutralize SARS-CoV-2 variants | medRxiv
  • 04/29 A molecular single-cell lung atlas of lethal COVID-19 | Nature
  • 04/29 COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets | Nature
  • 04/30 US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 | Coagulation Disorders | JAMA | JAMA Network
  • 04/30 COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program - Kentucky, March 2021 - PubMed
  • 04/30 Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose | Science
  • 04/30 Estimating the early impact of immunization against COVID-19 on deaths among elderly people in Brazil: analyses of secondary data on vaccine coverage and mortality | medRxiv

    May 2021

  • 05/01 Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet
  • 05/03 Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State | Science Translational Medicine
  • 05/03 COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters | Science Translational Medicine
  • 05/03 A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics | Nature Biomedical Engineering
  • 05/04 evolutionary portrait of the progenitor SARS-CoV-2 and its dominant offshoots in COVID-19 pandemic | Molecular Biology and Evolution | Oxford Academic
  • 05/04 Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes | Science
  • 05/04 Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-symptom onset: Cell Reports Medicine
  • 05/04 Testing at scale during the COVID-19 pandemic | Nature Reviews Genetics
  • 05/04 SARS-CoV-2 related Paediatric Acute-onset Neuropsychiatric Syndrome - The Lancet Child & Adolescent Health
  • 05/05 SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant | bioRxiv
  • 05/05 Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study | The BMJ
  • 05/05 Delayed production of neutralizing antibodies correlates with fatal COVID-19 | Nature Medicine
  • 05/05 Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants | NEJM
  • 05/05 Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant | NEJM
  • 05/05 Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data - The Lancet
  • 05/06 Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers | Health Care Workforce | JAMA | JAMA Network
  • 05/06 Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce | Infectious Diseases | JAMA | JAMA Network
  • 05/06 Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets: Immunity
  • 05/06 Aerosol generating procedures: are they of relevance for transmission of SARS-CoV-2? - The Lancet Respiratory Medicine
  • 05/06 The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity - The Lancet Respiratory Medicine
  • 05/07 Rapid antigen testing in COVID-19 responses | Science
  • 05/07 Vaccination boosts naturally enhanced neutralizing breadth to SARS-CoV-2 one year after infection | bioRxiv
  • 05/07 Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination | medRxiv
  • 05/07 TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines | Nature Immunology
  • 05/07 Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study - The Lancet Rheumatology
  • 05/08 Association Between Myocarditis and Mortality in SARS-CoV-2 Patients in a Large Registry by Frank Annie, Haytham Alkhaimy, Aravinda Nanjundappa, Ahmad Elashery :: SSRN
  • 05/08 Prospective Case-Control Study of Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers - ScienceDirect
  • 05/10 Real-World Effectiveness of Ad26.COV2.S Adenoviral Vector Vaccine for COVID-19 by Juan Corchado-Garcia, David Puyraimond-Zemmour‬, Travis Hughes, Tudor Cristea-Platon, Patrick Lenehan, Colin Pawlowski, Sairam Bade, John C. O'Horo, Gregory J. Gores, Amy W.
  • 05/10 A global database of COVID-19 vaccinations | Nature Human Behaviour
  • 05/10 Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses | Nature
  • 05/11 Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19—A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium | Neurology | JAMA Network Open | JAMA Network
  • 05/11 Towards psychological herd immunity: Cross-cultural evidence for two prebunking interventions against COVID-19 misinformation - Melisa Basol, Jon Roozenbeek, Manon Berriche, Fatih Uenal, William P. McClanahan, Sander van der Linden, 2021
  • 05/11 Catch me if you can: Superspreading of SARS-CoV-2: Trends in Microbiology
  • 05/11 JCI - A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19 - JCI
  • 05/11 Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases | medRxiv
  • 05/11 SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes | Nature Communications
  • 05/11 Reversed-engineered human alveolar lung-on-a-chip model | PNAS
  • 05/11 Automated, multiparametric monitoring of respiratory biomarkers and vital signs in clinical and home settings for COVID-19 patients | PNAS
  • 05/11 Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK - The Lancet Diabetes & Endocrinology
  • 05/12 Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series | Dermatology | JAMA Dermatology | JAMA Network
  • 05/12 mRNA vaccine-induced SARS-CoV-2-specific T cells recognize B.1.1.7 and B.1.351 variants but differ in longevity and homing properties depending on prior infection status | bioRxiv
  • 05/12 The epidemiological impact of the NHS COVID-19 App | Nature
  • 05/12 Structural basis for broad coronavirus neutralization | Nature Structural & Molecular Biology
  • 05/12 BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants | NEJM
  • 05/12 A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine - ScienceDirect
  • 05/12 Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial – Authors' reply - The Lancet
  • 05/12 Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial - The Lancet
  • 05/12 Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data - The Lancet
  • 05/13 Infections, Hospitalizations, and Deaths Averted Via Direct Effects of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Vaccination Campaign, Israel by Eric J. Haas, John M. McLaughlin, Farid Khan, Frederick J. Angulo, Emilia Anis, Marc
  • 05/13 Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome | Science
  • 05/14 Archival influenza virus genomes from Europe reveal genomic and phenotypic variability during the 1918 pandemic | bioRxiv
  • 05/14 Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19: Cell Host & Microbe
  • 05/14 Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial - The Lancet
  • 05/15 Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease | NEJM
  • 05/16 Identification of SARS-CoV-2 P.1-related lineages in Brazil provides new insights about the mechanisms of emergence of Variants of Concern - nCoV-2019 Genomic Epidemiology - Virological
  • 05/16 Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants | bioRxiv
  • 05/16 The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies | bioRxiv
  • 05/16 Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease.: Immunity
  • 05/17 High Seroprevalence of SARS-CoV-2 Eight Months After Introduction in Nairobi, Kenya by Isaac A. Ngere, Jeanette Dawa, Elizabeth Hunsperger, Nancy Otieno, Moses Masika, Patrick Amoth, Lyndah Makayotto, Carolyne Nasimiyu, Bronwyn Mei Gunn, Bryan Nyawanda, O
  • 05/17 Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection | Nature Medicine
  • 05/17 Genome-wide bioinformatic analyses predict key host and viral factors in SARS-CoV-2 pathogenesis | Communications Biology
  • 05/18 Fast SARS-CoV-2 virus detection using disposable cartridge strips and a semiconductor-based biosensor platform: Journal of Vacuum Science & Technology B: Vol 39, No 3
  • 05/18 Seropositivity in blood donors and pregnant women during the first year of SARS‐CoV‐2 transmission in Stockholm, Sweden - Castro Dopico - - Journal of Internal Medicine - Wiley Online Library
  • 05/18 Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2 | Science
  • 05/18 SARS-CoV-2 infects human pancreatic β-cells and elicits β-cell impairment: Cell Metabolism
  • 05/18 SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T cell recognition: Cell Reports Medicine
  • 05/19 Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 Infection | Infectious Diseases | JAMA Network Open | JAMA Network
  • 05/19 Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study | The BMJ
  • 05/19 Diverse Functional Autoantibodies in Patients with COVID-19 | Nature
  • 05/19 Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents | NEJM
  • 05/19 SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity - The Lancet Infectious Diseases
  • 05/20 Novel Canine Coronavirus Isolated from a Hospitalized Pneumonia Patient, East Malaysia | Clinical Infectious Diseases | Oxford Academic
  • 05/20 Preliminary Analysis of Association Between COVID-19 Vaccination and Sudden Hearing Loss Using US Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System Data | Vaccination | JAMA Otolaryngology–Head & Neck Surgery | JAMA Networ
  • 05/20 Dispersal dynamics of SARS-CoV-2 lineages during the first epidemic wave in New York City - PLOS
  • 05/20 Face masks effectively limit the probability of SARS-CoV-2 transmission | Science
  • 05/20 Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants | Science
  • 05/21 Nonreplicable publications are cited more than replicable ones | Science Advances
  • 05/21 SARS-CoV-2 Human T cell Epitopes: adaptive immune response against COVID-19.: Cell Host & Microbe
  • 05/21 SARS-CoV-2 infection of BNT162b2(mRNA)-vaccinated individuals is not restricted to variants of concern or high-risk exposure environments | medRxiv
  • 05/21 Single-dose SARS-CoV-2 vaccine in a prospective cohort of COVID-19 patients | medRxiv
  • 05/22 Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study - The Lancet
  • 05/24 Public Trust and Willingness to Vaccinate Against COVID-19 in the US From October 14, 2020, to March 29, 2021 | Infectious Diseases | JAMA | JAMA Network
  • 05/24 An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies: Cell
  • 05/24 Effectiveness of COVID-19 vaccines against the B.1.617.2 variant | medRxiv
  • 05/24 Rapid single-molecule detection of COVID-19 and MERS antigens via nanobody-functionalized organic electrochemical transistors | Nature Biomedical Engineering
  • 05/24 SARS-CoV-2 simulations go exascale to predict dramatic spike opening and cryptic pockets across the proteome | Nature Chemistry
  • 05/24 SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans | Nature
  • 05/24 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study - The Lancet Child & Adolescent Health
  • 05/25 Complement control for COVID-19 | Science Immunology
  • 05/25 SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees | Science Immunology
  • 05/25 Association Between Bitter Taste Receptor Phenotype and Clinical Outcomes Among Patients With COVID-19 | Infectious Diseases | JAMA Network Open | JAMA Network
  • 05/25 Estimating infectiousness throughout SARS-CoV-2 infection course | Science
  • 05/25 Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series | Annals of Internal Medicine
  • 05/25 Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series | Annals of Internal Medicine
  • 05/25 Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State | medRxiv
  • 05/25 Impacts of social distancing policies on mobility and COVID-19 case growth in the US | Nature Communications
  • 05/25 Immune response to SARS-CoV-2 variants of concern in vaccinated individuals | Nature Communications
  • 05/25 COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence | Nature Medicine
  • 05/25 Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection | Nature Metabolism
  • 05/25 Just 2% of SARS-CoV-2−positive individuals carry 90% of the virus circulating in communities | PNAS
  • 05/25 Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues | PNAS
  • 05/26 Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses | Science Advances
  • 05/26 Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review | Infectious Diseases | JAMA Network Open | JAMA Network
  • 05/26 Mask Use in Community Settings in the Context of COVID-19: A Systematic Review of Ecological Data by Nathan Ford, Haley K. Holmer, Roger Chou, Paul Villeneuve, April Baller, Maria Van Kerkhove, Benedetta Allegranzi :: SSRN
  • 05/26 Social media use in China before and during COVID-19: Preliminary results from an online retrospective survey - PubMed
  • 05/26 Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals | bioRxiv
  • 05/26 Emergence of a new SARS-CoV-2 variant from GR clade with a novel S glycoprotein mutation V1230L in West Bengal, India | medRxiv
  • 05/26 Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2 | Nature Medicine
  • 05/26 “Vaccine-Induced Covid-19 Mimicry” Syndrome:Splice reactions within the SARS-CoV-2 Spike open reading frame result in Spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines | Research Square
  • 05/27 Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry | Cardiology | JAMA Cardiology | JAMA Network
  • 05/27 Broad auto-reactive IgM responses are common in critically ill patients, including those with COVID-19: Cell Reports Medicine
  • 05/27 BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans | Nature
  • 05/27 SARS-CoV-2 variants of concern are emerging in India | Nature Medicine
  • 05/27 Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents | NEJM
  • 05/27 Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial - The Lancet Infectious Diseases
  • 05/27 Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac - The Lancet Infectious Diseases
  • 05/28 Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy | Infectious Diseases | JAMA Internal Medicine | JAMA Network
  • 05/28 Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer | Oncology | JAMA Oncology | JAMA Network
  • 05/29 Inferring SARS-CoV-2 variant within-host kinetics | medRxiv
  • 05/29 The indirect effect of mRNA-based Covid-19 vaccination on unvaccinated household members | medRxiv
  • 05/29 Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection | Nature Reviews Immunology
  • 05/30 Small Airways Disease is a Post-Acute Sequelae of SARS-CoV-2 Infection | medRxiv
  • 05/31 After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases | Nature Medicine
  • 05/31 AI for radiographic COVID-19 detection selects shortcuts over signal | Nature Machine Intelligence

    June 2021

  • 06/01 Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study - PLOS
  • 06/01 Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination | American Academy of Pediatrics
  • 06/01 SARS-CoV-2 cell-to-cell spread occurs rapidly and is insensitive to antibody neutralization | bioRxiv
  • 06/01 SARS-CoV-2 variants, spike mutations and immune escape | Nature Reviews Microbiology
  • 06/02 Proof of concept for real-time detection of SARS CoV-2 infection with an electronic nose - PLOS
  • 06/02 A global analysis of the impact of COVID-19 stay-at-home restrictions on crime | Nature Human Behaviour
  • 06/02 Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study | NEJM
  • 06/02 Can the USA return to pre-COVID-19 normal by July 4? - The Lancet Infectious Diseases
  • 06/03 Estimating epidemiologic dynamics from cross-sectional viral load distributions | Science
  • 06/03 Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants | Nature
  • 06/03 Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination - The Lancet
  • 06/04 A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T-cell responses: Cell Host & Microbe
  • 06/05 Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152 | bioRxiv
  • 06/05 The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies: Cell
  • 06/06 Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant | bioRxiv
  • 06/07 Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection | Cellular & Molecular Immunology
  • 06/07 SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care | Nature Communications
  • 06/07 Spread of a SARS-CoV-2 variant through Europe in the summer of 2020 | Nature
  • 06/08 Senolytics reduce coronavirus-related mortality in old mice | Science
  • 06/08 SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD and S2: Cell
  • 06/08 Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species: Immunity
  • 06/08 Structural basis for SARS-CoV-2 envelope protein recognition of human cell junction protein PALS1 | Nature Communications
  • 06/08 Collectivism predicts mask use during COVID-19 | PNAS
  • 06/08 Analyzing the vast coronavirus literature with CoronaCentral | PNAS
  • 06/08 Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis - The Lancet Rheumatology
  • 06/09 Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar | Global Health | JAMA | JAMA Network
  • 06/09 SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse | Nature Microbiology
  • 06/09 Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans | Nature
  • 06/09 First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland | Nature Medicine
  • 06/09 Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom | Nature Medicine
  • 06/09 Delayed Large Local Reactions to mRNA Covid-19 Vaccines in Blacks, Indigenous Persons, and People of Color | NEJM
  • 06/09 Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia | NEJM
  • 06/10 BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants | Nature
  • 06/10 Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals | Nature Medicine
  • 06/11 Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help: Cell Reports
  • 06/11 Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum: Cell
  • 06/11 In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies: Cell
  • 06/11 Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study | medRxiv
  • 06/14 Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant - Public library - PHE national - Knowledge Hub
  • 06/14 Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection | Nature
  • 06/14 Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals | Nature Medicine
  • 06/15 Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19 | Science Translational Medicine
  • 06/15 Predicted domination of variant Delta of SARS-CoV-2 before Tokyo Olympic games, Japan | medRxiv
  • 06/15 Divergent trajectories of antiviral memory after SARS-Cov-2 infection | Research Square
  • 06/16 Antibody and B cell responses to SARS-CoV-2 infection and vaccination: Cell Host & Microbe
  • 06/16 Reconstruction of a large-scale outbreak of SARS-CoV-2 infection in Iceland informs vaccination strategies | medRxiv
  • 06/16 Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial | medRxiv
  • 06/16 Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics | NEJM
  • 06/16 Treatment of Multisystem Inflammatory Syndrome in Children | NEJM
  • 06/17 Will we ever wash our hands of lubrication theory?: Physics of Fluids: Vol 33, No 8
  • 06/17 Sperm Parameters Before and After COVID-19 mRNA Vaccination | Urology | JAMA | JAMA Network
  • 06/17 SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion | bioRxiv
  • 06/17 Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19 | Nature Nanotechnology
  • 06/17 Causation or confounding: why controls are critical for characterizing long COVID | Nature Medicine
  • 06/17 Spike D614G — A Candidate Vaccine Antigen Against Covid-19 | NEJM
  • 06/18 Alarming COVID study indicates long-term loss of gray matter and other brain tissue - Medical News
  • 06/20 Rapid spread of the SARS-CoV-2 δ variant in the area of Paris (France) in June 2021 | medRxiv
  • 06/21 Assessing the Association Between Social Gatherings and COVID-19 Risk Using Birthdays | Public Health | JAMA Internal Medicine | JAMA Network
  • 06/21 In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains - PubMed
  • 06/22 Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients | Science Immunology
  • 06/22 COVID-19 vaccine side effects: The positives about feeling bad | Science Immunology
  • 06/22 Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice | Science
  • 06/22 The total number and mass of SARS-CoV-2 virions | PNAS
  • 06/22 SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough | Research Square
  • 06/22 Remote home monitoring (virtual wards) for confirmed or suspected COVID-19 patients: a rapid systematic review - EClinicalMedicine
  • 06/22 Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study - The Lancet Infectious Diseases
  • 06/22 Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study - The Lancet Infectious Diseases
  • 06/22 SARS-CoV-2 variants and considerations of inferring causality on disease severity - The Lancet Infectious Diseases
  • 06/23 Effect of Vaccination on Household Transmission of SARS-CoV-2 in England - PubMed
  • 06/23 Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses | ACS Nano
  • 06/23 Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity | Science
  • 06/23 Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants | Science
  • 06/23 Increased lung cell entry of B.1.617.2 and evasion of antibodies induced by infection and BNT162b2 vaccination | bioRxiv
  • 06/23 Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques | Nature
  • 06/23 Long COVID in a prospective cohort of home-isolated patients | Nature Medicine
  • 06/23 Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients | Scientific Reports
  • 06/23 Effect of Vaccination on Household Transmission of SARS-CoV-2 in England | NEJM
  • 06/23 Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients | NEJM
  • 06/23 Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study - The Lancet Infectious Diseases
  • 06/23 Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study - The Lancet Infectious Diseases
  • 06/23 Invasive mould disease in fatal COVID-19: a systematic review of autopsies - The Lancet Microbe
  • 06/24 Clinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis | Infectious Diseases | JAMA Network Open | JAMA Network
  • 06/25 Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test | Science Advances
  • 06/25 Pfizer-BioNTech Vaccine Effectiveness Against SARS-CoV-2 Infection: Findings From a Large Observational Study in Israel by Yaki Saciuk, Jennifer Kertes, Micha Mandel, Beatriz Hemo, Naama Shamir Stein, Anat Ekka Zohar :: SSRN
  • 06/25 Hybrid immunity | Science
  • 06/25 Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet
  • 06/25 Heterologous vaccine regimens against COVID-19 - The Lancet
  • 06/28 Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination | medRxiv
  • 06/28 SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses | Nature
  • 06/28 Wearable materials with embedded synthetic biology sensors for biomolecule detection | Nature Biotechnology
  • 06/28 AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC - The Lancet
  • 06/28 Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
  • 06/28 The SARS-CoV-2 B.1.1.7 variant and increased clinical severity—the jury is out - The Lancet Infectious Diseases
  • 06/28 COVID-19 vaccines for children younger than 12 years: are we ready? - The Lancet Infectious Diseases
  • 06/29 Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military | Cardiology | JAMA Cardiology | JAMA Network
  • 06/29 Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination | Cardiology | JAMA Cardiology | JAMA Network
  • 06/29 Thrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine | Annals of Internal Medicine
  • 06/29 Thrombosis After Vaccination With Messenger RNA–1273: Is This Vaccine-Induced Thrombosis and Thrombocytopenia or Thrombosis With Thrombocytopenia Syndrome? | Annals of Internal Medicine
  • 06/29 Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses: Cell
  • 06/29 Lessons from a local effort to screen for SARS-CoV-2 | PNAS
  • 06/30 Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants | Science
  • 06/30 SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern | Science
  • 06/30 Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 | Nature
  • 06/30 Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines | NEJM
  • 06/30 Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine | NEJM
  • 06/30 Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection - Science

    July 2021

  • 07/01 Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals: Cell Reports Medicine
  • 07/01 Cerebral Venous Thrombosis | NEJM
  • 07/02 Neutralization of Delta variant with sera of Covishield vaccinees and COVID-19 recovered vaccinated individuals | bioRxiv
  • 07/02 Temporal Maturation of Neutralizing Antibodies in COVID-19 Convalescent Individuals Improves Potency and Breadth to Circulating SARS-CoV-2 Variants: Immunity
  • 07/02 Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial | medRxiv
  • 07/03 The Emergence of SARS-CoV-2 Variant Lambda (C.37) in South America | medRxiv
  • 07/03 Prominent Spatiotemporal Waves of COVID-19 Incidence in the United States: Implications for Causality, Forecasting, and Control | medRxiv
  • 07/05 Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory | medRxiv
  • 07/05 Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality | Nature Medicine
  • 07/06 Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection | Open Forum Infectious Diseases | Oxford Academic
  • 07/06 Seroprevalence of and Risk Factors Associated With SARS-CoV-2 Infection in Health Care Workers During the Early COVID-19 Pandemic in Italy | Infectious Diseases | JAMA Network Open | JAMA Network
  • 07/06 Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-19 in an Outpatient Setting | Annals of Internal Medicine
  • 07/06 A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation: Cell
  • 07/07 Assessment of Prolonged Physiological and Behavioral Changes Associated With COVID-19 Infection | Infectious Diseases | JAMA Network Open | JAMA Network
  • 07/07 Long-Term Persistence of SARS-CoV-2 Neutralizing Antibody Responses After Infection and Estimates of the Duration of Protection by Eric H.Y. Lau, David S. C. Hui, Owen Tak-Yin Tsang, Wai-Hung Chan, Mike YE Kwan, Susan S. Chiu, Samuel MS Cheng, Ronald LW Ko, John KC Li, Sara Chaothai, Chi H. Tsang, Leo LM Poon, J.S. Malik Peiris :: SSRN
  • 07/07 Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States | Science Translational Medicine
  • 07/07 Viral infection and transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2 variant - SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology - Virological
  • 07/07 Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada, from December to July, 2021 | medRxiv
  • 07/07 Antibody epitopes in vaccine-induced immune thrombotic thrombocytopenia | Nature
  • 07/07 Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants | NEJM
  • 07/07 Breakthrough SARS-CoV-2 Infections in Prison after Vaccination | NEJM
  • 07/07 Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia | NEJM
  • 07/07 Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile | NEJM
  • 07/07 The Origins of SARS-CoV-2: A Critical Review | Zenodo
  • 07/08 Corneal confocal microscopy identifies corneal nerve fibre loss and increased dendritic cells in patients with long COVID | British Journal of Ophthalmology
  • 07/08 SARS-CoV-2 targets MAVS for immune evasion | Nature Cell Biology
  • 07/08 Mapping the human genetic architecture of COVID-19 | Nature
  • 07/08 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization | Nature
  • 07/08 After the pandemic: perspectives on the future trajectory of COVID-19 | Nature
  • 07/09 mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar | Nature Medicine
  • 07/10 SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET: Cell Chemical Biology
  • 07/12 Comparison of the Immunogenicity of BNT162b2 and CoronaVac COVID-19 Vaccines in Hong Kong: An Observational Cohort Study by Chris Ka Pun Mok, Carolyn A. Cohen, Samuel M.S. Cheng, Chunke Chen, Kin-On Kwok, Karen Yiu, Tat-On Chan, Maireid Bull, Kwun Cheung Ling, Zixi Dai, Susanna S. Ng, Grace C.Y. Lui, Chao Wu, Gaya K. Amarasinghe, Daisy W. Leung, Samuel Yeung Shan Wong, Sophie A. Valkenburg, J.S. Malik Peiris, David S. C. Hui :: SSRN
  • 07/12 Systems vaccinology of the BNT162b2 mRNA vaccine in humans | Nature
  • 07/13 Antibody response after second BNT162b2 dose in allogeneic HSCT recipients - The Lancet
  • 07/14 SnapShot: SARS-CoV-2 antibodies: Cell Host & Microbe
  • 07/14 SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape | Nature
  • 07/14 Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination | Nature Medicine
  • 07/14 Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination | NEJM
  • 07/14 Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination | NEJM
  • 07/14 Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 | NEJM
  • 07/14 Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study - The Lancet Child & Adolescent Health
  • 07/15 Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 - The Lancet
  • 07/15 Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19 - The Lancet Microbe
  • 07/17 Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study - The Lancet
  • 07/18 Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity in uninfected and previously infected individuals | medRxiv
  • 07/19 Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants | bioRxiv
  • 07/19 Cardiomyocytes Recruit Monocytes upon SARS-CoV-2 Infection by Secreting CCL2: Stem Cell Reports
  • 07/19 SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’ | Nature Communications
  • 07/19 Broad sarbecovirus neutralization by a human monoclonal antibody | Nature
  • 07/20 Post-Vaccination Symptomatic SARS-CoV-2 Infections are Minimal and Non-Serious: An Observational Multicenter Indian Cohort Study of 28342 Healthcare Workers by Raju Vaishya, Anupam Sibal, Arpita Malani, Sujoy Kar, Hari Prasad K., Kiran SV, Sangita Reddy,
  • 07/20 Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2 | Science
  • 07/20 SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting | Annals of Internal Medicine
  • 07/20 Screening for SARS-CoV-2 Antigen Before a Live Indoor Music Concert: An Observational Study | Annals of Internal Medicine
  • 07/20 Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells: Cell Reports Medicine
  • 07/20 Transparent communication about negative features of COVID-19 vaccines decreases acceptance but increases trust | PNAS
  • 07/20 Ongoing global and regional adaptive evolution of SARS-CoV-2 | PNAS
  • 07/21 Household Transmission of SARS-CoV-2 from Children and Adolescents | NEJM
  • 07/21 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant | NEJM
  • 07/21 Operation Nasal Vaccine—Lightning speed to counter COVID-19 | Science Immunology
  • 07/22 Longitudinal assessment of COVID-19 vaccine acceptance and uptake among frontline medical workers in Los Angeles, California | Clinical Infectious Diseases | Oxford Academic
  • 07/22 Optimizing testing for COVID-19 in India - PLOS
  • 07/22 Safety and Cross-Variant Immunogenicity of a Three-Dose COVID-19 mRNA Vaccine Regimen in Kidney Transplant Recipients by Filippo Massa, Marion Cremoni, Alexandre Gerard, Hanen Grabsi, Lory Rogier, Mathilde Blois, Nadia Ben Hassen, Matthieu Rouleau, Susana
  • 07/22 The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies - PubMed
  • 07/22 Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas | medRxiv
  • 07/22 Covid-19 Vaccine Acceptance in California State Prisons | NEJM
  • 07/22 Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines | NEJM
  • 07/22 Evidence for antibody as a protective correlate for COVID-19 vaccines - ScienceDirect
  • 07/23 Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses | Nephrology | JAMA | JAMA Network
  • 07/23 SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS, California, USA - Volume 27, Number 10—October 2021 - Emerging Infectious Diseases journal - CDC
  • 07/26 Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose | Vaccination | JAMA Internal Medicine | JAMA Network
  • 07/26 Long covid—mechanisms, risk factors, and management | The BMJ
  • 07/26 Emergence of an early SARS-CoV-2 epidemic in the United States: Cell
  • 07/26 Protection afforded by the BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without prior infection | medRxiv
  • 07/26 Mucosal vaccines — fortifying the frontiers | Nature Reviews Immunology
  • 07/26 A ‘mix and match’ approach to SARS-CoV-2 vaccination | Nature Medicine
  • 07/26 Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination | Nature Medicine
  • 07/26 Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines | Research Square
  • 07/27 Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques | mBio
  • 07/27 Minute-scale detection of SARS-CoV-2 using a low-cost biosensor composed of pencil graphite electrodes | PNAS
  • 07/27 Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis - The Lancet
  • 07/28 Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant dependent manner | medRxiv
  • 07/28 Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine | medRxiv
  • 07/28 Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine | medRxiv
  • 07/28 Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine | Nature
  • 07/29 Presumed SARS-CoV-2 Viral Particles in the Human Retina of Patients With COVID-19 | Ophthalmology | JAMA Ophthalmology | JAMA Network
  • 07/29 Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates | Science
  • 07/29 SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection | Nature Communications
  • 07/29 Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study - The Lancet
  • 07/30 Post-viral effects of COVID-19 in the olfactory system and their implications - The Lancet Neurology
  • 07/30 The mechanisms of smell loss after SARS-CoV-2 infection - The Lancet Neurology
  • 07/31 Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study | medRxiv

    August 2021

  • 08/02 Accelerated COVID-19 vaccine development: milestones, lessons, and prospects: Immunity
  • 08/02 Studying SARS-CoV-2 infectivity and therapeutic responses with complex organoids | Nature Cell Biology
  • 08/02 Behavioral Nudges Increase COVID-19 Vaccinations | Nature
  • 08/02 Understanding why superspreading drives the COVID-19 pandemic but not the H1N1 pandemic - The Lancet Infectious Diseases
  • 08/03 Broad betacoronavirus neutralization by a stem helix–specific human antibody | Science
  • 08/03 Estimating SARS-CoV-2 infections from deaths, confirmed cases, tests, and random surveys | PNAS
  • 08/03 Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2 - The Lancet Child & Adolescent Health
  • 08/04 Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 | NEJM
  • 08/05 Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort | medRxiv
  • 08/05 SARS-CoV-2 Variants in Patients with Immunosuppression | NEJM
  • 08/06 SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine | Infectious Diseases | JAMA Network Open | JAMA Network
  • 08/06 Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence | medRxiv
  • 08/06 Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses | Nature Communications
  • 08/07 The unique evolutionary dynamics of the SARS-CoV-2 Delta variant | medRxiv
  • 08/09 Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence | medRxiv
  • 08/09 Immunogenicity of BNT162b2 vaccine Against the Alpha and Delta Variants in Immunocompromised Patients | medRxiv
  • 08/10 Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam by Nguyen Van Vinh Chau, Nghiem My Ngoc, Lam Anh Nguyet, Vo Minh Quang, Nguyen Thi Han Ny, Dao Bach Khoa, Nguyen Thanh Phong, Le Mau Toan, Nguyen Thi Thu Hong, Nguyen Th - The Lancet
  • 08/10 Two doses of the SARS-CoV-2 BNT162b2 vaccine enhances antibody responses to variants in individuals with prior SARS-CoV-2 infection | Science Translational Medicine
  • 08/10 Full vaccination suppresses SARS-CoV-2 delta variant mutation frequency | medRxiv
  • 08/10 Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial | medRxiv
  • 08/10 Lipid nanoparticles for mRNA delivery | Nature Reviews Materials
  • 08/10 Pairing facts with imagined consequences improves pandemic-related risk perception | PNAS
  • 08/10 Elite party cues increase vaccination intentions among Republicans | PNAS
  • 08/10 Empirical evidence to understand the human factor for effective rapid testing against SARS-CoV-2 | PNAS
  • 08/11 Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants | bioRxiv
  • 08/11 Shedding of Infectious SARS-CoV-2 Despite Vaccination when the Delta Variant is Prevalent - Wisconsin, July 2021 | medRxiv
  • 08/11 BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar | medRxiv
  • 08/11 Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients | NEJM
  • 08/11 Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents | NEJM
  • 08/12 Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants | Science
  • 08/12 Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination: Immunity
  • 08/12 Transmission dynamics and epidemiological characteristics of Delta variant infections in China | medRxiv
  • 08/12 Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave - The Lancet
  • 08/12 Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study - The Lancet Respiratory Medicine
  • 08/13 Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants | Science
  • 08/13 Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant | bioRxiv
  • 08/13 Protective heterologous T cell immunity in COVID-19 induced by the trivalent Measles-Mumps-Rubella and Tetanus-Diptheria-Pertussis vaccine antigens: Med
  • 08/13 Transmission dynamics and epidemiological characteristics of Delta variant infections in China | medRxiv
  • 08/13 Rapid genome sequencing in hospitals to identify potential vaccine-escape SARS-CoV-2 variants - The Lancet Infectious Diseases
  • 08/14 Delta variant and mRNA Covid-19 vaccines effectiveness: higher odds of vaccine infection breakthroughs | medRxiv
  • 08/16 Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers | Infectious Diseases | JAMA Internal Medicine | JAMA Network
  • 08/16 Association of Age and Pediatric Household Transmission of SARS-CoV-2 Infection | Infectious Diseases | JAMA Pediatrics | JAMA Network
  • 08/16 Vaccine nationalism and the dynamics and control of SARS-CoV-2 | Science
  • 08/16 A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants: Immunity
  • 08/17 Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant | bioRxiv
  • 08/17 Live Imaging of SARS-CoV-2 Infection in Mice Reveals that Neutralizing Antibodies Require Fc Function for Optimal Efficacy: Immunity
  • 08/17 SARS-CoV-2 aerosol transmission in schools: the effectiveness of different interventions | medRxiv
  • 08/17 No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencing - ScienceDirect
  • 08/17 SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination - The Lancet
  • 08/17 Early Release - Real-Time Genomics for Tracking Severe Acute Respiratory Syndrome Coronavirus 2 Border Incursions after Virus Elimination, New Zealand - Volume 27, Number 9—September 2021 - Emerging Infectious Diseases journal - CDC
  • 08/18 The Origins of SARS-CoV-2: A Critical Review: Cell
  • 08/18 A third COVID-19 vaccine shot markedly boosts neutralizing antibody potency and breadth | medRxiv
  • 08/18 Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children | Nature Biotechnology
  • 08/18 Early Convalescent Plasma for High-Risk Outpatients with Covid-19 | NEJM
  • 08/18 Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors | NEJM
  • 08/19 Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths | Science Immunology
  • 08/19 Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection | medRxiv
  • 08/19 A glycan gate controls opening of the SARS-CoV-2 spike protein | Nature Chemistry
  • 08/22 The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines | bioRxiv
  • 08/22 The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants: Cell Reports
  • 08/23 COVID-19 Transmission Dynamics Among Close Contacts of Index Patients With COVID-19: A Population-Based Cohort Study in Zhejiang Province, China | Global Health | JAMA Internal Medicine | JAMA Network
  • 08/23 Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study by Sara Y. Tartof, Jeff M. Slezak, Heidi Fischer, Vennis Hong, Bradley K. Ackerson, Omesh N. Ranasinghe, Timothy B. Frankland, O
  • 08/23 Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study by Sara Y. Tartof, Jeff M. Slezak, Heidi Fischer, Vennis Hong, Bradley K. Ackerson, Omesh N. Ranasinghe, Timothy B. Frankland, Oluwaseye A. Ogun, Joann M. Zamparo, Sharon Gray, Srinivas R. Valluri, Kaijie Pan, Frederick J. Angulo, Luis Jodar, John M. McLaughlin :: SSRN
  • 08/23 Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19 | Science Translational Medicine
  • 08/23 mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern | bioRxiv
  • 08/24 Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome | PNAS
  • 08/24 Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis | PNAS
  • 08/24 Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain | Research Square
  • 08/25 Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections | medRxiv
  • 08/25 mRNA vaccines for infectious diseases: principles, delivery and clinical translation | Nature Reviews Drug Discovery
  • 08/26 SARS-CoV-2 identified by transmission electron microscopy in lymphoproliferative and ischaemic intestinal lesions of COVID-19 patients with acute abdominal pain: two case reports | BMC Gastroenterology
  • 08/26 SARS-CoV-2 Omicron variant escapes neutralising antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents.: Cell Reports Medicine
  • 08/26 The continuous evolution of SARS-CoV-2 in South Africa: a new lineage with rapid accumulation of mutations of concern and global detection | medRxiv
  • 08/26 Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting | medRxiv
  • 08/26 Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers | medRxiv
  • 08/26 Burden and characteristics of COVID-19 in the United States during 2020 | Nature
  • 08/26 CoronaVac induces lower neutralising activity against variants of concern than natural infection - The Lancet Infectious Diseases
  • 08/27 Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar | medRxiv
  • 08/27 Geometric deep learning of RNA structure - Science
  • 08/27 Piercing the fog of the RNA structure-ome - Science
  • 08/27 Importance of epidemiological factors in the evaluation of transmissibility and clinical severity of SARS-CoV-2 variants - The Lancet Infectious Diseases
  • 08/27 Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study - The Lancet Infectious Diseases
  • 08/27 COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses - The Lancet Rheumatology
  • 08/28 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study - The Lancet
  • 08/29 COVID-19-associated hospitalizations among vaccinated and unvaccinated adults ≥18 years – COVID-NET, 13 states, January 1 – July 24, 2021 | medRxiv
  • 08/29 Effect of Salt Substitution on Cardiovascular Events and Death | NEJM
  • 08/30 Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 | Vaccination | JAMA | JAMA Network
  • 08/30 Durability of Spike Immunoglobin G Antibodies to SARS-CoV-2 Among Health Care Workers With Prior Infection | Infectious Diseases | JAMA Network Open | JAMA Network
  • 08/30 Intramuscular SARS-CoV-2 vaccines elicit varying degrees of plasma and salivary antibody responses as compared to natural infection | medRxiv
  • 08/30 Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history | Scientific Reports
  • 08/31 Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk | Allergy and Clinical Immunology | JAMA Network Open | JAMA Network
  • 08/31 Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine Escape | bioRxiv
  • 08/31 Hybrid immunity versus vaccine-induced immunity against SARS CoV2 in Patients with Autoimmune Rheumatic Diseases | medRxiv
  • 08/31 Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 Vaccine | medRxiv
  • 08/31 Intensity and frequency of extreme novel epidemics | PNAS
  • 08/31 Systemic COVID-19 vaccination also enhances the humoral immune response after SARS CoV-2 infection. An approach to criteria for COVID-19 re-immunization is needed. Do we need a third dose? | Research Square
  • 08/31 Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination - Science

    September 2021

  • 09/01 Kidney Outcomes in Long COVID | American Society of Nephrology
  • 09/01 Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccine | medRxiv
  • 09/01 Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce | NEJM
  • 09/01 Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) - The Lancet
  • 09/01 Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine - The Lancet
  • 09/01 Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study - The Lancet Infectious Diseases
  • 09/01 Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial - The Lancet Respiratory Medicine
  • 09/01 Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial - The Lancet Respiratory Medicine
  • 09/02 Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine | Infectious Diseases | JAMA Network Open | JAMA Network
  • 09/02 Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort Study by Katia Bruxvoort, Lina S. Sy, Lei Qian, Bradley K. Ackerson, Yi Luo, Gina S. Lee, Yun Tian, Ana Florea, Harpreet S. Takhar, Julia E. Tubert, Carla A. Talarico, Hung Fu Tseng :: SSRN
  • 09/02 Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy | The BMJ
  • 09/02 Longitudinal analysis of SARS-CoV-2 vaccine breakthrough infections reveal limited infectious virus shedding and restricted tissue distribution | medRxiv
  • 09/02 Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2 - Science
  • 09/03 Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination - Science
  • 09/03 Hospitalisation associated with SARS-CoV-2 delta variant in Denmark - The Lancet Infectious Diseases
  • 09/05 No difference in risk of hospitalisation between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway | medRxiv
  • 09/06 The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages: Cell
  • 09/07 Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera | bioRxiv
  • 09/07 Effectiveness of the mRNA BNT162b2 vaccine six months after vaccination: findings from a large Israeli HMO | medRxiv
  • 09/07 The prevalence of adaptive immunity to COVID-19 and reinfection after recovery – a comprehensive systematic review and meta-analysis of 12 011 447 individuals | medRxiv
  • 09/07 Durability analysis of the highly effective BNT162b2 vaccine against COVID-19 | medRxiv
  • 09/07 Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy | Nature Medicine
  • 09/07 Assessment of Aerosol Generating Events During the Nasopharyngeal Swabbing for SARS-CoV-2 Detection | Research Square
  • 09/07 Hospitalisation among vaccine breakthrough COVID-19 infections - The Lancet Infectious Diseases
  • 09/08 Effect of Vaccination on Transmission of SARS-CoV-2 | NEJM
  • 09/09 Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial | Nature Medicine
  • 09/09 Early cross-coronavirus reactive signatures of humoral immunity against COVID-19 - Science
  • 09/09 Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study - The Lancet Infectious Diseases
  • 09/10 Breathing more breadth into COVID-19 T cell responses: Med
  • 09/13 Considerations in boosting COVID-19 vaccine immune responses - The Lancet
  • 09/14 BNT162b2-Elicited Neutralization of Delta Plus, Lambda, and Other Variants | bioRxiv
  • 09/14 A strategy to assess spillover risk of bat SARS-related coronaviruses in Southeast Asia | medRxiv
  • 09/14 Antibody responses to BNT162b2 mRNA vaccine: infection-naïve individuals with abdominal obesity warrant attention | medRxiv
  • 09/14 Short-range exposure to airborne virus transmission and current guidelines | PNAS
  • 09/14 Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells - Science
  • 09/14 Identification of resident memory CD8+ T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue - Science
  • 09/14 Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial - The Lancet
  • 09/14 Daily antigen testing to reduce disruption when schools return - The Lancet
  • 09/14 Prevention of host-to-host transmission by SARS-CoV-2 vaccines - The Lancet Infectious Diseases
  • 09/15 Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2: Cell Metabolism
  • 09/15 Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: the REACT-SCOT case-control study | medRxiv
  • 09/16 Association of Nursing Home Characteristics With Staff and Resident COVID-19 Vaccination Coverage | Geriatrics | JAMA Internal Medicine | JAMA Network
  • 09/17 The biological and clinical significance of emerging SARS-CoV-2 variants | Nature Reviews Genetics
  • 09/17 Coronaviruses with a SARS-CoV-2-like receptor-binding domain allowing ACE2-mediated entry into human cells isolated from bats of Indochinese peninsula | Research Square
  • 09/17 Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection - Science
  • 09/20 mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants: Immunity
  • 09/20 Quantitative measurement of infectious virus in SARS-CoV-2 Alpha, Delta and Epsilon variants reveals higher infectivity (viral titer:RNA ratio) in clinical samples containing the Delta and Epsilon variants | medRxiv
  • 09/20 EFFICACY OF THE MEASLES-MUMPS-RUBELLA (MMR) VACCINE IN THE REDUCING THE SEVERITY OF COVID-19: AN INTERIM ANALYSIS OF A RANDOMISED CONTROLLED CLINICAL TRIAL | medRxiv
  • 09/21 Measuring the COVID-19 Mortality Burden in the United States: A Microsimulation Study: Annals of Internal Medicine: Vol 0, No 0
  • 09/21 Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a sixteen-week interval between doses | medRxiv
  • 09/22 mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients? | medRxiv
  • 09/22 The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units | medRxiv
  • 09/22 Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge | medRxiv
  • 09/22 Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel | NEJM
  • 09/22 Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study - The Lancet Infectious Diseases
  • 09/24 High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines: Cell Reports
  • 09/24 mRNA COVID-19 Vaccination and Development of CMR-confirmed Myopericarditis | medRxiv
  • 09/26 Quantifying impacts of the COVID-19 pandemic through life-expectancy losses: a population-level study of 29 countries | International Journal of Epidemiology | Oxford Academic
  • 09/26 COVID-19 Vaccine Breakthrough Infections in Veterans Health Administration | medRxiv
  • 09/27 Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers: Cell Reports Medicine
  • 09/27 Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021 - Volume 27, Number 11—November 2021 - Emerging Infectious Diseases journal - CDC
  • 09/28 Identifying and prioritizing potential human-infecting viruses from their genome sequences - PLoS
  • 09/28 Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19 - PLoS
  • 09/28 Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants | medRxiv
  • 09/28 A prenylated dsRNA sensor protects against severe COVID-19 - Science
  • 09/29 Efficacy of COVID-19 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation Using Data From the ComPaRe e-Cohort in France by Viet-Thi Tran, Elodie Perrodeau, Julia Saldanha, Isabelle Pane, Philippe Ravaud :: SSRN
  • 09/29 No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups Infected with SARS-CoV-2 Delta Variant | medRxiv
  • 09/29 Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine | NEJM
  • 09/30 Durability of immune responses to the BNT162b2 mRNA vaccine | bioRxiv
  • 09/30 Eurosurveillance | Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021
  • 09/30 The origins of viruses: discovery takes time, international resources, and cooperation - The Lancet

    October 2021

  • 10/01 SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared to SARS-CoV-2 mRNA vaccinations | medRxiv
  • 10/01 The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study - The Lancet Microbe
  • 10/02 What data can reveal and conceal - The Lancet
  • 10/03 Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults | medRxiv
  • 10/04 Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older | Cardiology | JAMA Internal Medicine | JAMA Network
  • 10/04 Frequency of surveillance testing necessary to reduce transmission of SARS-CoV-2 | medRxiv
  • 10/04 Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study - The Lancet
  • 10/04 COVID-19 and metabolic disease: mechanisms and clinical management - The Lancet Diabetes & Endocrinology
  • 10/05 Type I interferon response and vascular alteration in chilblain‐like lesions during the COVID‐19 outbreak - Frumholtz - - British Journal of Dermatology - Wiley Online Library
  • 10/05 Association of Vaccination With the Persistence of Post-COVID Symptoms by Juan P. Wisnivesky, Usha Govindarajulu, Emilia Bagiella, Ruchir Goswami, Minal Kale, Kirk N. Campbell, Kristin Meliambro, Zijian Chen, Judith A. Aberg, Jenny J. Lin :: SSRN
  • 10/05 Racial and Ethnic Disparities in Excess Deaths During the COVID-19 Pandemic, March to December 2020 | Annals of Internal Medicine
  • 10/05 One-year Risks and Burdens of Incident Cardiovascular Disease in COVID-19: Cardiovascular Manifestations of Long COVID | Research Square
  • 10/06 Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans | Infectious Diseases | JAMA Network Open | JAMA Network
  • 10/06 Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar | NEJM
  • 10/06 Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months | NEJM
  • 10/07 genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene | Brain | Oxford Academic
  • 10/07 Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19 | medRxiv
  • 10/07 Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings | NEJM
  • 10/07 Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel | NEJM
  • 10/07 Can high SARS-CoV-2 adult vaccination rates help protect unvaccinated children? Evidence from a unique rapid mass vaccination campaign | Research Square
  • 10/07 Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas - The Lancet Infectious Diseases
  • 10/08 Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic - The Lancet
  • 10/09 COVID-19 Vaccine Effectiveness by Product and Timing in New York State | medRxiv
  • 10/10 Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico | medRxiv
  • 10/11 Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members | Infectious Diseases | JAMA Internal Medicine | JAMA Network
  • 10/11 Transmission of SARS-CoV-2 Delta Variant Among Vaccinated Healthcare Workers, Vietnam by Nguyen Van Vinh Chau, Nghiem My Ngoc, Lam Anh Nguyet, Vo Minh Quang, Nguyen Thi Han Ny, Dao Bach Khoa, Nguyen Thanh Phong, Le Mau Toan, Nguyen Thi Thu Hong, Nguyen Thi Kim Tuyen, Voong Vinh Phat, Le Nguyen Truc Nhu, Nguyen Huynh Thanh Truc, Bui Thi Ton That, Huynh Phuong Thao, Tran Nguyen Phuong Thao, Vo Trong Vuong, Tran Thi Thanh Tam, Ngo Tan Tai, Ho The Bao, Huynh Thi Kim Nhung, Nguyen Thi Ngoc Minh, Nguyen Thi My Tien, Nguy Cam Huy, Marc Choisy, Dinh Nguyen Huy Man, Dinh Thi Bich Ty, Nguyen To Anh, Le Thi Tam Uyen, Tran Nguyen Hoang Tu, Lam Minh Yen, Nguyen Thanh Dung, Le Manh Hung, Nguyen Thanh Truong, Tran Tan Thanh, Guy Thwaites, Le Van Tan, OUCRU COVID-19 Research Group :: SSRN
  • 10/11 Putative host origins of RNA insertions in SARS-CoV-2 genomes - SARS-CoV-2 coronavirus - Virological
  • 10/11 Immunity to SARS-CoV-2 up to 15 months after infection | bioRxiv
  • 10/11 Direct Comparison of Antibody Responses to Four SARS-CoV-2 Vaccines in Mongolia: Cell Host & Microbe
  • 10/11 Immunogenicity of a BNT162b2 vaccine booster in health-care workers - The Lancet Microbe
  • 10/12 Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner: Cell Host & Microbe
  • 10/13 Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review | Infectious Diseases | JAMA Network Open | JAMA Network
  • 10/13 Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report | medRxiv
  • 10/14 HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study - PLoS
  • 10/14 One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow | medRxiv
  • 10/14 Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 | medRxiv
  • 10/14 Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), August-September 2021, the Netherlands | medRxiv
  • 10/14 Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK | Nature Medicine
  • 10/14 Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India - Science
  • 10/14 mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern - Science
  • 10/15 COVID-19 mRNA Based Vaccine Immune-Response Assessment for Public Health Decision by David San Segundo, Alejandra Comins, Patricia Lamadrid, Juan Irure, José María Castillo, Reinhard Wallmann, Jorge Calvo, Carmela Baamonde, Isabel Sanchez Molina, Marina Lecue, Silvia Ventisca, Marcos Lopez-Hoyos :: SSRN
  • 10/15 Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine: Cell
  • 10/15 SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers | Nature Communications
  • 10/17 Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe
  • 10/18 Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: a cohort study using OpenSAFELY | medRxiv
  • 10/18 Time-varying effectiveness of the mRNA-1273, BNT162b2 and Ad26.COV2.S vaccines against SARS-CoV-2 infections and COVID-19 hospitalizations and deaths: an analysis based on observational data from Puerto Rico | medRxiv
  • 10/18 Long-term consequences of the misuse of ivermectin data - The Lancet Infectious Diseases
  • 10/18 Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet Respiratory Medicine
  • 10/19 Asymptomatic SARS-CoV-2 Vaccine Breakthrough Infections in Health Care Workers Identified Through Routine Universal Surveillance Testing | Annals of Internal Medicine
  • 10/19 Asymptomatic SARS-CoV-2 Vaccine Breakthrough Infections in Health Care Workers Identified Through Routine Universal Surveillance Testing | Annals of Internal Medicine
  • 10/19 Impact of SARS-CoV-2 infection on longitudinal vaccine immune responses | medRxiv
  • 10/19 The association of opening K–12 schools with the spread of COVID-19 in the United States: County-level panel data analysis | PNAS
  • 10/19 Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2 | PNAS
  • 10/19 Pregnancy influences immune responses to SARS-CoV-2 - Science
  • 10/20 Airborne transmission of SARS-CoV-2 over distances greater than two metres: a rapid systematic review | medRxiv
  • 10/20 Evidence of transmission from fully vaccinated individuals in a large outbreak of the SARS-CoV-2 Delta variant in Provincetown, Massachusetts | medRxiv
  • 10/21 Environmental contamination with SARS‐CoV‐2 in nursing homes - Mody - - Journal of the American Geriatrics Society - Wiley Online Library
  • 10/21 The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells | Nature Neuroscience
  • 10/21 Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? - The Lancet Respiratory Medicine
  • 10/22 Incidence of SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential Workers During a Prevaccination COVID-19 Surge in Arizona | JAMA Health Forum | JAMA Network
  • 10/22 Assessment of Cognitive Function in Patients After COVID-19 Infection | Dementia and Cognitive Impairment | JAMA Network Open | JAMA Network
  • 10/22 Post COVID-19 in children, adolescents, and adults: results of a matched cohort study including more than 150,000 individuals with COVID-19 | medRxiv
  • 10/23 Virology, transmission, and pathogenesis of SARS-CoV-2 | The BMJ
  • 10/24 Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway | bioRxiv
  • 10/25 Anti–SARS-CoV-2 and Autoantibody Profiles in the Cerebrospinal Fluid of 3 Teenaged Patients With COVID-19 and Subacute Neuropsychiatric Symptoms | Neurology | JAMA Neurology | JAMA Network
  • 10/25 Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada | CMAJ
  • 10/25 Ivermectin for COVID-19: addressing potential bias and medical fraud | Research Square
  • 10/26 Effectiveness of BNT162b2 mRNA COVID-19 vaccine against acquisitions of SARS-CoV-2 among health care workers in long-term care facilities: a prospective cohort study | Clinical Infectious Diseases | Oxford Academic
  • 10/26 Weekly SARS-CoV-2 screening of asymptomatic kindergarten to grade 12 students and staff helps inform strategies for safer in-person learning: Cell Reports Medicine
  • 10/26 Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and could prevent future surges in some populations | medRxiv
  • 10/26 Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections | medRxiv
  • 10/26 Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant - Science
  • 10/26 Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort - Science
  • 10/27 Invincibility threatens vaccination intentions during a pandemic - PLoS
  • 10/27 COVCOG 1: Factors predicting Cognitive Symptoms in Long COVID. A First Publication from the COVID and Cognition Study | medRxiv
  • 10/27 The impact of school opening model on SARS-CoV-2 community incidence and mortality | Nature Medicine
  • 10/27 No causal effect of school closures in Japan on the spread of COVID-19 in spring 2020 | Nature Medicine
  • 10/27 Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study | Nature Cancer
  • 10/27 Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex | NEJM
  • 10/27 Waning Immunity after the BNT162b2 Vaccine in Israel | NEJM
  • 10/27 Comment on “Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2” - Science
  • 10/27 Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study - The Lancet Regional Health – Europe
  • 10/27 Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial - The Lancet Global Health
  • 10/28 Age-Varying Susceptibility to the Delta Variant (B.1.617.2) of SARS-CoV-2 by June Young Chun, Hwichang Jeong, Yongdai Kim :: SSRN
  • 10/28 Differential dynamics of peripheral immune responses to acute SARS-CoV-2 infection in older adults | Nature Aging
  • 10/28 Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland - The Lancet
  • 10/28 COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network - The Lancet Haematology
  • 10/29 Anti-spike antibody response to natural SARS-CoV-2 infection in the general population | Nature Communications
  • 10/29 Evaluating and Deploying Covid-19 Vaccines — The Importance of Transparency, Scientific Integrity, and Public Trust | NEJM
  • 10/29 Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine - Science
  • 10/29 Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study - ScienceDirect
  • 10/29 Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet
  • 10/29 Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study - The Lancet Infectious Diseases

    November 2021

  • 11/01 Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar | Infectious Diseases | JAMA | JAMA Network
  • 11/01 Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection | Infectious Diseases | JAMA | JAMA Network
  • 11/01 High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort - The Lancet Global Health
  • 11/02 Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb: Cell
  • 11/02 An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 - Science
  • 11/02 Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant - Science
  • 11/02 BNT162b2 vaccination induces durable SARS-CoV-2 specific T cells with a stem cell memory phenotype - Science
  • 11/02 A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice - Science
  • 11/02 Has Spain reached herd immunity? - The Lancet Respiratory Medicine
  • 11/03 Effects of covid-19 pandemic on life expectancy and premature mortality in 2020: time series analysis in 37 countries | The BMJ
  • 11/03 Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge | NEJM
  • 11/04 Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus | Nature Genetics
  • 11/04 Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines | NEJM
  • 11/04 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months | NEJM
  • 11/04 Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase | NEJM
  • 11/04 Rapid assessment of SARS-CoV-2 evolved variants using virus-like particles - Science
  • 11/04 SARS-CoV-2 vaccine protection and deaths among US veterans during 2021 - Science
  • 11/08 A need of COVID19 vaccination for children aged < 12 years: Comparative evidence from the clinical characteristics in patients during a recent Delta surge (B.1.617.2)| medRxiv
  • 11/09 Current Insights Into Respiratory Virus Transmission and Potential Implications for Infection Control Programs: A Narrative Review: Annals of Internal Medicine: Vol 0, No 0
  • 11/09 Identification of a therapeutic interfering particle—A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance: Cell
  • 11/09 IJMS | Free Full-Text | SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape - IJMS
  • 11/09 Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort | medRxiv
  • 11/09 A novel SARS-CoV-2 related coronavirus in bats from Cambodia | Nature Communications
  • 11/09 Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age | NEJM
  • 11/09 SARS-CoV-2 indoor air transmission is a threat that can be addressed with science | PNAS
  • 11/09 Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants - Science
  • 11/09 T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study - The Lancet Microbe
  • 11/10 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant | NEJM
  • 11/11 COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection | medRxiv
  • 11/11 Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year | Nature Medicine
  • 11/11 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care — Preliminary Report | NEJM
  • 11/11 Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19 - The Lancet
  • 11/12 An outbreak of SARS-CoV-2 with high mortality in mink (Neovison vison) on multiple Utah farms - PLoS
  • 11/12 Total virome characterizations of game animals in China reveals a spectrum of emerging viral pathogens | bioRxiv
  • 11/14 Using high-resolution contact networks to evaluate SARS-CoV-2 transmission and control in large-scale multi-day events | medRxiv
  • 11/15 Infection, recovery and re-infection of farmed mink with SARS-CoV-2 - PLoS
  • 11/15 From Online Data Collection to Identification of Disease Mechanisms: The IL-1ß, IL-6 and TNF-α Cytokine Triad Is Associated With Post-Acute Sequelae of COVID-19 in a Digital Research Cohort by Christoph Schultheiß, Edith Willscher, Lisa Paschold, Cornelia Gottschick, Bianca Klee, Saskia Glasauer, Svenja-Sibylla Henkes, Lidia Bosurgi, Jochen Dutzmann, Daniel G. Sedding, Thomas Frese, Matthias Girndt, Jessica I. Höll, Michael Gekle, Rafael Mikolajczyk, Mascha Binder :: SSRN
  • 11/15 Long Covid after Breakthrough COVID-19: the post-acute sequelae of breakthrough COVID-19 | Research Square
  • 11/15 Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis - The Lancet Microbe
  • 11/16 Global Prevalence of Post-Acute Sequelae of COVID-19 (PASC) or Long COVID: A Meta-Analysis and Systematic Review | medRxiv
  • 11/17 Evaluating the potential for respiratory metagenomics to improve treatment of secondary infection and detection of nosocomial transmission on expanded COVID-19 intensive care units | Genome Medicine | Full Text
  • 11/17 SARS-CoV-2 Antibodies in Children: A One-Year Seroprevalence Study From June 2020 to May 2021 in Germany by Anna-Lisa Sorg, Leon Bergfeld, Marietta Jank, Victor M. Corman, Ilia Semmler, Anna Görtz, Andreas Beyerlein, Eva Verjans, Norbert Wagner, Horst von Bernuth, Fabian Lander, Katharina Weil, Markus Hufnagel, Ute Spiekerkoetter, Chao Cho-Ming, Lutz Nährlich, Ania C. Muntau, Ulf Schulze-Sturm, Gesine Hansen, Martin Wetzke, Anna-Maria Jung, Tim Niehues, Susanne Fricke-Otto, Ulrich von Both, Johannes Hübner, Uta Behrends, Johannes G. Liese, Christian Schwerk, Christian Drosten, Rüdiger von Kries, Horst Schroten :: SSRN
  • 11/17 Impact of SARS-CoV-2 Vaccines on Covid-19 Incidence and Mortality in the United States | medRxiv
  • 11/17 Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial - The Lancet Respiratory Medicine
  • 11/18 Growing Public Health Concern of COVID-19 Chronic Olfactory Dysfunction | Public Health | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
  • 11/18 Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease: Results of a Systematic Review and Meta-Regression by Daniel Feikin, Melissa M. Higdon, Laith J. Abu-Raddad, Nick Andrews, Rafael Araos, Yair Goldberg, Michelle Groome, Amit Huppert, Katherine O'Brien, Peter G. Smith, Annelies Wilder-Smith, Scott L Zeger, Maria D. Knoll, Minal Patel :: SSRN
  • 11/18 Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis | The BMJ
  • 11/18 Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage | NEJM
  • 11/18 Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines | NEJM
  • 11/18 COVID-19 targets human adrenal glands - The Lancet Diabetes & Endocrinology
  • 11/19 Changes in SARS-CoV-2 viral load and mortality during the initial wave of the pandemic in New York City - PLoS
  • 11/19 Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July—August 2021 | medRxiv
  • 11/21 Antibody titers before and after booster doses of SARS-CoV-2 mRNA vaccines in healthy adults | medRxiv
  • 11/22 Understanding and tracking the impact of long COVID in the United Kingdom | Nature Medicine
  • 11/23 Estimates of the stochasticity of droplet dispersion by a cough: Physics of Fluids: Vol 33, No 11
  • 11/23 Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma | Hematology | JAMA Network Open | JAMA Network
  • 11/23 Prevalence and determinants of healthcare avoidance during the COVID-19 pandemic: A population-based cross-sectional study - PLOS
  • 11/23 Adaptation, spread and transmission of SARS-CoV-2 in farmed minks and associated humans in the Netherlands | Nature Communications
  • 11/23 Plastic waste release caused by COVID-19 and its fate in the global ocean | PNAS
  • 11/23 Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial - Science
  • 11/23 Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study - The Lancet Infectious Diseases
  • 11/24 Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections | NEJM
  • 11/25 Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study | The BMJ
  • 11/25 Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents | NEJM
  • 11/26 Germany’s current COVID-19 crisis is mainly driven by the unvaccinated | medRxiv
  • 11/29 COVID-19 in Africa: Catalyzing change for sustainable development - PLOS
  • 11/29 Real-time alerting system for COVID-19 and other stress events using wearable data | Nature Medicine
  • 11/30 Report on Omicron Spike mutations on epitopes and immunological/epidemiological/kinetics effects from literature - nCoV-2019 Genomic Epidemiology - Virological
  • 11/30 Main protease mutants of SARS-CoV-2 variants remain susceptible to PF-07321332 | bioRxiv
  • 11/30 Nanometer-resolution in situ structure of the SARS-CoV-2 postfusion spike protein | PNAS
  • 11/30 Risk of COVID-19 hospital admission among children aged 5–17 years with asthma in Scotland: a national incident cohort study - The Lancet Respiratory Medicine

    December 2021

  • 12/01 Diminished amplification of SARS-CoV-2 ORF1ab in a commercial dual-target qRT-PCR diagnostic assay - PubMed
  • 12/01 The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 | bioRxiv
  • 12/01 Effectiveness and durability of protection against future SARS-CoV-2 infection conferred by COVID-19 vaccination and previous infection; findings from the UK SIREN prospective cohort study of healthcare workers March 2020 to September 2021 | medRxiv
  • 12/01 Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons | NEJM
  • 12/01 Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans | NEJM
  • 12/01 Covid-19 Vaccine Effectiveness in New York State | NEJM
  • 12/01 COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm - The Lancet Infectious Diseases
  • 12/02 Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques is coincident with anamnestic antibody response in the lung: Cell
  • 12/02 Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders | medRxiv
  • 12/02 BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant | NEJM
  • 12/02 Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19 | NEJM
  • 12/02 REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 | NEJM
  • 12/02 Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel | NEJM
  • 12/02 Myocarditis after Covid-19 Vaccination in a Large Health Care Organization | NEJM
  • 12/02 Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh
  • 12/02 Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial - The Lancet
  • 12/03 Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike protein | bioRxiv
  • 12/03 Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic - The Lancet
  • 12/03 Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era - The Lancet Microbe
  • 12/04 Willingness to vaccinate against SARS-CoV-2: The role of reasoning biases and conspiracist ideation - ScienceDirect
  • 12/05 Ad26.COV2.S or BNT162b2 Boosting of BNT162b2 Vaccinated Individuals | medRxiv
  • 12/05 Brain Injury in COVID-19 is Associated with Autoinflammation and Autoimmunity | medRxiv
  • 12/06 Predictions of the SARS-CoV-2 Omicron Variant (B.1.1.529) Spike Protein Receptor-Binding Domain Structure and Neutralizing Antibody Interactions | bioRxiv
  • 12/06 Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response: Cell Host & Microbe
  • 12/06 Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial - The Lancet
  • 12/07 Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants | mBio
  • 12/07 Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response - PubMed
  • 12/07 An upper bound on one-to-one exposure to infectious human respiratory particles | PNAS
  • 12/07 In vivo kinetics of SARS-CoV-2 infection and its relationship with a person’s infectiousness | PNAS
  • 12/07 Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals - Science
  • 12/08 Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies | medRxiv
  • 12/08 BNT162b2 Vaccine Booster and Mortality Due to Covid-19 | NEJM
  • 12/08 Protection against Covid-19 by BNT162b2 Booster across Age Groups | NEJM
  • 12/09 Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals | bioRxiv
  • 12/09 B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes | bioRxiv
  • 12/10 Breakthrough Infections with SARS-CoV-2 Omicron Variant Despite Booster Dose of mRNA Vaccine by Constanze Kuhlmann, Carla Konstanze Mayer, Mathilda Claassen, Tongai G. Maponga, Andrew D. Sutherland, Tasnim Suliman, Megan Shaw, Wolfgang Preiser :: SSRN
  • 12/10 Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection: Med
  • 12/11 SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals | medRxiv
  • 12/13 Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial | Critical Care Medicine | JAMA Internal Medicine | JAMA Network
  • 12/14 SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern | medRxiv
  • 12/14 Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis | Global Health | JAMA Network Open | JAMA Network
  • 12/14 Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection | medRxiv
  • 12/14 mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant | medRxiv
  • 12/14 mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant | medRxiv
  • 12/14 mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant | medRxiv
  • 12/14 Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection | Nature Medicine
  • 12/15 Estimated Effectiveness of COVID-19 Messenger RNA Vaccination Against SARS-CoV-2 Infection Among Older Male Veterans Health Administration Enrollees, January to September 2021 | Infectious Diseases | JAMA Network Open | JAMA Network
  • 12/15 Genomic determinants of Furin cleavage in diverse European SARS-related bat coronaviruses | bioRxiv
  • 12/15 HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta in human bronchus but with less severe infection in lung - News | HKUMed
  • 12/15 Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies | medRxiv
  • 12/15 Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico | NEJM
  • 12/15 Overview on the occurrence of microplastics in air and implications from the use of face masks during the COVID-19 pandemic - ScienceDirect
  • 12/16 Waning of mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar | medRxiv
  • 12/16 Capturing adaptive immunity against SARS-CoV-2 in patients with cancer | Nature Cancer
  • 12/16 Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients | NEJM
  • 12/16 A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates - Science
  • 12/17 Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers: Cell Host & Microbe
  • 12/20 Neutralization and Stability of SARS-CoV-2 Omicron Variant | bioRxiv
  • 12/20 Diagnostics for COVID-19: moving from pandemic response to control - The Lancet
  • 12/20 Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil - The Lancet
  • 12/21 Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study by Sara Y. Tartof, Jeff M. Slezak, Laura Puzniak, Vennis Hong, Timothy B. Frankland, Bradley K. Ackerson, Harpreet S. Takhar, Oluwaseye A. Ogun, Sarah Simmons, Joann M. Zamparo, Sharon Gray, Srinivas R. Valluri, Kaijie Pan, Luis Jodar, John M. McLaughlin :: SSRN
  • 12/21 COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System: A Target Trial Emulation Study: Annals of Internal Medicine
  • 12/21 Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma | medRxiv
  • 12/21 Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients | medRxiv
  • 12/21 Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa | medRxiv
  • 12/21 Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity
  • 12/22 Incidence and Estimated Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Among Persons Tested in US Retail Locations, May 1 to August 7, 2021 | Infectious Diseases | JAMA Network Open | JAMA Network
  • 12/22 SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion | bioRxiv
  • 12/22 Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection | bioRxiv
  • 12/22 SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans: Cell
  • 12/22 Analytical sensitivity of seven SARS-CoV-2 antigen-detecting rapid tests for Omicron variant | medRxiv
  • 12/22 Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift - Nature
  • 12/22 Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta | Nature
  • 12/22 Local and systemic responses to SARS-CoV-2 infection in children and adults | Nature
  • 12/22 Cross-reactive adaptive immunity against coronaviruses in young children | Nature Immunology
  • 12/22 Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection | Nature Immunology
  • 12/22 Boosted immunity to the common cold might protect children from COVID-19 | Nature Immunology
  • 12/22 Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel | NEJM
  • 12/22 Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients | NEJM
  • 12/23 mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant: Cell
  • 12/23 Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 - Nature
  • 12/23 Considerable escape of SARS-CoV-2 Omicron to antibody neutralization - Nature
  • 12/23 BNT162b2 Vaccine Booster and Mortality Due to Covid-19 | NEJM
  • 12/23 A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus - Science
  • 12/23 Transmission of Omicron (B.1.1.529) - SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19 - The Lancet Regional Health – Western Pacific
  • 12/24 COVID-19 Vaccination and Breakthrough Infections in Patients with Cancer - Annals of Oncology
  • 12/24 Evidence for a mouse origin of the SARS-CoV-2 Omicron variant - ScienceDirect
  • 12/26 A subset of Memory B-derived antibody repertoire from 3-dose vaccinees is ultrapotent against diverse and highly transmissible SARS-CoV-2 variants, including Omicron | bioRxiv
  • 12/26 The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters | bioRxiv
  • 12/27 Early Computational Detection of Potential High Risk SARS-CoV-2 Variants | bioRxiv
  • 12/27 High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron | medRxiv
  • 12/27 SARS-CoV-2 Omicron VOC Transmission in Danish Households | medRxiv
  • 12/28 Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US | HIV | JAMA Internal Medicine | JAMA Network
  • 12/28 SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19 | bioRxiv
  • 12/28 Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. | bioRxiv
  • 12/28 SARS-CoV-2 vaccination induces immunological memory able to cross-recognize variants from Alpha to Omicron | bioRxiv
  • 12/28 SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron | medRxiv
  • 12/28 Intranasal inhibitor blocks omicron and other variants of SARS-CoV-2 | Research Square
  • 12/29 Clinical Severity of COVID-19 Patients Admitted to Hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave by Waasila Jassat, Salim Abdool Karim, Caroline Mudara, Richard Welch, Lovelyn Ozougwu, Michelle Groome, Nevashan Govender, Anne von Gottberg, Nicole Wolter, DATCOV Author Group, Lucille Blumberg, Cheryl Cohen :: SSRN
  • 12/29 Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 Study. | medRxiv
  • 12/29 Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa | NEJM
  • 12/29 Attenuated replication and pathogenesis of SARS-CoV-2 B.1.1.529 Omicron | Research Square
  • 12/29 The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters | Research Square
  • 12/30 Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves | Global Health | JAMA | JAMA Network
  • 12/31 Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron - Nature

    January 2022

  • 01/01 Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants | medRxiv
  • 01/01 Preferential expansion upon boosting of cross-reactive “pre-existing” switched memory B cells that recognize the SARS-CoV-2 Omicron variant Spike protein | medRxiv
  • 01/02 Executive dysfunction following SARS-CoV-2 infection: A cross-sectional examination in a population-representative sample | medRxiv
  • 01/03 Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters | bioRxiv
  • 01/03 SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses: Cell
  • 01/03 Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant | medRxiv
  • 01/03 The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism | medRxiv
  • 01/03 Mapping the antigenic diversification of SARS-CoV-2 | medRxiv
  • 01/04 Association of Birth During the COVID-19 Pandemic With Neurodevelopmental Status at 6 Months in Infants With and Without In Utero Exposure to Maternal SARS-CoV-2 Infection | Child Development | JAMA Pediatrics | JAMA Network
  • 01/04 Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individuals | medRxiv
  • 01/04 Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant | medRxiv
  • 01/05 Test to release from isolation after testing positive for SARS-CoV-2 | medRxiv
  • 01/05 T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals | medRxiv
  • 01/06 Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant | medRxiv
  • 01/06 Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients infected between March 2020 and November 2021 | medRxiv
  • 01/06 Superior immunity that allows neutralization of all SARS-CoV-2 variants of concern develops in COVID-19 convalescents and naïve individuals after three vaccinations | Research Square
  • 01/06 COVID mortality in India: National survey data and health facility deaths - Science
  • 01/06 Using correlates to accelerate vaccinology - Science
  • 01/06 COVID mortality in India: National survey data and health facility deaths - Science
  • 01/07 Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System by George Ioannou, Emily Locke, Pamela Green, Kristin Berry :: SSRN
  • 01/07 Rapid Diagnostic Testing for SARS-CoV-2 | NEJM
  • 01/07 Innate immunological pathways in COVID-19 pathogenesis - Science
  • 01/08 Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants | medRxiv
  • 01/10 Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain | bioRxiv
  • 01/10 The Dynamics of SARS-CoV-2 Infectivity with Changes in Aerosol Microenvironment | medRxiv
  • 01/11 Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron | medRxiv
  • 01/11 Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California | medRxiv
  • 01/11 Predicting the mutational drivers of future SARS-CoV-2 variants of concern - Science
  • 01/12 Assessment of Functional Mobility After COVID-19 in Adults Aged 50 Years or Older in the Canadian Longitudinal Study on Aging | Geriatrics | JAMA Network Open | JAMA Network
  • 01/12 SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection
  • 01/12 Screening for SARS-CoV-2 persistence in Long COVID patients using sniffer dogs and scents from axillary sweats samples | medRxiv
  • 01/12 Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa | medRxiv
  • 01/12 Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting | NEJM
  • 01/12 Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents | NEJM
  • 01/13 US Insurer Spending on Ivermectin Prescriptions for COVID-19 | Health Care Economics, Insurance, Payment | JAMA | JAMA Network
  • 01/13 SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape: Cell Host & Microbe
  • 01/13 Omicron’s Message on Vaccines: Boosting Begets Breadth: Cell
  • 01/13 COVID infection severity in children under 5 years old before and after Omicron emergence in the US | medRxiv
  • 01/13 Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection | Nature Immunology
  • 01/13 SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland | Nature Medicine
  • 01/14 Β-Amyloid Deposits in Young COVID Patients by C. Harker Rhodes, David S. Priemer, Esma Karlovich, Daniel P. Perl, James Goldman :: SSRN
  • 01/14 Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron - Nature
  • 01/15 Generation of novel SARS-CoV-2 variants on B.1.1.7 lineage in three patients with advanced HIV disease | medRxiv
  • 01/16 Resilient T cell responses to B.1.1.529 (Omicron) SARS-CoV-2 variant | medRxiv
  • 01/17 Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021 | medRxiv
  • 01/17 Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination | medRxiv
  • 01/17 The UGT2A1/UGT2A2 locus is associated with COVID-19-related loss of smell or taste | Nature Genetics
  • 01/17 Post-acute neurological consequences of COVID-19: an unequal burden | Nature Medicine
  • 01/17 SARS-CoV-2 Omicron spike mediated immune escape and tropism shift | Research Square
  • 01/17 Detection of the Omicron (B.1.1.529) variant of SARS-CoV-2 in aircraft wastewater - ScienceDirect
  • 01/18 BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design by Sara Y. Tartof, Jeff M. Slezak, Laura Puzniak, Vennis Hong, Fagen Xie, Bradley K. Ackerson, Srinivas R. Valluri, Luis Jodar, John M. McLaughlin :: SSRN
  • 01/18 Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera - Science
  • 01/18 Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera - Science
  • 01/18 Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose - The Lancet
  • 01/19 Evaluation of SARS‐COV‐2 transmission and infection in airliner cabins - Wang - 2022 - Indoor Air - Wiley Online Library
  • 01/19 Structural basis for Nirmatrelvir in vitro efficacy against the Omicron variant of SARS-CoV-2 | bioRxiv
  • 01/19 SARS-CoV-2 breakthrough infections elicit potent, broad and durable neutralizing antibody responses: Cell
  • 01/19 SARS-CoV-2 infections in children: Understanding diverse outcomes: Immunity
  • 01/19 Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients: Med
  • 01/19 Milder disease with Omicron: is it the virus or the pre-existing immunity? | Nature Reviews Immunology
  • 01/19 Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar | NEJM
  • 01/19 Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming | NEJM
  • 01/19 Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis - The Lancet
  • 01/19 Three-dose vaccination elicits neutralising antibodies against omicron - The Lancet
  • 01/20 SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium | bioRxiv
  • 01/20 Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response | bioRxiv
  • 01/20 Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission: Cell Host & Microbe
  • 01/20 A blood atlas of COVID-19 defines hallmarks of disease severity and specificity: Cell
  • 01/20 Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses - Science
  • 01/20 Nervous system consequences of COVID-19 - Science
  • 01/20 SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex - Science
  • 01/21 Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants | Vaccination | JAMA | JAMA Network
  • 01/21 How the Supreme Court’s COVID-19 Vaccine Mandate Rulings Could Shape the Pandemic’s Next Phase | Law and Medicine | JAMA | JAMA Network
  • 01/21 Outbreak.info: A standardized, searchable platform to discover and explore COVID-19 resources and data | bioRxiv
  • 01/21 Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar | medRxiv
  • 01/21 SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters | Nature
  • 01/21 Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron | Nature
  • 01/22 Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine | bioRxiv
  • 01/23 SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron: Cell
  • 01/23 Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2) | medRxiv
  • 01/24 Perimeter leakage of face masks and its effect on the mask's efficacy: Physics of Fluids: Vol 34, No 5
  • 01/24 Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19 | Critical Care Medicine | JAMA | JAMA Network
  • 01/24 Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae: Cell
  • 01/24 Immune imprinting, breadth of variant recognition and germinal center response in human SARS-CoV-2 infection and vaccination: Cell
  • 01/24 SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys - The Lancet Respiratory Medicine
  • 01/25 Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 | Cardiology | JAMA | JAMA Network
  • 01/25 Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case–Control Study: Annals of Internal Medicine: Vol 0, No 0
  • 01/25 Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVD-19 respiratory disease: Immunity
  • 01/25 Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons | medRxiv
  • 01/25 Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome | Nature Communications
  • 01/25 SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response | Nature Aging
  • 01/25 Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement - Science
  • 01/25 Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants - Science
  • 01/26 Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome | Gut
  • 01/26 Unadjuvanted intranasal spike vaccine booster elicits robust protective mucosal immunity against sarbecoviruses | bioRxiv
  • 01/26 Lung Transplantation for Covid-19–Related Respiratory Failure in the United States | NEJM
  • 01/26 Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant | NEJM
  • 01/26 SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination | NEJM
  • 01/27 Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel - Science
  • 01/27 Indirect protection of children from SARS-CoV-2 infection through parental vaccination - Science
  • 01/27 Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy - The Lancet Infectious Diseases
  • 01/28 Transmission of SARS-CoV-2 (Variant Delta) from Pet Hamsters to Humans and Onward Human Propagation of the Adapted Strain: A Case Study by Hui-Ling Yen, Thomas HC Sit, Christopher J. Brackman, Shirley SY Chuk, Samuel M.S. Cheng, Haogao Gu, Lydia DJ Chang, Pavithra Krishnan, Daisy YM Ng, Gigi YZ Liu, Mani MY Hui, Sin Ying Ho, Karina WS Tam, Pierra YT Law, Wen Su, Sin Fun Sia, Ka-Tim Choy, Sammi SY Cheuk, Sylvia PN Lau, Amy WY Tang, Joe CT Koo, Louise Yung, Gabriel Leung, J.S. Malik Peiris, Leo LM Poon :: SSRN
  • 01/28 Early introduction and rise of the Omicron SARS-CoV-2 variant in highly vaccinated university populations | medRxiv
  • 01/28 Human genetic and immunological determinants of critical COVID-19 pneumonia | Nature
  • 01/28 Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants | Nature
  • 01/28 Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern | Nature Medicine
  • 01/30 Acute upper airway disease in children with the omicron (B.1.1.529) variant of SARS-CoV-2: a report from the National COVID Cohort Collaborative (N3C) | medRxiv
  • 01/30 Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households | medRxiv
  • 01/31 Omicron Neutralizing and Anti-SARS-CoV-2 S-RBD Antibodies in Naïve and Convalescent Populations After Homologous and Heterologous Boosting With an mRNA Vaccine by Matteo Pagliari, Eva Mazzetto, Michele Gastaldelli, Alessio Bortolami, Daniele Donà, Andrea Padoan, Costanza Di Chiara, Maria Diletta Pezzani, Chiara Cosma, Alessandra Napolitan, Erika Giorgia Quaranta, Edoardo Giussani, Alice Fusaro, Michela Pascarella, Ada Aita, Cecilia Liberati, Alessio Lorusso, Isabella Monne, Anita De Rossi, Daniela Basso, Stefano Porru, Antonia Ricci, Calogero Terregino, Mario Plebani, Evelina Tacconelli, Carlo Giaquinto, Francesco Bonfante :: SSRN
  • 01/31 Equitable access to COVID-19 vaccines makes a life-saving difference to all countries | Nature Human Behaviour
  • 01/31 T cell responses to SARS-CoV-2 spike cross-recognize Omicron | Nature
  • 01/31 Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron | Nature
  • 01/31 Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules | Nature Immunology
  • 01/31 Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study - The Lancet Respiratory Medicine

    February 2022

  • 02/01 Historically High Excess Mortality During the COVID-19 Pandemic in Switzerland, Sweden, and Spain | Annals of Internal Medicine
  • 02/01 SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer's-like neuropathology | bioRxiv
  • 02/01 Non-cell autonomous disruption of nuclear architecture as a potential cause of COVID-19 induced anosmia: Cell
  • 02/01 Protection by 4th dose of BNT162b2 against Omicron in Israel | medRxiv
  • 02/01 Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant | Nature
  • 02/01 Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity | Nature
  • 02/01 SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo | Nature
  • 02/01 Innate immunity: the first line of defense against SARS-CoV-2 | Nature Immunology
  • 02/01 The T cell immune response against SARS-CoV-2 | Nature Immunology
  • 02/01 Immunology of SARS-CoV-2 infection in children | Nature Immunology
  • 02/01 Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge | Research Square
  • 02/02 Face mask fit hacks: Improving the fit of KN95 masks and surgical masks with fit alteration techniques
  • 02/02 Utility of SARS-CoV-2 Rapid Antigen Testing for Patient Triage in the Emergency Department: A Clinical Implementation Study in Melbourne, Australia by Katherine Bond, Ben Smith, Emma Gardiner, Kwee Chin Liew, Eloise Williams, Nicola Walsham, Mark Putland, Deborah Williamson :: SSRN
  • 02/02 T-cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals: Cell
  • 02/02 High Rates of Rapid Antigen Test Positivity After 5 days of Isolation for COVID-19 | medRxiv
  • 02/02 Neutralization profile of Omicron variant convalescent individuals | medRxiv
  • 02/02 Durability of Omicron-neutralizing serum activity following mRNA booster immunization in elderly individuals | medRxiv
  • 02/02 Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant | NEJM
  • 02/03 Prevalence and Durability of SARS-CoV-2 Antibodies Among Unvaccinated US Adults by History of COVID-19 | Coronavirus (COVID-19) | JAMA | JAMA Network
  • 02/03 Complications Following SARS-CoV-2 Infection in Victoria, Australia: A Record Linkage Study by Stacey L. Rowe, Karin Leder, Kylie Dyson, Lalitha Sundaresan, Dennis Wollersheim, Brigid M. Lynch, Ifrah Abdullahi, Benjamin C. Cowie, Nicola Stephens, Terry Nolan, Sheena Sullivan, Brett Sutton, Cheng AC :: SSRN
  • 02/03 Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater | Nature Communications
  • 02/03 Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses | Nature Immunology
  • 02/03 Lethal mutagenesis as an antiviral strategy - Science
  • 02/03 When viruses become more virulent - Science
  • 02/03 Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients - Science
  • 02/04 Comparative Analysis of the Risks of Hospitalisation and Death Associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants in England by Tommy Nyberg, Neil M. Ferguson, Sophie G. Nash, Harriet H. Webster, Seth Flaxman, Nick Andrews, Wes Hinsley, Jamie Lopez Bernal, Meaghan Kall, Samir Bhatt, Paula Bianca Blomquist, Asad Zaidi, Erik Volz, Nurin Abdul Aziz, Katie Harman, Russell Hope, Andre Charlett, Meera A. Chand, Azra Ghani, Shaun Seaman, Gavin Dabrera, Daniela DeAngelis, Anne M. Presanis, Simon Thelwall :: SSRN
  • 02/04 mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron | bioRxiv
  • 02/04 Pediatric Croup during the COVID-19 Omicron Variant Surge | medRxiv
  • 02/04 The costs and benefits of primary prevention of zoonotic pandemics - Science
  • 02/07 Long-Term Mortality Following COVID-19 Infection: A National Cohort Study From Estonia by Anneli Uuskula, Tuuli Jürgenson, Heti Pisarev, Raivo Kolde, Tatjana Meister, Anna Tisler, Kadri Suija, Ruth Kalda, Marko Piirsoo, Krista Fischer :: SSRN
  • 02/07 Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques | bioRxiv
  • 02/07 Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status: Cell Host & Microbe
  • 02/07 Protection of COVID-19 vaccination and previous infection against Omicron BA.1 and Delta SARS-CoV-2 infections, the Netherlands, 22 November 2021- 19 January 2022 | medRxiv
  • 02/07 Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational Study | medRxiv
  • 02/07 Rapid and ultrasensitive electromechanical detection of ions, biomolecules and SARS-CoV-2 RNA in unamplified samples | Nature Biomedical Engineering
  • 02/07 Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection | Nature Microbiology
  • 02/07 Long-term cardiovascular outcomes of COVID-19 | Nature Medicine
  • 02/07 Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study - The Lancet Child & Adolescent Health
  • 02/07 Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study - The Lancet Child & Adolescent Health
  • 02/07 Assessing the impact of the pandemic in children and adolescents: SARS-CoV-2 infection and beyond - The Lancet Child & Adolescent Health
  • 02/08 OSF Preprints | The role of schools in driving SARS-CoV-2 transmission: not just an open-and-shut case
  • 02/08 Boosting of Serum Neutralizing Activity Against the Omicron Variant Among Recovered COVID-19 Patients by BNT162b2 and Coronavac Vaccines by Lu Lu, Lin-Lei Chen, Ricky Rui-Qi Zhang, Owen Tak-Yin Tsang, Jacky Man-Chun Chan, Anthony Raymond Tam, Wai-Shing Leung, Thomas Shiu-Hong Chik, Daphne Pui-Ling Lau, Chris Yau-Chung Choi, Carol Ho-Yan Fong, Jian-Piao Cai, Hoi-Wah Tsoi, Charlotte Yee-Ki Choi, Xiaojuan Zhang, Syed Muhammad Umer Abdullah, Brian Pui-Chun Chan, Kwok-Hung Chan, Kwok-Yung Yuen, Ivan Fan-Ngai Hung, Kelvin Kai-Wang To :: SSRN
  • 02/08 Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2: Cell
  • 02/08 SARS-CoV-2 infects, replicates, elevates angiotensin II and activates immune cells in human testes | medRxiv
  • 02/08 Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study | medRxiv
  • 02/08 Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar | medRxiv
  • 02/08 Multiple spillovers from humans and onward transmission of SARS-CoV-2 in white-tailed deer | PNAS
  • 02/08 Rapid increase in Omicron infections in England during December 2021: REACT-1 study - Science
  • 02/08 A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection - Science
  • 02/09 An anchor in troubled times: Trust in science before and within the COVID-19 pandemic - PLOS
  • 02/09 Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice | bioRxiv
  • 02/09 The mechanism of RNA capping by SARS-CoV-2 | bioRxiv
  • 02/09 Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study | The BMJ
  • 02/09 Instructing durable humoral immunity for COVID-19 and other vaccinable diseases: Immunity
  • 02/09 Early prediction of preeclampsia in pregnancy with cell-free RNA | Nature
  • 02/09 Protection against the Omicron Variant from Previous SARS-CoV-2 Infection | NEJM
  • 02/09 Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S | NEJM
  • 02/10 Antiviral agents for the treatment of COVID-19: progress and challenges: Cell Reports Medicine
  • 02/10 Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial | Nature Medicine
  • 02/13 Coronavirus Disease 2019 (COVID-19) Vaccine Boosting in Persons Already Protected by Natural or Vaccine-Induced Immunity | medRxiv
  • 02/13 Excess COVID-19 associated deaths among the unvaccinated population ≥18 years old in the US, May 30 – December 4, 2021 | medRxiv
  • 02/14 Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study - The Lancet Regional Health – Americas
  • 02/15 The Human Nose Organoid Respiratory Virus Model: an Ex Vivo Human Challenge Model To Study Respiratory Syncytial Virus (RSV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pathogenesis and Evaluate Therapeutics | mBio
  • 02/15 The Effectiveness of mRNA Vaccine Boosters for Laboratory-Confirmed COVID-19 During a Period of Predominance of the Omicron Variant of SARS-CoV-2 by Susana Monge, Ayelén Rojas-Benedicto, Carmen Olmedo, Clara Mazagatos, María José Sierra, Aurora Limia, Elisa Martín-Merino, Amparo Larrauri, Miguel A. Hernán :: SSRN
  • 02/15 Virological characteristics of SARS-CoV-2 BA.2 variant | bioRxiv
  • 02/15 Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose | bioRxiv
  • 02/15 Distinguishing Admissions Specifically for COVID-19 from Incidental SARS-CoV-2 Admissions: A National EHR Research Consortium Study | medRxiv
  • 02/15 Co-infection with SARS-COV-2 Omicron and Delta Variants Revealed by Genomic Surveillance | medRxiv
  • 02/15 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC | medRxiv
  • 02/15 The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern | Nature Communications
  • 02/15 Germinal centre-driven maturation of B cell response to mRNA vaccination | Nature
  • 02/15 Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection - Science
  • 02/16 SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies | bioRxiv
  • 02/16 Risks of mental health outcomes in people with covid-19: cohort study | The BMJ
  • 02/16 The Effectiveness Of Government Masking Mandates On COVID-19 County-Level Case Incidence Across The United States, 2020 | Health Affairs
  • 02/16 Bat coronaviruses related to SARS-CoV-2 and infectious for human cells | Nature
  • 02/16 mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants | Scientific Reports
  • 02/16 Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19 | NEJM
  • 02/16 Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM
  • 02/16 Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection | NEJM
  • 02/16 Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19 | NEJM
  • 02/17 Immunogenicity of a BNT162b2 Vaccine Booster Against SARS-CoV-2 Delta and Omicron Variants in Older People by Enagnon Kazali Alidjinou, Julie Demaret, Bénédicte Corroyer-Simovic, Julien Labreuche, Anne Goffard, Jacques Trauet, Daniela Lupau, Sophie Miczek, Fanny Vuotto, Arnaud Dendooven, Dominique Huvent-Grelle, Juliette Podvin, Daniel Dreuil, Karine Faure, Dominique Deplanque, Laurence Bocket, Alain Duhamel, Annie Sobaszek, Didier Hober, Michael Hisbergues, François Puisieux, Brigitte Autran, Yazdan Yazdanpanah, Myriam Labalette, Guillaume Lefèvre :: SSRN
  • 02/17 Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2: Cell Host & Microbe
  • 02/17 Viruses | Free Full-Text | SARS-CoV-2 Delta Variant (AY.3) in the Feces of a Domestic Cat - MDPI
  • 02/18 Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial | Complementary and Alternative Medicine | JAMA Internal Medicine | JAMA Network
  • 02/18 Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study - The Lancet Child & Adolescent Health
  • 02/19 Clinical severity of Omicron sub-lineage BA.2 compared to BA.1 in South Africa | medRxiv
  • 02/19 Risk of SARS-CoV-2 reinfection 18 months after primary infection: population-level observational study | medRxiv
  • 02/21 Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis | Allergy and Clinical Immunology | JAMA Internal Medicine | JAMA Network
  • 02/21 An Analysis of Joe Rogan’s COVID-19 Apology by Gavriel Steiger :: SSRN
  • 02/21 Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants | Nature Medicine
  • 02/21 Screening for SARS-CoV-2 Persistence in Long COVID Patients using Sniffer Dogs and Scents from Axillary Sweats Samples - ResearchGate
  • 02/22 Symptoms After COVID-19 Vaccination in Patients with Post-Acute Sequelae of SARS-CoV-2 | SpringerLink
  • 02/22 Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine | bioRxiv
  • 02/22 A neural population selective for song in human auditory cortex: Current Biology
  • 02/22 Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection | medRxiv
  • 02/22 The major genetic risk factor for severe COVID-19 is associated with protection against HIV | PNAS
  • 02/23 Population Immunity and Covid-19 Severity with Omicron Variant in South Africa | NEJM
  • 02/24 Multiple early factors anticipate post-acute COVID-19 sequelae: Cell
  • 02/24 Risk of Long Covid in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study | medRxiv
  • 02/24 Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses | Nature Immunology
  • 02/25 Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage | medRxiv
  • 02/25 Risk of COVID-19 related deaths for SARS-CoV-2 Omicron (B.1.1.529) compared with Delta (B.1.617.2) | medRxiv
  • 02/28 An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques | bioRxiv
  • 02/28 Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant | medRxiv
  • 02/28 Post-acute symptoms, new onset diagnoses and health problems 6 to 12 months after SARS-CoV-2 infection: a nationwide questionnaire study in the adult Danish population | medRxiv
  • 02/28 Multiscale PHATE identifies multimodal signatures of COVID-19 | Nature Biotechnology
  • 02/28 Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults - The Lancet Infectious Diseases

    March 2022

  • 03/01 Modeling the filtration efficiency of a woven fabric: The role of multiple lengthscales: Physics of Fluids: Vol 34, No 3
  • 03/01 Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID | Neurology Neuroimmunology & Neuroinflammation
  • 03/01 Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions | Annals of Internal Medicine
  • 03/01 Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review - The Lancet Global Health
  • 03/02 Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and signs of neurodegeneration: a prospective cross-sectional study | medRxiv
  • 03/02 Recurrent SARS-CoV-2 Mutations in Immunodeficient Patients | medRxiv
  • 03/02 Detection of COVID-19 using multimodal data from a wearable device: results from the first TemPredict Study | Scientific Reports
  • 03/02 Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant | NEJM
  • 03/03 Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents | Adolescent Medicine | JAMA Network Open | JAMA Network
  • 03/03 Evidence of co-infection during Delta and Omicron variants of concern co-circulation, weeks 49-2021 to 02-2022, France | medRxiv
  • 03/03 Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease | Nature Genetics
  • 03/03 Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong - eBioMedicine
  • 03/07 The mutational steps of SARS-CoV-2 to become like Omicron within seven months: the story of immune escape in an immunocompromised patient | medRxiv
  • 03/07 SARS-CoV-2 is associated with changes in brain structure in UK Biobank | Nature
  • 03/08 Toward Unbiased Evaluation of Postacute Sequelae of SARS-CoV-2 Infection: Challenges and Solutions for the Long Haul Ahead | Annals of Internal Medicine
  • 03/08 SARS-CoV-2 Infection Induces Ferroptosis of Sinoatrial Node Pacemaker Cells | Circulation Research
  • 03/08 Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study - The Lancet Public Health
  • 03/09 Social Determinants of Health Factors for Gene–Environment COVID‐19 Research: Challenges and Opportunities - Phuong - - Advanced Genetics - Wiley Online Library
  • 03/09 School Masking Policies and Secondary SARS-CoV-2 Transmission | Pediatrics | American Academy of Pediatrics
  • 03/09 Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study | The BMJ
  • 03/09 Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody: Cell
  • 03/09 Boosters protect against SARS-CoV-2 infections in young adults during an Omicron-predominant period | medRxiv
  • 03/09 Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use | NEJM
  • 03/09 Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 | NEJM
  • 03/09 Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar | NEJM
  • 03/10 Observed Protection Against SARS-CoV-2 Reinfection Following a Primary Infection: A Danish Cohort Study Using Two Years of Nationwide PCR-Test Data by Daniela Michlmayr, Christian Holm Hansen, Sophie Madeleine Gubbels, Palle Valentiner-Branth, Peter Michael Bager, Niels Obel, Birgitte Drewes, Camilla Holten Møller, Frederik Trier Møller, Rebecca Legarth, Kåre Mølbak, Steen Ethelberg :: SSRN
  • 03/10 Trends, regional variation and clinical characteristics of recipients of antivirals and neutralising monoclonal antibodies for non-hospitalised COVID-19: a descriptive cohort study of 23.4 million people in OpenSAFELY | medRxiv
  • 03/10 The changing epidemiology of SARS-CoV-2 - Science
  • 03/10 The immunology and immunopathology of COVID-19 - Science
  • 03/10 COVID-19 vaccination: The road ahead - Science
  • 03/10 COVID-19 - lessons for zoonotic disease - Science
  • 03/10 Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 - The Lancet
  • 03/12 Transmission of SARS-CoV-2 delta variant (AY.127) from pet hamsters to humans, leading to onward human-to-human transmission: a case study - The Lancet
  • 03/13 High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron | medRxiv
  • 03/13 Vaccination against SARS-CoV-2 in UK school-aged children and young people decreases infection rates and reduces COVID-19 symptoms | medRxiv
  • 03/14 SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21 - The Lancet Infectious Diseases
  • 03/15 Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa - Science
  • 03/15 Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant–Infected Vaccinees - Volume 28, Number 5—May 2022 - Emerging Infectious Diseases journal - CDC
  • 03/16 Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity: Cell
  • 03/16 Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants | NEJM
  • 03/16 Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron | NEJM
  • 03/17 Getting to the (germinal) center of humoral immune responses to SARS-CoV-2: Cell
  • 03/18 Protection of prior natural infection compared to mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar | medRxiv
  • 03/21 Intrinsic Severity of SARS-CoV-2 Omicron BA.2 in Uninfected, Unvaccinated Children: A Population-Based, Case-Control Study on Hospital Complications by Winnie Wan Yee Tso, Mike Kwan, Yu Liang Wang, Lok Kan Leung, Daniel Leung, Gilbert T. Chua, Patrick Ip, Wilfred Hing Sang Wong, Sophelia Hoi Shan Chan, Jasper Fuk-Woo Chan, J.S. Malik Peiris, Yu Lung Lau, Jaime Sou Rosa Duque :: SSRN
  • 03/21 Identification of a Novel SARS-CoV-2 Delta-Omicron Recombinant Virus in the United States | bioRxiv
  • 03/21 Bacterial and Fungal Isolation from Face Masks: Newly Emerged Hygiene Issues Under COVID-19 Pandemic | Research Square
  • 03/21 Risks and burdens of incident diabetes in long COVID: a cohort study - The Lancet Diabetes & Endocrinology
  • 03/21 Rising diabetes diagnosis in long COVID - The Lancet Diabetes & Endocrinology
  • 03/22 Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar | medRxiv
  • 03/22 Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong | medRxiv
  • 03/22 Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong | medRxiv
  • 03/22 An evolutionary insight into Severe Acute Respiratory Syndrome Coronavirus 2 Omicron variant of concern. - ScienceDirect
  • 03/23 Post-acute sequelae of COVID-19: A metabolic perspective | eLife
  • 03/23 Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning? | Journal of Virology
  • 03/23 Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection | NEJM
  • 03/23 Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine | NEJM
  • 03/23 SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study - The Lancet Microbe
  • 03/24 Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine | bioRxiv
  • 03/24 SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated individuals: Cell Host & Microbe
  • 03/24 SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals: Cell Host & Microbe
  • 03/24 mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron: Cell
  • 03/24 Relative Effectiveness of Four Doses Compared to Three Dose of the BNT162b2 Vaccine in Israel | medRxiv
  • 03/24 Inconsistent directions of change in case severity across successive SARS-CoV-2 variant waves suggests an unpredictable future | medRxiv
  • 03/24 Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old | Research Square
  • 03/24 Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529 - Science
  • 03/24 Understanding T-cell responses to COVID-19 is essential for informing public health strategies - Science
  • 03/25 Levels of SARS-CoV-2 Antibodies Among Fully-Vaccinated Individuals With Delta or Omicron Variant Breakthrough Infections: A Prospective Cohort Study by Nina Breinholt Stærke, Joanne Reekie, Henrik Nielsen, Thomas Benfield, Lothar Wiese, Lene Surland Knudsen, Mette Brouw Iversen, Kasper Karmark Iversen, Kamille Fogh, Jacob Bodilsen, Maria Ruwald Juhl, Susan Olaf Lindvig, Anne Øvrehus, Lone Wulff Madsen, Vibeke Klastrup, Sidsel Dahl Andersen, Anna Karina Juhl, Signe Rode Andreasen, Sisse Rye Ostrowski, Christian Erikstrup, Thea K. Fischer, Martin Tolstrup, Lars Jørgen Østergaard, Isik S. Johansen, Jens Lundgren, Ole S. Søgaard :: SSRN
  • 03/25 SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses - The Lancet
  • 03/26 Monitoring of the SARS-CoV-2 Omicron BA.1/BA.2 variant transition in the Swedish population reveals higher viral quantity in BA.2 cases | medRxiv
  • 03/27 Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants: Cell
  • 03/27 Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice: Cell
  • 03/27 Global Reports of Myocarditis Following COVID-19 Vaccination: A Systematic Review and Meta-Analysis | medRxiv
  • 03/28 Intrinsic Generation Time of the SARS-CoV-2 Omicron Variant: An Observational Study of Household Transmission by Mattia Manica, Alfredo De Bellis, Giorgio Guzzetta, Pamela Mancuso, Massimo Vicentini, Francesco Venturelli, Eufemia Bisaccia, Maria Litvinova, Piero Poletti, Valentina Marziano, Agnese Zardini, Valeria d'Andrea, Filippo Trentini, Antonino Bella, Flavia Riccardo, Patrizio Pezzotti, Marco Ajelli, Paolo Giorgi Rossi, Stefano Merler :: SSRN
  • 03/28 Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination: Cell Reports Medicine
  • 03/28 Detection of a BA.1/BA.2 recombinant in travelers arriving in Hong Kong, February 2022 | medRxiv
  • 03/28 A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic | Nature
  • 03/28 Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2 - The Lancet Microbe
  • 03/29 mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions - Science
  • 03/29 mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions | Science Translational Medicine
  • 03/29 Estimating Relative Abundance of 2 SARS-CoV-2 Variants through Wastewater Surveillance at 2 Large Metropolitan Sites, United States - Volume 28, Number 5—May 2022 - Emerging Infectious Diseases journal - CDC
  • 03/30 Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2 | bioRxiv
  • 03/30 Smart toilets for monitoring COVID-19 surges: passive diagnostics and public health | npj Digital Medicine
  • 03/30 Effect of Early Treatment with Ivermectin among Patients with Covid-19 | NEJM
  • 03/30 BNT162b2 Protection against the Omicron Variant in Children and Adolescents | NEJM
  • 03/30 SARS-CoV-2 infection of airway cells causes intense viral and cell shedding, two spreading mechanisms affected by IL-13 | PNAS
  • 03/30 Vaccine effectiveness against infection and COVID-19-associated hospitalisation with the Omicron (B.1.1.529) variant after vaccination with the BNT162b2 or mRNA-1273 vaccine: A nationwide Danish cohort study | Research Square
  • 03/31 Emissions rebound from the COVID-19 pandemic | Nature Climate Change
  • 03/31 Defining the risk of SARS-CoV-2 variants on immune protection | Nature
  • 03/31 Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults | Nature Medicine
  • 03/31 Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study - The Lancet Infectious Diseases
  • 03/31 Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden - The Lancet Infectious Diseases
  • 03/31 Interplay of infection and vaccination in long-term protection from COVID-19 - The Lancet Infectious Diseases

    April 2022

  • 04/01 Projecting COVID-19 Mortality as States Relax Nonpharmacologic Interventions - JAMA Health Forum
  • 04/01 Incidence Rates and Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in Children Younger Than 5 Years in the US | Infectious Diseases | JAMA Pediatrics | JAMA Network
  • 04/01 Safety of COVID-19 Vaccines During Pregnancy: A Systematic Review and Meta-Analysis by Agustin Ciapponi, Mabel Berrueta, Ariel Bardach, Agustina Mazzoni, Steven A. Anderson, Fernando J. Argento, Jamile Ballivian, Karin Bok, Daniel Comandé, Erin Goucher, Beate Kampmann, Edward Parker, Federico Rodriguez Cairoli, María Victoria Santa María, Andy Stergachis, Gerald Voss, Xu Xiong, Natalia Zamora, Pierre M. Buekens, Sabra Zaraa :: SSRN
  • 04/01 Omicron breakthrough infection drives cross-variant neutralization and memory B cell formation | bioRxiv
  • 04/02 The Evolution and Biology of SARS-CoV-2 Variants - Perspectives in Medicine
  • 04/03 Humanized mice reveal a macrophage-enriched gene signature defining human lung tissue protection during SARS-CoV-2 infection: Cell Reports
  • 04/03 Cardiac impairment in Long Covid 1-year post-SARS-CoV-2 infection | medRxiv
  • 04/04 Rapid characterization of a Delta-Omicron SARS-CoV-2 recombinant detected in Europe | Research Square
  • 04/05 Studying severe long COVID to understand post-infectious disorders beyond COVID-19 | Nature Medicine
  • 04/05 Protection by a Fourth Dose of BNT162b2 against Omicron in Israel | NEJM
  • 04/05 SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies - Science
  • 04/06 Spiral: Twin peaks: the Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England - Imperial College London
  • 04/06 Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study | The BMJ
  • 04/06 Pulse Oximetry for Monitoring Patients with Covid-19 at Home — A Pragmatic, Randomized Trial | NEJM
  • 04/06 Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers | NEJM
  • 04/06 COVID-19 therapeutics: Challenges and directions for the future | PNAS
  • 04/07 Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike | bioRxiv
  • 04/07 Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine: Cell
  • 04/07 Epidemiology of infections with SARS-CoV-2 Omicron BA.2 variant in Hong Kong, January-March 2022 | medRxiv
  • 04/07 Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines | Nature Nanotechnology
  • 04/07 Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron | NEJM
  • 04/08 Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients | medRxiv
  • 04/08 Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2 | Nature Medicine
  • 04/08 An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques | Research Square
  • 04/08 Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis - The Lancet
  • 04/11 Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19 | Infectious Diseases | JAMA Neurology | JAMA Network
  • 04/11 SARS-CoV-2 Infection and Associated Cardiovascular Manifestations and Complications in Children and Young Adults: A Scientific Statement From the American Heart Association | Circulation
  • 04/11 Prevalence, Characteristics, and Outcomes of COVID-19–Associated Acute Myocarditis | Circulation
  • 04/11 Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection | medRxiv
  • 04/11 Understanding COVID-19 through genome-wide association studies | Nature Genetics
  • 04/11 Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis - The Lancet Respiratory Medicine
  • 04/12 Evolution of nasal and olfactory infection characteristics of SARS-CoV-2 variants | bioRxiv
  • 04/12 Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection: Med
  • 04/12 Admissions to a large tertiary care hospital and Omicron BA.1 and BA.2 SARS-CoV-2 PCR positivity: primary, contributing, or incidental COVID-19 | medRxiv
  • 04/12 SARS-CoV-2 spike protein–induced cell fusion activates the cGAS-STING pathway and the interferon response - Science
  • 04/12 Population-level implications of the Israeli booster campaign to curtail COVID-19 resurgence - Science
  • 04/12 Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3 - The Lancet Infectious Diseases
  • 04/13 Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants: Med
  • 04/13 Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting | NEJM
  • 04/14 To mask, or not to mask, Alice and Bob’s dating dilemma | medRxiv
  • 04/14 Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 | NEJM
  • 04/14 High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron | Research Square
  • 04/14 A SARS-CoV-2 omicron (B.1.1.529) variant outbreak in a primary school in Geneva, Switzerland - The Lancet Infectious Diseases
  • 04/15 Acute Upper Airway Disease in Children With the Omicron (B.1.1.529) Variant of SARS-CoV-2—A Report From the US National COVID Cohort Collaborative | Pediatrics | JAMA Pediatrics | JAMA Network
  • 04/19 Inter-individual variation in objective measure of reactogenicity following COVID-19 vaccination via smartwatches and fitness bands | npj Digital Medicine
  • 04/19 An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses -Science
  • 04/20 The Evolution and Biology of SARS-CoV-2 Variants
  • 04/20 Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide Danish cohort study | medRxiv
  • 04/20 Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 | NEJM
  • 04/21 Impact of the additional/booster dose of COVID-19 vaccine against severe disease during the epidemic phase characterized by the predominance of the Omicron variant in Italy, November 2021 - March 2022 | medRxiv
  • 04/21 Brain changes after COVID-19 — how concerned should we be? | Nature Reviews Neurology
  • 04/21 Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost | Nature
  • 04/21 Policy stringency and mental health during the COVID-19 pandemic: a longitudinal analysis of data from 15 countries - The Lancet Public Health
  • 04/22 Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 Trial by Thomas L. Holland, Adit A. Ginde, Roger Paredes, Thomas A. Murray, Nicole Engen, Greg Grandits, Andrew Vekstein, Noel Ivey, Ahmad Mourad, Uriel Sandkovsky, Robert L. Gottlieb, Mezgebe Berhe, Mamta Jain, Rubria Marines-Price, Barbine Tchamba Agbor Agbor, Lourdes Mateu, Sergio Espana-Cueto, Gemma Llados, Eleftherios Mylonakis, Ralph Rogers, Fadi Shehadeh, Michael R. Filbin, Kathryn A. Hibbert, Kami Kim, Thanh Tran, Peter E. Morris, Evan P. Cassity, Barbara Trautner, Lavannya M. Pandit, Kirk U. Knowlton, Lindsay Leither, Michael A. Matthay, Angela J. Rogers, Wonder Drake, Beatrice Jones, Garyfallia Poulakou, Konstantinos N. Syrigos, Eduardo Fernandez-Cruz, Marisa Di Natale, Eyad Almasri, Leire Balerdi-Sarasola, Sanjay R. Bhagani, Katherine L. Boyle, Jonathan D. Casey, Peter Chen, David J. Douin, D. Clark Files, Huldrych F. Günthard, R. Duncan Hite, Robert C. Hyzy, Akram Khan, Moses Kibirige, Robert Kidega, Ivan Kimuli, Francis Kiweewa, Jens Ulrik Stæhr Jensen, Bradley G. Leshnower, Joseph K. Lutaakome, Prasad Manian, Vidya Menon, Jose Luis Morales-Rull, Darragh O'Mahony, J. Scott Overcash, Srikant Ramachandruni, Jay S. Steingrub, Hassan S. Taha, Michael Waters, Barnaby E. Young, Andrew N. Phillips, Daniel D. Murray, Tomas O. Jensen, Maria L. Padilla, David Sahner, Katy Shaw-Saliba, Robin L. Dewar, Marc Teitelbaum, Ven Natarajan, M. Tauseef Rehman, Sarah Pett, Fleur Hudson, Giota Touloumi, Samuel M. Brown, Wesley H. Self, Christina C. Chang, Adriana Sanchez, Amy C. Weintrob, Timothy Hatlen, Birgit Grund, Shweta Sharma, Cavan S. Reilly, Pedro Garbes, Mark T. Esser, Alison Templeton, Abdel G. Babiker, Victoria J. Davey, Annetine C. Gelijns, Elizabeth S. Higgs, Virginia Kan, Gail Matthews, B. Taylor Thompson, James D. Neaton, H. Clifford Lane, Jens Lundgren :: SSRN
  • 04/22 Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study - The Lancet Respiratory Medicine
  • 04/23 Excess all-cause mortality across counties in the United States, March 2020 to December 2021 | medRxiv
  • 04/23 Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health
  • 04/23 Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study - The Lancet Respiratory Medicine
  • 04/24 Hospitalized patients with severe COVID-19 during the Omicron wave in Israel - benefits of a fourth vaccine dose | medRxiv
  • 04/25 A living WHO guideline on drugs for covid-19 | The BMJ
  • 04/25 Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the SARS-CoV-2 BA.1 and BA.2 Omicron variants: Med
  • 04/25 Impact of population mixing between vaccinated and unvaccinated subpopulations on infectious disease dynamics: implications for SARS-CoV-2 transmission | CMAJ
  • 04/25 Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
  • 04/26 Rapid Relapse of Symptomatic SARS-CoV-2 Infection Following Early Suppression with Nirmatrelvir/Ritonavir | Research Square
  • 04/27 Public health impact of covid-19 vaccines in the US: observational study | The BMJ
  • 04/27 Impact of the additional/booster dose of COVID-19 vaccine against severe disease during the epidemic phase characterized by the predominance of the Omicron variant in Italy, November 2021 - March 2022 | medRxiv
  • 04/27 An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron | Nature Microbiology
  • 04/28 A Pan-Coronavirus Vaccine Candidate: Nine Amino Acid Substitutions in the ORF1ab Gene Attenuate 99% of 365 Unique Coronaviruses: A Comparative Effectiveness Research Study | bioRxiv
  • 04/28 Evidence for Aerosol Transfer of SARS-CoV2-specific Humoral Immunity | medRxiv
  • 04/28 Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness | Nature Microbiology
  • 04/28 SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals | Nature Microbiology
  • 04/28 Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting | NEJM
  • 04/29 Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination | medRxiv
  • 04/29 Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions | Signal Transduction and Targeted Therapy
  • 04/30 BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection | bioRxiv

    May 2022

  • 05/01 Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike: Cell
  • 05/01 Continued Emergence and Evolution of Omicron in South Africa: New BA.4 and BA.5 lineages | medRxiv
  • 05/01 Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort - ScienceDirect
  • 05/01 The performance of wearable sensors in the detection of SARS-CoV-2 infection: a systematic review - The Lancet Digital Health
  • 05/03 SARS-CoV-2 Rapid Antigen Test Sensitivity and Viral Load in Freshly Symptomatic Hospital Employees, December 2020 to February 2022 by Leonie Meiners, Johanna Horn, Barbara Mühlemann, Marie Luisa Schmidt, Felix Walper, Peter Menzel, Rolf Schwarzer, Ruben Rose, Andi Krumbholz, Terry C. Jones, Victor M. Corman, Joachim Seybold, Christian Drosten :: SSRN
  • 05/03 Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies | bioRxiv
  • 05/04 Long Covid: A Systematic Review and Meta-Analysis of 120,970 Patients by Francesco Di Gennaro, Alessandra Belati, Ottavia Tulone, Lucia Diella, Davide Fiore Bavaro, Roberta Bonica, Vincenzo Genna, Lee Smith, Mike Trott, Olivier Bruyere, Luigi Mirarchi, Claudia Cusumano, Mario Barbagallo, Ligia Juliana Dominguez Rodriguez, Annalisa Saracino, Nicola Veronese :: SSRN
  • 05/04 Face masking and COVID-19: potential effects of variolation on transmission dynamics | Journal of The Royal Society Interface
  • 05/04 Protection against omicron severe disease 0-7 months after BNT162b2 booster | medRxiv
  • 05/04 Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa | NEJM
  • 05/04 Long COVID: aiming for a consensus - The Lancet Respiratory Medicine
  • 05/05 Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates | PLOS Biology
  • 05/05 SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies: Cell Host & Microbe
  • 05/05 Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model - Science
  • 05/06 Omicron infection enhances Delta antibody immunity in vaccinated persons | Nature
  • 05/07 Omicron: increased transmissibility and decreased pathogenicity | Signal Transduction and Targeted Therapy
  • 05/08 Imprinted antibody responses against SARS-CoV-2 Omicron sublineages | bioRxiv
  • 05/09 Persistent serum protein signatures define an inflammatory subset of long COVID | bioRxiv
  • 05/09 The clinical progress of mRNA vaccines and immunotherapies | Nature Biotechnology
  • 05/09 Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/ Post-Acute Sequelae of COVID-19 (PASC) | Research Square
  • 05/10 Modeling transmission of SARS-CoV-2 Omicron in China | Nature Medicine
  • 05/10 Antibodies induced by ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1 - Science
  • 05/11 Impaired exercise capacity in post-COVID syndrome: the role of VWF-ADAMTS13 axis | Blood Advances | American Society of Hematology
  • 05/11 Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study - The Lancet Respiratory Medicine
  • 05/12 Effectiveness of a Second COVID-19 Vaccine Booster on All-Cause Mortality in Long-Term Care Facility Residents and in the Oldest Old: A Nationwide, Retrospective Cohort Study in Sweden by Peter Nordström, Marcel Ballin, Anna Nordström :: SSRN
  • 05/12 A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells: Cell Metabolism
  • 05/13 Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants | PNAS
  • 05/13 Detecting anti–SARS-CoV-2 antibodies in urine samples: A noninvasive and sensitive way to assay COVID-19 immune conversion - Science
  • 05/13 Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens - The Lancet Gastroenterology & Hepatology
  • 05/13 Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study - The Lancet Infectious Diseases
  • 05/16 Omicron Infection Induces Low-Level, Narrow-Range SARS-CoV-2 Neutralizing Activity by Priscilla Turelli, María-Eugenia Zaballa, Charlène Raclot, Craig Fenwick, Laurent Kaiser, Isabella Eckerle, Giuseppe Pantaleo, Idris Guessous, Silvia Stringhini, Didier Trono :: SSRN
  • 05/16 A live attenuated vaccine confers superior mucosal and systemic immunity to SARS-CoV-2 variants | bioRxiv
  • 05/16 Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants | bioRxiv
  • 05/16 Neutralization Escape by the SARS-CoV-2 Omicron Variants BA.2.12.1 and BA.4/BA.5 | medRxiv
  • 05/16 BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality | Nature Microbiology
  • 05/16 Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2 | Nature
  • 05/16 The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies | PNAS
  • 05/17 Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study | PLOS Medicine
  • 05/17 Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalisation in Community COVID-19 Patients by Cheuk Fung Yip, Grace C.Y. Lui, Mandy Sze Man Lai, Vincent Wai-Sun Wong, Yee-Kit Tse, Bosco Hon-Ming Ma, Elsie Hui, Maria KW Leung, Henry Lik-Yuen Chan, David S. C. Hui, David Shu-Cheong Hui :: SSRN
  • 05/17 How local partisan context conditions prosocial behaviors: Mask wearing during COVID-19 | PNAS
  • 05/18 Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study | The BMJ
  • 05/18 Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination | Nature
  • 05/18 Unexplained post-acute infection syndromes | Nature Medicine
  • 05/18 Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants | NEJM
  • 05/18 Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment | Research Square
  • 05/19 Potent cross-reactive antibodies following Omicron breakthrough in vaccinees: Cell
  • 05/19 Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong’s Omicron BA.2 wave: an observational study | medRxiv
  • 05/20 Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial - The Lancet Respiratory Medicine
  • 05/21 Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum | bioRxiv
  • 05/21 Variant-specific symptoms of COVID-19 among 1,542,510 people in England | medRxiv
  • 05/22 Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: an observational cohort study using the OpenSAFELY platform | medRxiv
  • 05/23 Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms | Infectious Diseases | JAMA Network Open | JAMA Network
  • 05/23 Variant-specific symptoms of COVID-19 among 1,542,510 people in England | medRxiv
  • 05/23 A multisystem, cardio-renal investigation of post-COVID-19 illness | Nature Medicine
  • 05/23 Multisystem involvement is common in post-COVID-19 syndrome | Nature Medicine
  • 05/23 Aerosol particle emission increases exponentially above moderate exercise intensity resulting in superemission during maximal exercise | PNAS
  • 05/24 A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings | Annals of Internal Medicine
  • 05/24 Virologic characterization of symptom rebound following nirmatrelvir-ritonavir treatment for COVID-19 | medRxiv
  • 05/24 Generalizable Long COVID Subtypes: Findings from the NIH N3C and RECOVER Programs | medRxiv
  • 05/24 Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness - Science
  • 05/24 Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness -Science
  • 05/24 COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England - The Lancet Infectious Diseases
  • 05/24 Co-infection with SARS-CoV-2 omicron BA.1 and BA.2 subvariants in a non-vaccinated woman - The Lancet Microbe
  • 05/25 Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5 | bioRxiv
  • 05/25 Intrahost evolution and forward transmission of a novel SARS-CoV-2 Omicron BA.1 subvariant | medRxiv
  • 05/25 Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism | npj Vaccines - Nature
  • 05/25 Long COVID after breakthrough SARS-CoV-2 infection | Nature Medicine
  • 05/25 Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron | NEJM
  • 05/25 Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 | NEJM
  • 05/26 SARS-CoV-2 Omicron BA.2.12.1, BA.4, and BA.5 subvariants evolved to extend antibody evasion | bioRxiv
  • 05/26 Virological characteristics of the novel SARS-CoV-2 Omicron variants including BA.2.12.1, BA.4 and BA.5 | bioRxiv
  • 05/26 Structure, receptor recognition and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein: Cell
  • 05/26 Humoral and cellular immune memory to four COVID-19 vaccines: Cell
  • 05/26 The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants: Immunity
  • 05/26 Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study | medRxiv
  • 05/26 Protection against Omicron conferred by mRNA primary vaccine series, boosters, and prior infection | medRxiv
  • 05/26 Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age | NEJM
  • 05/27 Association between Self-reported Masking Behavior and SARS-CoV-2 Infection Wanes from Pre-Delta to Omicron-Predominant Periods — North Carolina COVID-19 Community Research Partnership | medRxiv
  • 05/28 Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data | medRxiv
  • 05/29 Risk of incident diabetes post-COVID-19: A systematic review and meta-analysis - Primary Care Diabetes
  • 05/30 Replication of SARS-CoV-2 Omicron BA.2 Variant in <i>Ex Vivo</i> Cultures of the Human Upper and Lower Respiratory Tract by Kenrie PY Hui, Ka-Chun Ng, John CW Ho, Hin-Wo Yeung, Rachel HH Ching, Haogao Gu, Joseph CK Chung, Velda LY Chow, Ko-Yung Sit, Michael KY Hsin, Timmy WK Au, Leo LM Poon, J.S. Malik Peiris, John M. Nicholls, Michael CW Chan :: SSRN
  • 05/30 An early warning system for emerging SARS-CoV-2 variants | Nature Medicine
  • 05/31 Analysis of overdispersion in airborne transmission of COVID-19: Physics of Fluids: Vol 34, No 5
  • 05/31 Racial and Ethnic Discrepancy in Pulse Oximetry and Delayed Identification of Treatment Eligibility Among Patients With COVID-19 | Health Disparities | JAMA Internal Medicine | JAMA Network
  • 05/31 Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis | The BMJ
  • 05/31 Mask wearing in community settings reduces SARS-CoV-2 transmission | PNAS

    June 2022

  • 06/01 Diagnostic accuracy of non-invasive detection of SARS-CoV-2 infection by canine olfaction | PLOS ONE
  • 06/01 COVID-19 vaccine misinformation in English-language news media: retrospective cohort study - PubMed
  • 06/01 Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron Surge | Research Square
  • 06/02 Distinct smell and taste disorder phenotype of post-acute COVID-19 sequelae | medRxiv
  • 06/02 COVID-19 vaccination mandates and vaccine uptake | Nature Human Behaviour
  • 06/02 Does the World Still Need New Covid-19 Vaccines? | NEJM
  • 06/02 Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes - Science
  • 06/02 Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes -Science
  • 06/02 FIND documents dramatic reduction in COVID-19 testing - The Lancet Infectious Diseases
  • 06/03 Distinct smell and taste disorder phenotype of post-acute COVID-19 sequelae | medRxiv
  • 06/03 The circadian immune system - Science
  • 06/07 Reducing SARS-CoV-2 in Shared Indoor Air | Infectious Diseases | JAMA | JAMA Network
  • 06/07 Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro | bioRxiv
  • 06/07 The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir | bioRxiv
  • 06/07 Persistence of residual SARS-CoV-2 viral antigen and RNA in tissues of patients with long COVID-19 | Research Square
  • 06/07 SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations post recovery - Science
  • 06/07 Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial - The Lancet Respiratory Medicine
  • 06/08 Concordance of SARS-CoV-2 RNA in Aerosols From a Nurses Station and in Nurses and Patients During a Hospital Ward Outbreak | Infectious Diseases | JAMA Network Open | JAMA Network
  • 06/08 Herpesvirus and neurological manifestations in patients with severe coronavirus disease | Virology Journal | Full Text
  • 06/08 Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum: Cell
  • 06/08 Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California | Nature Medicine
  • 06/08 SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients | NEJM
  • 06/08 COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records - The Lancet Digital Health
  • 06/08 Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies - The Lancet Infectious Diseases
  • 06/08 Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform - The Lancet Rheumatology
  • 06/09 Neurodevelopmental Outcomes at 1 Year in Infants of Mothers Who Tested Positive for SARS-CoV-2 During Pregnancy | Child Development | JAMA Network Open | JAMA Network
  • 06/09 Mitigation of SARS-CoV-2 transmission at a large public university | Nature Communications
  • 06/09 Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection | PNAS
  • 06/12 Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation: Cell
  • 06/13 Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR | Nature Biotechnology
  • 06/13 Four areas of health innovation boosted by the pandemic | Nature Medicine
  • 06/13 Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic | PNAS
  • 06/14 Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United States | medRxiv
  • 06/14 Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae | medRxiv
  • 06/14 Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure - Science
  • 06/16 Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance | Nature Medicine
  • 06/16 Protective Policy Index (PPI) global dataset of origins and stringency of COVID 19 mitigation policies | Scientific Data
  • 06/17 BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection | Nature
  • 06/17 Outcomes of SARS-CoV-2 Reinfection | Research Square
  • 06/18 Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2 - The Lancet
  • 06/19 What SARS-CoV-2 does to our brains: Immunity
  • 06/20 Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment | Clinical Infectious Diseases | Oxford Academic
  • 06/20 Smartphone apps in the COVID-19 pandemic | Nature Biotechnology
  • 06/20 Drivers of adaptive evolution during chronic SARS-CoV-2 infections | Nature Medicine
  • 06/20 Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection - The Lancet Infectious Diseases
  • 06/21 Investigation of the use of a sensor bracelet for the presymptomatic detection of changes in physiological parameters related to COVID-19: an interim analysis of a prospective cohort study (COVI-GAPP) | BMJ Open
  • 06/21 Hybrid measurement of respiratory aerosol reveals a dominant coarse fraction resulting from speech that remains airborne for minutes | PNAS
  • 06/21 A pilot randomized controlled trial of supervised, at-home, self-administered transcutaneous auricular vagus nerve stimulation (taVNS) to manage long COVID symptoms | Research Square
  • 06/22 Analyzing COVID-19 disinformation on Twitter using the hashtags #scamdemic and #plandemic: Retrospective study | PLOS ONE
  • 06/22 Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5 | NEJM
  • 06/22 Covid-19 Vaccination during Pregnancy — Two for the Price of One | NEJM
  • 06/22 Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants | NEJM
  • 06/22 Long COVID symptoms in SARS-CoV-2-positive children aged 0–14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study - The Lancet Child & Adolescent Health
  • 06/23 Long-COVID in children and adolescents: a systematic review and meta-analyses | Scientific Reports
  • 06/23 Posttranslational modifications optimize the ability of SARS-CoV-2 spike for effective interaction with host cell receptors | PNAS
  • 06/23 Pathogen-sugar interactions revealed by universal saturation transfer analysis - Science
  • 06/23 Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters - Science
  • 06/23 Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct - Science
  • 06/23 Global impact of the first year of COVID-19 vaccination: a mathematical modelling study - The Lancet Infectious Diseases
  • 06/27 The humoral response and antibodies against SARS-CoV-2 infection | Nature Immunology
  • 06/27 Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa | Nature Medicine
  • 06/28 All-Cause Maternal Mortality in the US Before vs During the COVID-19 Pandemic | Health Disparities | JAMA Network Open | JAMA Network
  • 06/28 Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir | bioRxiv
  • 06/28 The dynamics of SARS-CoV-2 infectivity with changes in aerosol microenvironment | PNAS
  • 06/28 Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5 - The Lancet Infectious Diseases
  • 06/29 COVID-19 Neuropathology: evidence for SARS-CoV-2 invasion of Human Brainstem Nuclei | bioRxiv
  • 06/29 Long distance airborne transmission of SARS-CoV-2: rapid systematic review | The BMJ
  • 06/29 Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection | NEJM
  • 06/29 Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine | NEJM
  • 06/29 BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age | NEJM
  • 06/29 The Vaccine-Hesitant Moment | NEJM
  • 06/29 A broad and potent neutralization epitope in SARS-related coronaviruses | PNAS
  • 06/30 BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design by Sara Y. Tartof, Jeff M. Slezak, Laura Puzniak, Vennis Hong, Fagen Xie, Bradley K. Ackerson, Srinivas R. Valluri, Luis Jodar, John M. McLaughlin :: SSRN
  • 06/30 IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2 - Science
  • 06/30 Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study - The Lancet Diabetes & Endocrinology

    July 2022

  • 07/01 Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers | Vaccination | JAMA | JAMA Network
  • 07/01 Analysis of COVID-19–Related Croup and SARS-CoV-2 Variant Predominance in the US | Emergency Medicine | JAMA Network Open | JAMA Network
  • 07/04 Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine | Nature Biomedical Engineering - Nature
  • 07/04 Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine | Nature Biomedical Engineering
  • 07/05 Leading Causes of Death in the US During the COVID-19 Pandemic, March 2020 to October 2021 | Population Health | JAMA Internal Medicine | JAMA Network
  • 07/05 How long and effective does a mask protect you from an infected person who emits corona virus-laden particles: by implementing physics-based modeling | medRxiv
  • 07/05 Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models - Science
  • 07/06 Past SARS-CoV-2 Infection Protection Against Reinfection: A Systematic Review and Meta-Analysis by COVID-19 Forecasting Team, SS Lim :: SSRN
  • 07/06 Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study | The BMJ
  • 07/06 SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns: Cell Host & Microbe
  • 07/06 Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines | NEJM
  • 07/07 SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern | medRxiv
  • 07/07 Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission | Nature
  • 07/07 Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5 | NEJM
  • 07/07 SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice - Science
  • 07/08 Brain imaging and neuropsychological assessment of individuals recovered from mild to moderate SARS-CoV-2 infection | medRxiv
  • 07/08 The effect of COVID certificates on vaccine uptake, health outcomes, and the economy | Nature Communications - Nature
  • 07/08 Long COVID and symptom trajectory in a representative sample of Americans in the first year of the pandemic | Scientific Reports
  • 07/08 Immune determinants of chronic sequelae after respiratory viral infection - Science
  • 07/11 Protection of SARS-CoV-2 natural infection against reinfection with the Omicron BA.4 or BA.5 subvariants | medRxiv
  • 07/11 SARS-CoV-2 infection and the brain: direct evidence for brain changes in milder cases | Signal Transduction and Targeted Therapy
  • 07/12 Enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants BA.4 and BA.5 | bioRxiv
  • 07/12 SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses | medRxiv
  • 07/12 Omicron: a shift in the biology of SARS-CoV-2 | Nature Microbiology
  • 07/12 Tropism of SARS-CoV-2 for human cortical astrocytes | PNAS
  • 07/12 Universal healthcare and the pandemic mortality gap | PNAS
  • 07/12 ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies - Science
  • 07/12 Broadly neutralizing antibodies target the coronavirus fusion peptide - Science
  • 07/13 Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review | The BMJ
  • 07/13 Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope: Cell
  • 07/13 Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: A nationwide, retrospective cohort study in Sweden - The Lancet Regional Health - Europe
  • 07/14 Neutralization sensitivity of Omicron BA.2.75 to therapeutic monoclonal antibodies | bioRxiv
  • 07/14 Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages | bioRxiv
  • 07/14 Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2 | Nature Microbiology
  • 07/14 Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries | Nature Genetics
  • 07/14 Abrupt decreases in infectivity of SARS-CoV-2 in aerosols | PNAS
  • 07/14 SARS-CoV-2-specific T cells in unexposed adults display broad trafficking potential and cross-react with commensal antigens - Science
  • 07/14 SARS-CoV-2-specific T cells in unexposed adults display broad trafficking potential and cross-react with commensal antigens | Science Immunology
  • 07/15 SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses | medRxiv
  • 07/15 The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2 | PNAS
  • 07/17 Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2: Cell Host & Microbe
  • 07/18 Risk of Reinfection, Vaccine Protection, and Severity of Infection with the BA.5 Omicron Subvariant: A Danish Nation-Wide Population-Based Study by Christian Holm Hansen, Nikolaj Ulrik Friis, Peter Bager, Marc Stegger, Jannik Fonager, Anders Fomsgaard, Mie Agermose Gram, Lasse Engbo Christiansen, Steen Ethelberg, Rebecca Legarth, Tyra Grove Krause, Henrik Ullum, Palle Valentiner-Branth :: SSRN
  • 07/18 Viral variant-resolved wastewater surveillance of SARS-CoV-2 at national scale | Nature Biotechnology
  • 07/18 In SARS-CoV-2, astrocytes are in it for the long haul | PNAS
  • 07/18 A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab - The Lancet Infectious Diseases
  • 07/19 Cardiometabolic outcomes up to 12 months after COVID-19 infection. A matched cohort study in the UK | PLOS Medicine
  • 07/19 Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic: Cell Host & Microbe
  • 07/19 Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines | Science
  • 07/19 Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination | Science Immunology
  • 07/20 Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age | NEJM
  • 07/20 Tunneling nanotubes provide a route for SARS-CoV-2 spreading | Science Advances
  • 07/21 Operation Nasal Vaccine—Lightning speed to counter COVID-19 | Science Immunology
  • 07/21 Finite neutralisation breadth of omicron after repeated vaccination - The Lancet Microbe
  • 07/22 Post–COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection | Pediatrics | JAMA Network Open | JAMA Network
  • 07/22 Interferon resistance of emerging SARS-CoV-2 variants | PNAS
  • 07/22 Treatment of Long COVID with nirmatrelvir/ritonavir and tocilizumab in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence: a case report | Research Square
  • 07/25 Preventive Medication for COVID-19 Infection | Infectious Diseases | JAMA | JAMA Network
  • 07/25 SARS-CoV-2 BA.5 vaccine breakthrough risk and severity compared with BA.2: a case-case and cohort study using Electronic Health Records in Portugal | medRxiv
  • 07/25 Symptoms and risk factors for long COVID in non-hospitalized adults | Nature Medicine
  • 07/25 SARS-CoV-2 impairs interferon production via NSP2-induced repression of mRNA translation | PNAS
  • 07/26 Update Alert 8: Masks for Prevention of Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community Settings | Annals of Internal Medicine
  • 07/26 The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2 - Science
  • 07/26 The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic - Science
  • 07/26 SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children | Science Translational Medicine
  • 07/27 Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection | Infectious Diseases | JAMA Network Open | JAMA Network
  • 07/27 Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves | The BMJ
  • 07/27 Evolution of SARS-CoV-2 Shedding in Exhaled Breath Aerosols | medRxiv
  • 07/27 Risk of severe COVID-19 infection among adults with prior exposure to children | PNAS
  • 07/27 Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2–induced lung exudative vasculitis and predicts COVID-19 severity | PNAS
  • 07/27 SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies | Science Translational Medicine
  • 07/28 Risk of BA.5 infection in individuals exposed to prior SARS-CoV-2 variants | medRxiv
  • 07/28 The Efficacy of Facemasks in the Prevention of COVID-19: A Systematic Review | medRxiv
  • 07/30 Comparative effectiveness of BNT162b2 versus mRNA-1273 boosting in England: a cohort study in OpenSAFELY-TPP | medRxiv
  • 07/30 Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis - The Lancet
  • 07/31 Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75 | bioRxiv
  • 07/31 The Efficacy of Facemasks in the Prevention of COVID-19: A Systematic Review | medRxiv

    August 2022

  • 08/01 Vaccine Effectiveness of BNT162b2 Against Omicron in Children Aged 5-11 Years: A Test-Negative Design by Pierre-Philippe Piché-Renaud, Sarah Swayze, Sarah Buchan, Sarah Wilson, Peter C. Austin, Shaun K. Morris, Sharifa Nasreen, Kevin L. Schwartz, Mina Tadrous, Nisha Thampi, Kumanan Wilson, Jeffrey C. Kwong, Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators Group :: SSRN
  • 08/01 Coenzyme Q10 as Treatment of Post COVID-19 Condition by Kristoffer Skaalum Hansen, Trine Hyrup Mogensen, Jane Agergaard, Berit Schiøttz-Christensen, Lars Jørgen Østergaard, Line Khalidan Vibholm, Steffen Leth :: SSRN
  • 08/01 JCI - Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches - Journal of Clinical Investigation
  • 08/02 Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel | Infectious Diseases | JAMA Network Open | JAMA Network
  • 08/02 Viral and Symptom Rebound in Untreated COVID-19 Infection | medRxiv
  • 08/03 Rate of SARS-CoV-2 Reinfection During an Omicron Wave in Iceland | Infectious Diseases | JAMA Network Open | JAMA Network
  • 08/03 Comparative COVID-19 Vaccines Effectiveness in Preventing Infections, Hospitalizations, and Deaths with SARS-CoV-2 BA.5 and Ba.2 Omicron Lineages: A Case-Case and Cohort Study Using Electronic Health Records in Portugal by Irina Kislaya, Pedro Casaca, Vítor Borges, Carlos Sousa, Bibiana I. Ferreira, Ana Fonte, Eugenia Fernandes, Carlos Matias Dias, Silvia Duarte, José Pedro Almeida, Inês Grenho, Luís Coelho, Rita Ferreira, Patrícia Pita Ferreira, Cláudia Medeiros Borges, Joana Isidro, Miguel Pinto, Luís Menezes, Daniel Sobral, Alexandra Nunes, Daniela Santos, António Maia Gonçalves, Luís Vieira, João Paulo Gomes, Pedro Pinto Leite, Baltazar Nunes, Ausenda Machado, André Peralta-Santos :: SSRN
  • 08/03 A first update on mapping the human genetic architecture of COVID-19 | Nature
  • 08/04 Child Deaths by Gun Violence in the US During the COVID-19 Pandemic | Firearms | JAMA Network Open | JAMA Network
  • 08/04 Two-Year Prevalence and Recovery Rate of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19 | Olfaction and Taste | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
  • 08/04 mRNA vaccines and hybrid immunity use different B cell germlines to neutralize Omicron BA.4 and BA.5 | bioRxiv
  • 08/04 Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein: Cell Host & Microbe
  • 08/04 COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period | medRxiv
  • 08/04 Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants | NEJM
  • 08/04 An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif | Science Immunology
  • 08/04 Maintaining genomic surveillance using whole-genome sequencing of SARS-CoV-2 from rapid antigen test devices - The Lancet Infectious Diseases
  • 08/05 COVID-19 burden among unaccompanied minors in United States custody | Clinical Infectious Diseases | Oxford Academic
  • 08/05 Examination of SARS-CoV-2 In-Class Transmission at a Large Urban University With Public Health Mandates Using Epidemiological and Genomic Methodology | Genetics and Genomics | JAMA Network Open | JAMA Network
  • 08/05 Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5 | bioRxiv
  • 08/05 The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern | medRxiv
  • 08/05 Understanding COVID-19-associated coagulopathy | Nature Reviews Immunology
  • 08/06 COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period | medRxiv
  • 08/06 Understanding Covid Vaccine Efficacy over Time — Bridging a Gap Between Public Health and Health Care | NEJM
  • 08/06 Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study - The Lancet
  • 08/07 Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir | bioRxiv
  • 08/07 Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors | bioRxiv
  • 08/07 Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 | bioRxiv
  • 08/08 Monitoring of the SARS-CoV-2 Omicron BA.1/BA.2 lineage transition in the Swedish population reveals increased viral RNA levels in BA.2 cases: Med
  • 08/08 A lab-on-a-chip for the concurrent electrochemical detection of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies in saliva and plasma | Nature Biomedical Engineering
  • 08/09 Impact of SARS-CoV-2 Omicron on Rapid Antigen Testing Developed for Early-Pandemic SARS-CoV-2 Variants | Microbiology Spectrum
  • 08/09 Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants | bioRxiv
  • 08/09 Covid-19: What we know about the BA.4 and BA.5 omicron variants | The BMJ
  • 08/09 Distinguishing features of Long COVID identified through immune profiling | medRxiv
  • 08/09 SARS-CoV-2 hybrid immunity: silver bullet or silver lining? | Nature Reviews Immunology
  • 08/09 Global patterns of antigen receptor repertoire disruption across adaptive immune compartments in COVID-19 | PNAS
  • 08/09 CD8 T Cells Contribute to Vaccine Protection Against SARS-CoV-2 in Macaques
  • 08/10 Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques | Science Translational Medicine
  • 08/11 The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination: Immunity
  • 08/11 Morphological, cellular, and molecular basis of brain infection in COVID-19 patients | PNAS
  • 08/11 Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study - The Lancet Infectious Diseases
  • 08/11 Safety of mRNA COVID-19 vaccines during pregnancy - The Lancet Infectious Diseases
  • 08/12 Comparison of Pregnancy and Birth Outcomes Before vs During the COVID-19 Pandemic | Neonatology | JAMA Network Open | JAMA Network
  • 08/12 Health Impairments in Children and Adolescents After Hospitalization for Acute COVID-19 or MIS-C | Pediatrics | American Academy of Pediatrics
  • 08/12 BNT162b2 induced neutralizing and non-neutralizing antibody functions against SARSCoV-2 diminish with age | medRxiv
  • 08/14 Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant | bioRxiv
  • 08/15 Risk of SARS-CoV-2 Acquisition in Health Care Workers According to Cumulative Patient Exposure and Preferred Mask Type | Infectious Diseases | JAMA Network Open | JAMA Network
  • 08/15 The Role of Nightlife Settings in Sustained COVID-19 Transmission by Takeaki Imamura, Aika Watanabe, Yusuke Serizawa, Manami Nakashita, Mayuko Saito, Mayu Okada, Asamoe Ogawa, Yukiko Tabei, Yoshiko Soumura, Yoko Nadaoka, Naoki Nakatsubo, Takashi Chiba, Kenji Sadamasu, Kazuhisa Yoshimura, Yoshihiro Noda, Yuko Iwashita, Yuji Ishimaru, Naomi Seki, Kanako Otani, Tadatsugu Imamura, Matthew Myers Griffith, Kelly DeToy, Motoi Suzuki, Michihiko Yoshida, Atsuko Tanaka, Mariko Yauchi, Tomoe Shimada, Hitoshi Oshitani :: SSRN
  • 08/15 Multiple BCG vaccinations for prevention of COVID-19 and other infectious diseases in Type 1 diabetes: Cell Reports Medicine
  • 08/15 Early Release - Rapid Increase in Suspected SARS-CoV-2 Reinfections, Clark County, Nevada, USA, December 2021 - Volume 28, Number 10—October 2022 - Emerging Infectious Diseases journal - CDC
  • 08/16 Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients | Geriatrics | JAMA | JAMA Network
  • 08/16 SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity - Journal of Experimental Medicine
  • 08/16 Rapid waning of protection induced by prior BA.1/BA.2 infection against BA.5 infection | medRxiv
  • 08/16 The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2 | PNAS
  • 08/17 SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic.: Immunity
  • 08/17 Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine | Science Translational Medicine
  • 08/17 Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients - The Lancet Psychiatry
  • 08/17 Neuropsychiatric sequelae of COVID-19: long-lasting, but not uniform - The Lancet Psychiatry
  • 08/18 SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization | Nature Communications
  • 08/18 Nanotechnology-based strategies against SARS-CoV-2 variants | Nature Nanotechnology
  • 08/18 Time to Stop Using Ineffective Covid-19 Drugs | NEJM
  • 08/18 T cell immunity to COVID-19 vaccines | Science
  • 08/18 Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study - The Lancet Respiratory Medicine
  • 08/19 Epidemiology of ventilator-associated pneumonia in ICU COVID-19 patients: an alarming high rate of multidrug-resistant bacteria | SpringerLink
  • 08/20 Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19 | Clinical Infectious Diseases | Oxford Academic
  • 08/20 Persistent Circulation of Soluble/EV-Linked Spike Protein and Viral RNA in Individuals with Post-Acute Sequelae of COVID-19 by Vaughn Craddock, Aatish Mahajan, Balaji Krishnamachary, Leslie Spikes, Prabhakar Chalise, Navneet Dhillon :: SSRN
  • 08/21 What were the historical reasons for the resistance to recognizing airborne transmission during the COVID‐19 pandemic? - Jimenez - 2022 - Indoor Air - Wiley Online Library
  • 08/21 Neutralizing Antibody to Omicron BA.1, BA.2 and BA.5 in COVID-19 Patients | medRxiv
  • 08/22 Physical activity and risk of infection, severity and mortality of COVID-19: a systematic review and non-linear dose–response meta-analysis of data from 1 853 610 adults | British Journal of Sports Medicine
  • 08/22 Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis | Infectious Diseases | JAMA Network Open | JAMA Network
  • 08/22 SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern | PNAS
  • 08/23 Significant impacts of the COVID-19 pandemic on race/ethnic differences in US mortality | PNAS
  • 08/24 Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge | NEJM
  • 08/24 Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study - The Lancet Infectious Diseases
  • 08/25 Moral distress among clinicians working in US safety net practices during the COVID-19 pandemic: a mixed methods study | BMJ Open
  • 08/25 SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export | PLOS Pathogens
  • 08/25 Predicting the efficacy of variant-modified COVID-19 vaccine boosters | medRxiv
  • 08/25 Persistence, prevalence, and polymorphism of sequelae after COVID-19 in unvaccinated, young adults of the Swiss Armed Forces: a longitudinal, cohort study (LoCoMo) - The Lancet Infectious Diseases
  • 08/25 COVID-19 sequelae: can long-term effects be predicted? - The Lancet Infectious Diseases
  • 08/26 Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore | Infectious Diseases | JAMA Network Open | JAMA Network
  • 08/26 Wearable technology and COVID-19 - The Lancet Respiratory Medicine
  • 08/30 The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19 | Annals of Internal Medicine
  • 08/30 Recent SARS-CoV-2 infection abrogates antibody and B-cell responses to booster vaccination | medRxiv
  • 08/30 SARS-CoV-2 variant spike and accessory gene mutations alter pathogenesis | PNAS
  • 08/31 Neuroinvasion and anosmia are independent phenomena upon infection with SARS-CoV-2 and its variants | bioRxiv
  • 08/31 Dysregulated naïve B cells and de novo autoreactivity in severe COVID-19 | Nature

    September 2022

  • 09/01 SARS-CoV-2 requires acidic pH to infect cells | PNAS
  • 09/01 Evasion of neutralising antibodies by omicron sublineage BA.2.75 - The Lancet Infectious Diseases
  • 09/03 SARS-CoV-2 Omicron Variant: Clinical Presentation and Occupational Implications in Young and Healthy IDF Soldiers - PubMed
  • 09/04 The prevalence of SARS-CoV-2 infection and long COVID in US adults during the BA.5 surge, June-July 2022 | medRxiv
  • 09/05 Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75: Cell Host & Microbe
  • 09/05 Long-term cardiac pathology in individuals with mild initial COVID-19 illness | Nature Medicine
  • 09/06 Resistance of SARS-CoV-2 Omicron Subvariant BA.4.6 to Antibody Neutralization | bioRxiv
  • 09/06 Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage - The Lancet Infectious Diseases
  • 09/07 Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment | NEJM
  • 09/07 Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75 | NEJM
  • 09/07 Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants | NEJM
  • 09/08 COVID-19 infection and transmission includes complex sequence diversity | PLOS Genetics
  • 09/08 Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants | NEJM
  • 09/09 Mucosal vaccination for SARS-CoV-2 elicits superior systemic T central memory function and cross-neutralizing antibodies against variants of concern | bioRxiv
  • 09/09 Nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. | medRxiv
    | Main | News | Articles | Papers| About |